[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4391
1. Jacquemin C, Molto A, Servy H, Sellam J, Foltz V, Gandjbakhch F, Hudry C, Mitrovic S, Granger B, Fautrel B, Gossec L: Flares assessed weekly in patients with rheumatoid arthritis or axial spondyloarthritis and relationship with physical activity measured using a connected activity tracker: a 3-month study. RMD Open; 2017;3(1):e000434

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flares assessed weekly in patients with rheumatoid arthritis or axial spondyloarthritis and relationship with physical activity measured using a connected activity tracker: a 3-month study.
  • METHODS: This prospective observational study (ActConnect) included patients with definite clinician-confirmed RA or axSpA, owning a smartphone.
  • RESULTS: In all, 170/178 patients (91 patients with RA and 79 patients with axSpA; 1553 time points) were analysed: mean age was 45.5±12.4 years, mean disease duration was 10.3±8.7 years, 60 (35.3%) were men and 90 (52.9%) received biologics.
  • Patients self-reported flares in 28.2%±28.1% of the weekly assessments.
  • CONCLUSION: Flares were frequent but usually of short duration in these stable patients with RA and axSpA.
  • Persistent flares were related to a moderate decrease in physical activity, confirming objectively the functional impact of patient-reported flares.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rheumatology (Oxford). 2012 Jan;51(1):69-76 [21565901.001]
  • [Cites] J Rheumatol. 2015 Dec;42(12 ):2369-75 [26523021.001]
  • [Cites] Rheumatology (Oxford). 2008 Aug;47(8):1213-8 [18539622.001]
  • [Cites] Ann Rheum Dis. 2009 Jun;68(6):777-83 [19297344.001]
  • [Cites] Rheumatology (Oxford). 2010 May;49(5):929-32 [20123954.001]
  • [Cites] Joint Bone Spine. 2013 Jul;80(4):393-8 [23453478.001]
  • [Cites] Arthritis Care Res (Hoboken). 2012 Dec;64(12):1886-94 [22745014.001]
  • [Cites] Arthritis Rheum. 1995 Jan;38(1):44-8 [7818570.001]
  • [Cites] Joint Bone Spine. 2008 Mar;75(2):167-71 [18296097.001]
  • [Cites] Arthritis Care Res (Hoboken). 2016 Aug;68(8):1069-77 [26784571.001]
  • [Cites] Arthritis Rheum. 2010 Sep;62(9):2582-91 [20872596.001]
  • [Cites] J Med Internet Res. 2014 Aug 15;16(8):e192 [25131661.001]
  • [Cites] Rheumatology (Oxford). 2014 Apr;53(4):722-31 [24369410.001]
  • [Cites] Ann Rheum Dis. 2016 Jun;75(6):991-6 [26847821.001]
  • [Cites] J Rheumatol. 1997 Oct;24(10):1954-8 [9330938.001]
  • [Cites] Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S14-36 [22588741.001]
  • [Cites] Arthritis Rheum. 2001 Aug;45(4):372-7 [11501725.001]
  • [Cites] BMC Sports Sci Med Rehabil. 2015 Oct 12;7:24 [26464801.001]
  • [Cites] J Rheumatol. 2015 Nov;42(11):2185-9 [25684764.001]
  • [Cites] Rheumatology (Oxford). 2012 Aug;51(8):1500-7 [22539478.001]
  • [Cites] Rheumatology (Oxford). 2014 May;53(5):923-6 [24459221.001]
  • [Cites] Ann Rheum Dis. 2012 Nov;71(11):1855-60 [22772326.001]
  • [Cites] Arthritis Rheumatol. 2017 Feb;69(2):309-319 [27636400.001]
  • [Cites] Rheumatology (Oxford). 2015 Sep;54(9):1563-72 [25802399.001]
  • [Cites] RMD Open. 2016 May 26;2(1):e000225 [27252895.001]
  • [Cites] J Rheumatol. 2005 Nov;32(11):2250-6 [16265712.001]
  • [Cites] J Rheumatol. 2014 Feb;41(2):227-34 [24334643.001]
  • [Cites] Ann Rheum Dis. 2011 Jun;70(6):935-42 [21540201.001]
  • [Cites] Clin Rheumatol. 2011 Nov;30(11):1425-32 [21892767.001]
  • [Cites] JMIR Mhealth Uhealth. 2017 Mar 24;5(3):e37 [28341616.001]
  • [Cites] Ann Rheum Dis. 2011 Nov;70(11):1975-80 [21803751.001]
  • [Cites] PLoS One. 2014 Feb 28;9(2):e85309 [24586239.001]
  • [Cites] Arthritis Rheum. 1983 Nov;26(11):1346-53 [6639693.001]
  • [Cites] Semin Arthritis Rheum. 2013 Jun;42(6):619-26 [23351615.001]
  • [Cites] J Rheumatol. 1994 Dec;21(12):2286-91 [7699630.001]
  • [Cites] Ann Rheum Dis. 2015 May;74(5):830-5 [24399232.001]
  • [Cites] J Clin Epidemiol. 2005 Jun;58(6):595-602 [15878473.001]
  • (PMID = 28879046.001).
  • [ISSN] 2056-5933
  • [Journal-full-title] RMD open
  • [ISO-abbreviation] RMD Open
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Physical activity / axial spondyloarthritis / disease activity / flare / patient-reported outcomes / rheumatoid arthritis
  •  go-up   go-down


2. Richards DA, Rhodes S, Ekers D, McMillan D, Taylor RS, Byford S, Barrett B, Finning K, Ganguli P, Warren F, Farrand P, Gilbody S, Kuyken W, O'Mahen H, Watkins E, Wright K, Reed N, Fletcher E, Hollon SD, Moore L, Backhouse A, Farrow C, Garry J, Kemp D, Plummer F, Warner F, Woodhouse R: Cost and Outcome of BehaviouRal Activation (COBRA): a randomised controlled trial of behavioural activation versus cognitive-behavioural therapy for depression. Health Technol Assess; 2017 Aug;21(46):1-366

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PARTICIPANTS: Adults aged ≥ 18 years with major depressive disorder (MDD) recruited from primary care and psychological therapy services.
  • OUTCOMES: Primary: depression severity (as measured via the Patient Health Questionnaire-9; PHQ-9) at 12 months.
  • We explored cost-effectiveness by collecting direct treatment and other health- and social-care costs and calculating quality-adjusted life-years (QALYs) using the EuroQol-5 Dimensions, three-level version, at 18 months.
  • We found a significant difference in mean intervention costs (BA, £975; CBT, £1235; <i>p</i> < 0.001), but no differences in non-intervention (hospital, community health, social care and medication costs) or total (non-intervention plus intervention) costs.
  • The probability of BA being cost-effective compared with CBT was almost 80% at the National Institute for Health and Care Excellence's preferred willingness-to-pay threshold of £20,000-30,000 per QALY.
  • FUTURE WORK: Settings and countries with a paucity of professionally qualified psychological therapists, might choose to investigate the delivery of effective psychological therapy for depression without the need to develop an extensive and costly professional infrastructure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28857042.001).
  • [ISSN] 2046-4924
  • [Journal-full-title] Health technology assessment (Winchester, England)
  • [ISO-abbreviation] Health Technol Assess
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


3. Fachin F, Spuhler P, Martel-Foley JM, Edd JF, Barber TA, Walsh J, Karabacak M, Pai V, Yu M, Smith K, Hwang H, Yang J, Shah S, Yarmush R, Sequist LV, Stott SL, Maheswaran S, Haber DA, Kapur R, Toner M: Monolithic Chip for High-throughput Blood Cell Depletion to Sort Rare Circulating Tumor Cells. Sci Rep; 2017 Sep 07;7(1):10936
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We quantified the size and EpCAM expression of over 2,500 CTCs from 38 patient samples obtained from breast, prostate, lung cancers, and melanoma.
  • The results show significant heterogeneity between and within single patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):6302-9 [18829513.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1715-20 [16551854.001]
  • [Cites] Sci Rep. 2013;3:1259 [23405273.001]
  • [Cites] Science. 2004 May 14;304(5673):987-90 [15143275.001]
  • [Cites] BMC Cancer. 2012 May 16;12 :178 [22591372.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3213-21 [18591556.001]
  • [Cites] Biomed Microdevices. 2014 Aug;16(4):537-48 [24668439.001]
  • [Cites] J Clin Oncol. 1995 May;13(5):1195-200 [7537803.001]
  • [Cites] Phys Biol. 2012 Feb;9(1):016002 [22306736.001]
  • [Cites] BMC Cancer. 2014 Sep 03;14 :651 [25182808.001]
  • [Cites] Crit Care. 2007;11(3):R62 [17550592.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4218-24 [16857794.001]
  • [Cites] Nature. 2012 Jul 26;487(7408):510-3 [22763454.001]
  • [Cites] Analyst. 2014 Jul 7;139(13):3245-55 [24840240.001]
  • [Cites] Biomed Microdevices. 2013 Aug;15(4):699-709 [23504045.001]
  • [Cites] Breast Cancer Res. 2008;10 (4):R69 [18687126.001]
  • [Cites] Phys Biol. 2012 Feb;9(1):016003 [22306768.001]
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):8-12 [16317435.001]
  • [Cites] Cancer. 1964 May;17:637-42 [14159810.001]
  • [Cites] Annu Rev Med. 2012;63:199-215 [22053740.001]
  • [Cites] J Natl Cancer Inst. 2009 Jan 7;101(1):61-6 [19116383.001]
  • [Cites] Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1123-1128 [28096363.001]
  • [Cites] Transl Oncol. 2013 Oct 01;6(5):528-38 [24151533.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18392-7 [20930119.001]
  • [Cites] PLoS One. 2012;7(11):e49144 [23145101.001]
  • [Cites] Cancer Res. 2009 Apr 1;69(7):2912-8 [19339269.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1420-30 [15735118.001]
  • [Cites] N Engl J Med. 2004 Aug 19;351(8):781-91 [15317891.001]
  • [Cites] Mol Cancer Res. 2011 Aug;9(8):997-1007 [21665936.001]
  • [Cites] PLoS One. 2012;7(4):e35976 [22558290.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6897-904 [15501967.001]
  • [Cites] Sci Transl Med. 2013 Apr 3;5(179):179ra47 [23552373.001]
  • [Cites] PLoS One. 2014 Jan 08;9(1):e85264 [24416373.001]
  • [Cites] Nature. 2007 Dec 20;450(7173):1235-9 [18097410.001]
  • [Cites] Nat Protoc. 2014 Mar;9(3):694-710 [24577360.001]
  • [Cites] Ann Oncol. 2009 Jul;20(7):1223-9 [19282466.001]
  • [Cites] Acta Oncol. 2011 Jun;50(5):700-10 [21261508.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):366-77 [18596266.001]
  • [Cites] Int J Oncol. 2005 Jul;27(1):49-57 [15942643.001]
  • [Cites] PLoS One. 2013 Apr 23;8(4):e61770 [23626725.001]
  • [Cites] Science. 2014 Jul 11;345(6193):216-20 [25013076.001]
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):920-8 [17289886.001]
  • [Cites] J Transl Med. 2014 May 23;12 :143 [24886394.001]
  • [Cites] Anal Chem. 2014 Apr 15;86(8):3735-42 [24641782.001]
  • [Cites] Sci Rep. 2015 Jun 10;5:11300 [26061253.001]
  • [Cites] Breast Cancer Res. 2009;11(4):R46 [19589136.001]
  • [Cites] Annu Rev Med. 2013;64:31-44 [23092385.001]
  • [Cites] Annu Rev Biomed Eng. 2014 Jul 11;16:371-96 [24905880.001]
  • [Cites] Cancer Discov. 2012 Nov;2(11):995-1003 [23093251.001]
  • [Cites] Ann Oncol. 2010 Sep;21(9):1851-7 [20147742.001]
  • [Cites] Science. 2013 Feb 1;339(6119):580-4 [23372014.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):4993-7 [15958538.001]
  • [Cites] Am J Pathol. 2000 Jan;156(1):57-63 [10623654.001]
  • (PMID = 28883519.001).
  • [ISSN] 2045-2322
  • [Journal-full-title] Scientific reports
  • [ISO-abbreviation] Sci Rep
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / P41 EB002503; United States / NIBIB NIH HHS / EB / U01 EB012493
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Burté F, Houghton D, Lowes H, Pyle A, Nesbitt S, Yarnall A, Yu-Wai-Man P, Burn DJ, Santibanez-Koref M, Hudson G: metabolic profiling of Parkinson's disease and mild cognitive impairment. Mov Disord; 2017 Jun;32(6):927-932

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Early diagnosis of Parkinson's disease and mild cognitive impairment is important to enable prompt treatment and improve patient welfare, yet no standard diagnostic test is available.
  • METHODS: This study compared the serological metabolomic profiles of early-stage Parkinson's patients (diagnosed < 12 months) to asymptomatic matched controls using an established array based detection system (DiscoveryHD4™, Metabolon, UK), correlating metabolite levels to clinical measurements of cognitive impairment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
  • [Cites] Nucleic Acids Res. 2015 Jul 1;43(W1):W251-7 [25897128.001]
  • [Cites] Minerva Med. 2011 Dec;102(6):441-59 [22193376.001]
  • [Cites] Br J Psychiatry. 1986 Dec;149:698-709 [3790869.001]
  • [Cites] Ann Neurol. 2002 Sep;52(3):276-84 [12205639.001]
  • [Cites] BMC Genomics. 2006 Jun 08;7:142 [16762068.001]
  • [Cites] Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3270-5 [21289278.001]
  • [Cites] Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):E4901-10 [26283345.001]
  • [Cites] Front Behav Neurosci. 2015 Sep 15;9:253 [26441580.001]
  • [Cites] J Neurosci. 2001 May 15;21(10 ):RC143 [11319241.001]
  • [Cites] Eur J Neurol. 2013 Jan;20(1):16-34 [23279440.001]
  • [Cites] Mov Disord. 2008 Apr 30;23(6):837-44 [18307261.001]
  • [Cites] Mov Disord. 2013 Oct;28(12):1653-60 [23873789.001]
  • [Cites] Mov Disord. 2011 Apr;26(5):889-92 [21520278.001]
  • [Cites] J Proteome Res. 2015 Jan 2;14(1):467-78 [25271123.001]
  • [Cites] Schizophr Res. 1995 Jan;14(2):93-104 [7711000.001]
  • [Cites] Sci Rep. 2015 Sep 14;5:13888 [26365159.001]
  • [Cites] J Am Geriatr Soc. 2005 Apr;53(4):695-9 [15817019.001]
  • [Cites] J Neurol. 2010 Apr;257(4):540-5 [19847468.001]
  • [Cites] Int J Epidemiol. 2013 Aug;42(4):1111-9 [23838602.001]
  • [Cites] Anal Chem. 2008 Jan 1;80(1):115-22 [18027910.001]
  • [Cites] J Cereb Blood Flow Metab. 2008 Jan;28(1):1-16 [17684514.001]
  • [Cites] Am J Epidemiol. 2003 Jun 1;157(11):1015-22 [12777365.001]
  • [Cites] Am J Manag Care. 2012 Sep;18(7 Suppl):S183-8 [23039867.001]
  • [Cites] Dev Neurosci. 1998;20(4-5):348-57 [9778571.001]
  • [Cites] Adv Exp Med Biol. 2010;709:95-107 [21618891.001]
  • [Cites] Public Health. 1992 Sep;106(5):393-5 [1410224.001]
  • [Cites] Handb Clin Neurol. 2013;113:1675-88 [23622388.001]
  • [Cites] Agents Actions. 1994 Jun;41 Spec No:C5-8 [7976804.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):368-76 [18344392.001]
  • [Cites] Anal Chem. 2009 Aug 15;81(16):6656-67 [19624122.001]
  • [Cites] PLoS One. 2009 Oct 22;4(10 ):e7551 [19847307.001]
  • [Cites] Brain. 2008 Feb;131(Pt 2):389-96 [18222993.001]
  • [Cites] Neurology. 2014 Jan 28;82(4):308-16 [24363137.001]
  • [Cites] Clin Chim Acta. 1972 Oct;41:199-207 [4630229.001]
  • [Cites] Nat Rev Mol Cell Biol. 2016 Jul;17 (7):451-9 [26979502.001]
  • (PMID = 28394042.001).
  • [ISSN] 1531-8257
  • [Journal-full-title] Movement disorders : official journal of the Movement Disorder Society
  • [ISO-abbreviation] Mov. Disord.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Parkinson's Disease / fatty acid beta oxidation / metabolomics
  •  go-up   go-down


5. Orban JC, Novain M, Cattet F, Plattier R, Nefzaoui M, Hyvernat H, Raguin O, Kaidomar M, Kerever S, Ichai C: Association of serum lactate with outcome after out-of-hospital cardiac arrest treated with therapeutic hypothermia. PLoS One; 2017;12(3):e0173239
Hazardous Substances Data Bank. LACTIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our study aimed to assess the prognosis value of lactate in out-of-hospital cardiac arrest patients treated with therapeutic hypothermia.
  • METHODS: This retrospective observational study included out-of-hospital cardiac arrest patients treated with therapeutic hypothermia in four ICUs.
  • RESULTS: Two hundred and seventy-two patients were included, 89 good outcome and 183 poor outcome.
  • In the latter group, 171 patients died, from multiorgan failure in 30% and neurologic failure in 70%.
  • Lactate levels were higher in the poor compared to the good outcome patients at admission (5.4 (3.3-9.4) vs. 2.2 (1.5-3.6) mmol/L; p<0.01), 12 hours (2.5 (1.6-4.7) vs. 1.4 (1.0-2.2) mmol/L; p<0.01) and 24 hours (1.8 (1.1-2.8) vs. 1.3 (0.9-2.1) mmol/L; p<0.01).
  • Patients succumbing from multiorgan failure exhibited higher lactate levels compared to those dying from neurologic failure at admission (7.9 (3.9-12.0) vs. 5.2 (3.3-8.8) mmol/L; p<0.01), H12 (4.9 (2.1-8.9) vs. 2.2 (1.4-3.4) mmol/L; p<0.01) and H24 (3.3 (1.8-5.5) vs. 1.4 (1.1-2.5) mmol/L; p<0.01).
  • Patients dying from multiorgan failure exhibit higher initial lactate concentrations than patients succumbing from neurological failure.
  • [MeSH-minor] Aged. Female. Humans. Intensive Care Units. Male. Middle Aged. Odds Ratio. Patient Discharge. Prognosis. Retrospective Studies. Risk Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Resuscitation. 2003 Aug;58(2):209-17 [12909384.001]
  • [Cites] PLoS One. 2012;7(9):e45284 [23049783.001]
  • [Cites] Intensive Care Med. 2013 Nov;39(11):1972-80 [23942856.001]
  • [Cites] Ann Emerg Med. 1993 Nov;22(11):1652-8 [8214853.001]
  • [Cites] Resuscitation. 2005 Feb;64(2):181-6 [15680527.001]
  • [Cites] Lancet. 2015 Jan 10;385(9963):117-71 [25530442.001]
  • [Cites] Resuscitation. 2005 Dec;67 Suppl 1:S39-86 [16321716.001]
  • [Cites] Resuscitation. 2015 Oct;95:202-22 [26477702.001]
  • [Cites] Medicine (Baltimore). 2004 Sep;83(5):274-9 [15342971.001]
  • [Cites] Resuscitation. 2007 Feb;72(2):207-13 [17097795.001]
  • [Cites] Lancet. 1999 Aug 7;354(9177):505-8 [10465191.001]
  • [Cites] Chest. 1991 Apr;99(4):956-62 [2009802.001]
  • [Cites] Resuscitation. 2013 Oct;84(10):1382-6 [23528678.001]
  • [Cites] Crit Care Med. 2014 Aug;42(8):1804-11 [24776606.001]
  • [Cites] Resuscitation. 2014 Mar;85(3):376-80 [24300012.001]
  • [Cites] Crit Care Med. 2014 Jun;42(6):1340-7 [24463859.001]
  • [Cites] Resuscitation. 2007 Nov;75(2):229-34 [17583412.001]
  • [Cites] Anesth Analg. 2010 May 1;110(5):1328-35 [20418296.001]
  • [Cites] Intensive Care Med. 2014 Jun;40(6):846-54 [24658912.001]
  • [Cites] Intensive Care Med. 2014 Dec;40(12):1816-31 [25398304.001]
  • [Cites] Am J Emerg Med. 1985 Mar;3(2):120-4 [3970767.001]
  • [Cites] Resuscitation. 2010 Oct;81(10):1219-76 [20956052.001]
  • [Cites] JAMA. 2008 Sep 24;300(12):1423-31 [18812533.001]
  • [Cites] Crit Care. 2013 Oct 31;17(5):R260 [24172276.001]
  • [Cites] Resuscitation. 2013 Jan;84(1):60-5 [22743354.001]
  • [Cites] Am J Emerg Med. 2015 Feb;33(2):167-72 [25432592.001]
  • [Cites] Heart. 1998 Apr;79(4):356-61 [9616342.001]
  • [Cites] Resuscitation. 2013 Aug;84(8):1078-82 [23402966.001]
  • [Cites] Crit Care Med. 2014 Dec;42(12):2537-45 [25083981.001]
  • [Cites] Crit Care Med. 2005 Oct;33(10):2235-40 [16215376.001]
  • [Cites] Resuscitation. 2011 Apr;82(4):404-9 [21227564.001]
  • [Cites] Minerva Anestesiol. 2011 Nov;77(11):1063-71 [21597442.001]
  • [Cites] Am J Respir Crit Care Med. 1998 Apr;157(4 Pt 1):1021-6 [9563714.001]
  • [Cites] Crit Care Med. 2008 Nov;36(11 Suppl):S447-53 [20449909.001]
  • [Cites] Intensive Care Med. 1997 Nov;23(11):1138-43 [9434919.001]
  • (PMID = 28282398.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 33X04XA5AT / Lactic Acid
  •  go-up   go-down


6. Weiss CR, Akinwande O, Paudel K, Cheskin LJ, Holly B, Hong K, Fischman AM, Patel RS, Shin EJ, Steele KE, Moran TH, Kaiser K, Park A, Shade DM, Kraitchman DL, Arepally A: Clinical Safety of Bariatric Arterial Embolization: Preliminary Results of the BEAT Obesity Trial. Radiology; 2017 May;283(2):598-608
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Purpose To conduct a pilot prospective clinical trial to evaluate the feasibility, safety, and short-term efficacy of bariatric embolization, a recently developed endovascular procedure for the treatment of obesity, in patients with severe obesity.
  • Five severely obese patients (four women, one man) who were 31-49 years of age and who had a mean body mass index of 43.8 kg/m<sup>2</sup> ± 2.9 with no clinically important comorbidities were enrolled in this study.
  • Results The left gastric artery, with or without the gastroepiploic artery, was embolized in five patients, with a technical success rate of 100%.
  • A hospital stay of less than 48 hours for routine supportive care was provided for three patients.
  • Conclusion Bariatric embolization is feasible and appears to be well tolerated in severely obese patients.
  • In this small patient cohort, it appears to induce appetite suppression and may induce weight loss.

  • Genetic Alliance. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diabetes. 2001 Aug;50(8):1714-9 [11473029.001]
  • [Cites] Cardiovasc Intervent Radiol. 2012 Dec;35(6):1460-6 [22367009.001]
  • [Cites] Obes Surg. 2015 Mar;25(3):550-8 [25511751.001]
  • [Cites] Adv Ther. 2012 Nov;29(11):970-8 [23149862.001]
  • [Cites] JACC Cardiovasc Interv. 2015 Oct;8(12):1641-4 [26493259.001]
  • [Cites] Am J Prev Med. 2008 Aug;35(2):118-26 [18617080.001]
  • [Cites] Ann Surg. 2006 Jan;243(1):108-14 [16371744.001]
  • [Cites] Gastroenterology. 2007 May;132(6):2253-71 [17498516.001]
  • [Cites] Obesity (Silver Spring). 2008 Jun;16(6):1413-20 [18421273.001]
  • [Cites] Radiology. 2008 Oct;249(1):127-33 [18796671.001]
  • [Cites] N Engl J Med. 2002 May 23;346(21):1623-30 [12023994.001]
  • [Cites] Ann Surg. 2007 Nov;246(5):780-5 [17968169.001]
  • [Cites] Ann Pharmacother. 2000 Sep;34(9):1066-9 [10981254.001]
  • [Cites] J Obes. 2014;2014:185349 [25349724.001]
  • [Cites] Int J Obes (Lond). 2009 Apr;33 Suppl 1:S33-40 [19363506.001]
  • [Cites] N Engl J Med. 2011 Oct 27;365(17):1597-604 [22029981.001]
  • [Cites] J Radiol Case Rep. 2015 Sep 30;9(9):36-43 [26629307.001]
  • [Cites] Arch Surg. 2006 Mar;141(3):262-8 [16549691.001]
  • [Cites] Int J Obes (Lond). 2014 Sep;38(9):1147-52 [24352292.001]
  • [Cites] Radiology. 2013 Feb;266(2):471-9 [23204538.001]
  • [Cites] Trends Endocrinol Metab. 2010 Jun;21(6):337-44 [20133150.001]
  • [Cites] Nat Med. 2012 May 04;18(5):666-7 [22561823.001]
  • [Cites] J Am Diet Assoc. 2010 Apr;110(4):571-84 [20338283.001]
  • [Cites] Arch Surg. 2003 Apr;138(4):389-96 [12686525.001]
  • [Cites] Nat Med. 2012 May 04;18(5):668-9 [22561824.001]
  • [Cites] J Vasc Interv Radiol. 2014 Mar;25(3):455-61 [24462005.001]
  • [Cites] Radiology. 2007 Jul;244(1):138-43 [17581899.001]
  • (PMID = 28195823.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB017615; United States / NIBIB NIH HHS / EB / T32 EB006351
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemostatics
  •  go-up   go-down


7. Damelin M, Bankovich A, Bernstein J, Lucas J, Chen L, Williams S, Park A, Aguilar J, Ernstoff E, Charati M, Dushin R, Aujay M, Lee C, Ramoth H, Milton M, Hampl J, Lazetic S, Pulito V, Rosfjord E, Sun Y, King L, Barletta F, Betts A, Guffroy M, Falahatpisheh H, O'Donnell CJ, Stull R, Pysz M, Escarpe P, Liu D, Foord O, Gerber HP, Sapra P, Dylla SJ: A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. Sci Transl Med; 2017 Jan 11;9(372)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therapies that target tumor-initiating cells (TICs) should improve patient survival by eliminating the cells that can drive tumor recurrence and metastasis.
  • We demonstrate that protein tyrosine kinase 7 (PTK7), a highly conserved but catalytically inactive receptor tyrosine kinase in the Wnt signaling pathway, is enriched on TICs in low-passage TNBC, OVCA, and NSCLC patient-derived xenografts (PDXs).
  • The PTK7-targeted ADC induced sustained tumor regressions and outperformed standard-of-care chemotherapy.
  • Together, these preclinical data demonstrate the potential for the PTK7-targeted ADC to improve the long-term survival of cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017, American Association for the Advancement of Science.
  • (PMID = 28077676.001).
  • [ISSN] 1946-6242
  • [Journal-full-title] Science translational medicine
  • [ISO-abbreviation] Sci Transl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R, McNary TJ, Churakova Y, Cheung C, Triscott J, Pisapia D, Rao R, Mosquera JM, Robinson B, Faltas BM, Emerling BE, Gadi VK, Bernard B, Elemento O, Beltran H, Demichelis F, Kemp CJ, Grandori C, Cantley LC, Rubin MA: Personalized &lt;i&gt;In Vitro&lt;/i&gt; and &lt;i&gt;In Vivo&lt;/i&gt; Cancer Models to Guide Precision Medicine. Cancer Discov; 2017 May;7(5):462-477

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we describe the development of a robust precision cancer care platform that integrates whole-exome sequencing with a living biobank that enables high-throughput drug screens on patient-derived tumor organoids.
  • To date, 56 tumor-derived organoid cultures and 19 patient-derived xenograft (PDX) models have been established from the 769 patients enrolled in an Institutional Review Board-approved clinical trial.
  • Because genomics alone was insufficient to identify therapeutic options for the majority of patients with advanced disease, we used high-throughput drug screening to discover effective treatment strategies.
  • This platform thereby promotes the discovery of novel therapeutic approaches that can be assessed in clinical trials and provides personalized therapeutic options for individual patients where standard clinical options have been exhausted.
  • <b>Significance:</b> Integration of genomic data with drug screening from personalized <i>in vitro</i> and <i>in vivo</i> cancer models guides precision cancer care and fuels next-generation research.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2017 American Association for Cancer Research.
  • [Cites] Nucleic Acids Res. 2008 Apr;36(7):2446-56 [18304946.001]
  • [Cites] Oncotarget. 2015 May 30;6(15):13731-41 [25915532.001]
  • [Cites] Cell. 2015 May 7;161(4):933-45 [25957691.001]
  • [Cites] Nat Rev Drug Discov. 2013 Aug;12(8):569 [23903212.001]
  • [Cites] Cancer Cytopathol. 2016 Mar;124(3):167-73 [26641771.001]
  • [Cites] Cancer Discov. 2016 May;6(5):479-91 [26969689.001]
  • [Cites] Nat Rev Drug Discov. 2011 Feb;10(2):87 [21283095.001]
  • [Cites] Analyst. 2015 Jun 21;140(12):3910-20 [25923379.001]
  • [Cites] Am J Physiol. 1997 Oct;273(4 Pt 1):C1109-23 [9357753.001]
  • [Cites] Mol Cancer Res. 2008 Jan;6(1):21-30 [18184972.001]
  • [Cites] J Biol Chem. 2008 May 9;283(19):13021-30 [18339627.001]
  • [Cites] Front Genet. 2014 Feb 20;5:31 [24600470.001]
  • [Cites] Trends Cancer. 2016 Apr;2(4):176-190 [27135056.001]
  • [Cites] Genome Biol. 2014 Aug 26;15(8):439 [25160065.001]
  • [Cites] Nat Med. 2015 Nov;21(11):1364-71 [26501191.001]
  • [Cites] Nature. 2013 Jul 11;499(7457):214-8 [23770567.001]
  • [Cites] JAMA Oncol. 2015 Jul;1(4):466-74 [26181256.001]
  • [Cites] Oncogene. 2009 Jan 22;28(3):461-8 [18978815.001]
  • [Cites] Nat Genet. 2013 Oct;45(10):1134-40 [24071852.001]
  • [Cites] Hum Mutat. 2015 Apr;36(4):E2423-9 [25703262.001]
  • [Cites] Cell. 2016 Jul 28;166(3):740-54 [27397505.001]
  • [Cites] Drug Des Devel Ther. 2013 Nov 01;7:1315-22 [24204124.001]
  • [Cites] Nat Rev Cancer. 2006 Oct;6(10 ):813-23 [16990858.001]
  • [Cites] Sci Rep. 2013 Oct 02;3:2650 [24084849.001]
  • [Cites] Cell. 2014 Sep 25;159(1):176-87 [25201530.001]
  • [Cites] N Engl J Med. 2011 Jun 30;364(26):2507-16 [21639808.001]
  • [Cites] Crit Rev Oncol Hematol. 2000 Nov-Dec;36(2-3):123-39 [11033302.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Oct;8(10):839-45 [17684528.001]
  • [Cites] N Engl J Med. 2013 Jun 20;368(25):2385-94 [23724913.001]
  • [Cites] J Cell Sci. 2012 Jul 1;125(Pt 13):3015-24 [22797912.001]
  • [Cites] Nature. 2012 Mar 28;483(7391):603-7 [22460905.001]
  • [Cites] Nature. 2015 Apr 16;520(7547):290-1 [25877189.001]
  • [Cites] BMC Med Genomics. 2015 Mar 01;8:9 [25889339.001]
  • [Cites] Nat Rev Drug Discov. 2010 Mar;9(3):203-14 [20168317.001]
  • [Cites] Cancer Res. 2011 May 15;71(10):3635-48 [21464044.001]
  • [Cites] Cell. 2016 Jun 16;165(7):1586-97 [27315476.001]
  • [Cites] Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11139-44 [25024180.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3719-28 [10999766.001]
  • [Cites] Cell. 2015 Jan 15;160(1-2):324-38 [25557080.001]
  • [Cites] Cancer Res. 2015 Mar 1;75(5):892-901 [25592149.001]
  • [Cites] Nat Biotechnol. 2013 Mar;31(3):213-9 [23396013.001]
  • [Cites] PLoS One. 2012;7(7):e40332 [22808135.001]
  • [CommentIn] Nature. 2017 Aug 3;548(7665):40-41 [28723897.001]
  • (PMID = 28331002.001).
  • [ISSN] 2159-8290
  • [Journal-full-title] Cancer discovery
  • [ISO-abbreviation] Cancer Discov
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM041890; United States / NCI NIH HHS / CA / U54 CA132381; United States / NCI NIH HHS / CA / R35 CA197588; United States / NCI NIH HHS / CA / U01 CA176303; United States / NCI NIH HHS / CA / R01 CA116337; United States / NCI NIH HHS / CA / U01 CA111275
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Rossignol P, Agarwal R, Canaud B, Charney A, Chatellier G, Craig JC, Cushman WC, Gansevoort RT, Fellström B, Garza D, Guzman N, Holtkamp FA, London GM, Massy ZA, Mebazaa A, Mol PGM, Pfeffer MA, Rosenberg Y, Ruilope LM, Seltzer J, Shah AM, Shah S, Singh B, Stefánsson BV, Stockbridge N, Stough WG, Thygesen K, Walsh M, Wanner C, Warnock DG, Wilcox CS, Wittes J, Pitt B, Thompson A, Zannad F: Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints. Eur Heart J; 2017 Apr 18;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints.
  • Although cardiovascular disease is a major health burden for patients with chronic kidney disease, most cardiovascular outcome trials have excluded patients with advanced chronic kidney disease.
  • Moreover, the major cardiovascular outcome trials that have been conducted in patients with end-stage renal disease have not demonstrated a treatment benefit.
  • Thus, clinicians have limited evidence to guide the management of cardiovascular disease in patients with chronic kidney disease, particularly those on dialysis.
  • Challenges associated with conducting trials in this population include patient heterogeneity, complexity of renal pathophysiology and its interaction with cardiovascular disease, and competing risks for death.
  • The group identified several research priorities, summarized in this paper, that should be pursued to advance the field towards achieving improved cardiovascular outcomes for these patients.
  • Cardiovascular and renal clinical trialists must partner to address the uncertainties in the field through collaborative research and design clinical trials that reflect the specific needs of the chronic and end-stage kidney disease populations, with the shared goal of generating robust evidence to guide the management of cardiovascular disease in patients with kidney disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017. For permissions, please email: journals.permissions@oup.com.
  • (PMID = 28431138.001).
  • [ISSN] 1522-9645
  • [Journal-full-title] European heart journal
  • [ISO-abbreviation] Eur. Heart J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Cardiovascular diseases / Chronic kidney failure / Chronic renal insufficiency / Clinical trials as topic
  •  go-up   go-down


10. Yunos NM, Bellomo R, Taylor DM, Judkins S, Kerr F, Sutcliffe H, Hegarty C, Bailey M: Renal effects of an emergency department chloride-restrictive intravenous fluid strategy in patients admitted to hospital for more than 48 hours. Emerg Med Australas; 2017 Jun 08;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal effects of an emergency department chloride-restrictive intravenous fluid strategy in patients admitted to hospital for more than 48 hours.
  • OBJECTIVE: Patients commonly receive i.v. fluids in the ED.
  • It is still unclear whether the choice of i.v. fluids in this setting influences renal or patient outcomes.
  • During the control period (18 February 2008 to 17 August 2008), patients received standard i.v. fluids.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Australasian College for Emergency Medicine and Australasian Society for Emergency Medicine.
  • (PMID = 28597505.001).
  • [ISSN] 1742-6723
  • [Journal-full-title] Emergency medicine Australasia : EMA
  • [ISO-abbreviation] Emerg Med Australas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Keywords] NOTNLM ; acute kidney injury / chloride / emergency department / saline
  •  go-up   go-down


11. Negredo A, de la Calle-Prieto F, Palencia-Herrejón E, Mora-Rillo M, Astray-Mochales J, Sánchez-Seco MP, Bermejo Lopez E, Menárguez J, Fernández-Cruz A, Sánchez-Artola B, Keough-Delgado E, Ramírez de Arellano E, Lasala F, Milla J, Fraile JL, Ordobás Gavín M, Martinez de la Gándara A, López Perez L, Diaz-Diaz D, López-García MA, Delgado-Jimenez P, Martín-Quirós A, Trigo E, Figueira JC, Manzanares J, Rodriguez-Baena E, Garcia-Comas L, Rodríguez-Fraga O, García-Arenzana N, Fernández-Díaz MV, Cornejo VM, Emmerich P, Schmidt-Chanasit J, Arribas JR, Crimean Congo Hemorrhagic Fever@Madrid Working Group: Autochthonous Crimean-Congo Hemorrhagic Fever in Spain. N Engl J Med; 2017 07 13;377(2):154-161
LANL Hemorrhagic Fever Virus sequence database. LANL Hemorrhagic Fever Virus sequence database .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The index patient acquired the disease through a tick bite in the province of Ávila - 300 km away from the province of Cáceres, where viral RNA from ticks was amplified in 2010.
  • The second patient was a nurse who became infected while caring for the index patient.
  • Both were infected with the African 3 lineage of this virus. (Funded by Red de Investigación Cooperativa en Enfermedades Tropicales [RICET] and Efficient Response to Highly Dangerous and Emerging Pathogens at EU [European Union] Level [EMERGE].).
  • [MeSH-minor] Colon / pathology. Contact Tracing. Fatal Outcome. Female. Humans. Infectious Disease Transmission, Patient-to-Professional. Liver / pathology. Male. Middle Aged. Necrosis. Polymerase Chain Reaction. Spain

  • Genetic Alliance. consumer health - Hemorrhagic fever.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28700843.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Investigator] Vázquez A; Hernández L; Herrero L; Molero F; Alami Tajri B; Alba Suarez AM; Aldeanueva Serrano ME; Alonso Domingo JJ; Aparicio Plaza E; Arabi Fernández O; Arsuaga Vicente M; Armijo Castillo MO; Avila Borja RM; Barrientos Martínez MI; Borrego Prieto P; Bretín Zornoza M; Cabildo Fajardo ML; Cachafeiro Fuciños L; Del Campo Ortún E; Campos Higueras JE; Casado Fernández L; Castaño Carmona AM; Castillo Portellano C; Cerón Serrano A; Cuesta Herrero Y; Del Carmen De Dompablo Ferrándiz M; Díaz Menendez M; Enriquez Calatrava V; Fernández Puntero B; Flores Cabeza EM; Galvez Charro M; García Hernandez R; García Expósito MA; Garcia Gonzalez C; García Sánchez M; Gómez Campos AM; Gómez Rodríguez E; Gómez Del Pulgar Carrillo E; González Herrero MA; González Herrezuelo I; González Navarro A; González Del Castillo AI; González Espinosa S; Gracia Pasamar JC; Granizo Lopez R; Gutierrez Plana C; Gutierrez Prieto M; Hermida Rodriguez J; Hernández Bernal M; Herrero Benito C; Herrero Alonso MT; Jara Orozco PA; Jiménez Castellano R; León Pérez M; López Lorente P; López Alvir C; López Díaz-Plaza Y; Lorenzo Velez C; Lucas Burgos V; Machón Rodríguez B; Mármol Martínez F; Marote Martín C; Martínez Corral C; Martínez Nieto SA; Martínez Quintana JI; Molins Bustamante C; Moreno Lozano E; Moreno Martinez C; Del Carmen Muñoz Gil M; Ortega Lucena C; Patrón Barambio PA; Perez Pacheco M; Del Rosario Rivero Gómez M; Rodriguez Diez R; San Juan Rodríguez A; Sanchez Arroyo V; Sanchez Villarejo M; Silva Montero AI; del Carmen Solera Martin De Nicolas M; Soriano Sánchez MA; Tapia García MR; Torres Hidalgo A; Robustillo Rodela A; Elola Vicente P; Arnalich F; Buño Soto A; García de Lorenzo A; Núñez C; Garcia-Pando CR; Martins Muñoz G; Velasquez-Alcala SG; Ángeles Sánchez-Castillo M; Rey-Cuevas E; Del Rosario Férnandez-Acevedo M; Borobia A; Aguirre Martín-Gil R; Alvarez-Castillo MC; Aragón-Peña A; de Burgos-Lunar C; Córdoba-Deorador E; Diezma-Criado JC; Domínguez-Berjón F; Esteban-Niveiro MJ; Bernardo-Ferrer Simó J; Fuentes-Rodriguez CY; Fuster F; Garcia-Mañosa I; Gil-Montalbán E; Ibáñez-Martí C; Insua Marisquerena E; Lasheras-Carbajo MD; Latasa-Zamalloa P; Angeles Lópaz-Perez M; Marino E; Martin-Martínez F; Martinez-Vidal M; de Miguel-Moro JI; Nieto-Juliá A; Noguerales-De la Obra R; Ortiz-Marrón H; Palomino-Lopez MT; Sanchez-Diaz J; Sánchez-Gómez A; Torrijano-Castillo MJ; Wijers I; Sierra-Matamoros MJ; Simón-Soria F; García Bordas J; Muñoz García P; Fernández RA; Goyanes MJ; Gijón Vidaurreta P; Martín-Rabadán P; Sánchez Carrillo C; Bouza E; Barrios JC; Guerrero JE; Bibiano C; Medina Iglesias P; Pacheco Puig R; Aguilar Huertas JL; Sanz de Miguel E; de Sansegundo Reyes M; Camacho Muñoz I; Cava F
  •  go-up   go-down


12. Gramatzki D, Kickingereder P, Hentschel B, Felsberg J, Herrlinger U, Schackert G, Tonn JC, Westphal M, Sabel M, Schlegel U, Wick W, Pietsch T, Reifenberger G, Loeffler M, Bendszus M, Weller M: Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. Neurology; 2017 Apr 11;88(15):1422-1430
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To explore an association with survival of modifying the current standard of care for patients with newly diagnosed glioblastoma of surgery followed by radiotherapy plus concurrent and 6 cycles of maintenance temozolomide chemotherapy (TMZ/RT → TMZ) by extending TMZ beyond 6 cycles.
  • METHODS: The German Glioma Network cohort was screened for patients with newly diagnosed glioblastoma who received TMZ/RT → TMZ and completed ≥6 cycles of maintenance chemotherapy without progression.
  • Associations of clinical patient characteristics, molecular markers, and residual tumor determined by magnetic resonance imaging after 6 cycles of TMZ with progression-free survival (PFS) and overall survival (OS) were analyzed with the log-rank test.
  • RESULTS: Sixty-one of 142 identified patients received at least 7 maintenance TMZ cycles (median 11, range 7-20).
  • Patients with extended maintenance TMZ treatment had better PFS (20.5 months, 95% confidence interval [CI] 17.7-23.3, vs 17.2 months, 95% CI 10.2-24.2, <i>p</i> = 0.035) but not OS (32.6 months, 95% CI 28.9-36.4, vs 33.2 months, 95% CI 25.3-41.0, <i>p</i> = 0.126).
  • CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that in patients with newly diagnosed glioblastoma, prolonged TMZ chemotherapy does not significantly increase PFS or OS.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Academy of Neurology.
  • (PMID = 28298550.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; YF1K15M17Y / temozolomide
  •  go-up   go-down


13. Tang LH, Kikkenborg Berg S, Christensen J, Lawaetz J, Doherty P, Taylor RS, Langberg H, Zwisler AD: Patients' preference for exercise setting and its influence on the health benefits gained from exercise-based cardiac rehabilitation. Int J Cardiol; 2017 Apr 01;232:33-39

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients' preference for exercise setting and its influence on the health benefits gained from exercise-based cardiac rehabilitation.
  • OBJECTIVE: To assess patient preference for exercise setting and examine if choice of setting influences the long-term health benefit of exercise-based cardiac rehabilitation.
  • METHODS: Patients participating in a randomised controlled trial following either heart valve surgery, or radiofrequency ablation for atrial fibrillation were given the choice to perform a 12-week exercise programme in either a supervised centre-based, or a self-management home-based setting.
  • RESULTS: Across the 158 included patients, an equivalent proportion preferred to undertake exercise rehabilitation in a centre-based setting (55%, 95% CI: 45% to 63%) compared to a home-based setting (45%, 95% CI: 37% to 53%, p=0.233).
  • CONCLUSION: The preference of patients to participate in home-based and centre-based exercise programmes appears to be equivalent and provides similar health benefits.
  • Whilst these findings support that patients should be given the choice between exercise-settings when initiating cardiac rehabilitation, further confirmatory evidence is needed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017. Published by Elsevier B.V.
  • (PMID = 28159358.001).
  • [ISSN] 1874-1754
  • [Journal-full-title] International journal of cardiology
  • [ISO-abbreviation] Int. J. Cardiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Atrial fibrillation / Cardiac rehabilitation / Exercise setting / Exercise training / Heart valve diseases / Patient preference
  •  go-up   go-down


14. Christie SA, Kornblith LZ, Howard BM, Conroy AS, Kunitake RC, Nelson MF, Hendrickson CM, Calfee CS, Callcut RA, Cohen MJ: Characterization of distinct coagulopathic phenotypes in injury: Pathway-specific drivers and implications for individualized treatment. J Trauma Acute Care Surg; 2017 Jun;82(6):1055-1062
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we identified injury/patient characteristics and coagulation factors that drive contact pathway, tissue factor pathway (TF), and common pathway dysfunction by examining injured patients with discordant coagulopathies.
  • We hypothesized that patients with INR/PTT discordance reflect differing phenotypes representing contact versus tissue factor pathway perturbations and that characterization will provide targets to guide individualized resuscitation.
  • METHODS: Plasma samples were prospectively collected from 1,262 critically injured patients at a single Level I trauma center.
  • RESULTS: Fourteen percent of patients were coagulopathic on admission.
  • All coagulopathic patients had factor V deficits, but activity was lowest in BOTH, suggesting an additive downstream effect of disordered activation pathways.
  • Patients with PTT-CONTACT received half as much packed red blood cell and fresh frozen plasma as did the other groups (p < 0.001).
  • Despite resuscitation, mortality was higher for coagulopathic patients; mortality was highest in BOTH and higher in PTT-CONTACT than in INR-TF (71%, 60%, 41%; p = 0.04).
  • Recognition and treatment of pathway-specific factor deficiencies driving different coagulopathic phenotypes in injured patients may individualize resuscitation and improve outcomes.

  • MedlinePlus Health Information. consumer health - Bleeding Disorders.
  • MedlinePlus Health Information. consumer health - Wounds and Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28338598.001).
  • [ISSN] 2163-0763
  • [Journal-full-title] The journal of trauma and acute care surgery
  • [ISO-abbreviation] J Trauma Acute Care Surg
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / K01 ES026834
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9001-25-6 / Factor VII; 9001-27-8 / Factor VIII
  •  go-up   go-down


15. Stacchiotti S, Gronchi A, Fossati P, Akiyama T, Alapetite C, Baumann M, Blay JY, Bolle S, Boriani S, Bruzzi P, Capanna R, Caraceni A, Casadei R, Colia V, Debus J, Delaney T, Desai A, Dileo P, Dijkstra S, Doglietto F, Flanagan A, Froelich S, Gardner PA, Gelderblom H, Gokaslan ZL, Haas R, Heery C, Hindi N, Hohenberger P, Hornicek F, Imai R, Jeys L, Jones RL, Kasper B, Kawai A, Krengli M, Leithner A, Logowska I, Martin Broto J, Mazzatenta D, Morosi C, Nicolai P, Norum OJ, Patel S, Penel N, Picci P, Pilotti S, Radaelli S, Ricchini F, Rutkowski P, Scheipl S, Sen C, Tamborini E, Thornton KA, Timmermann B, Torri V, Tunn PU, Uhl M, Yamada Y, Weber DC, Vanel D, Varga PP, Vleggeert-Lankamp CLA, Casali PG, Sommer J: Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group. Ann Oncol; 2017 Jun 01;28(6):1230-1242

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Until recently, there was no consensus among experts regarding appropriate clinical management of chordoma, resulting in inconsistent care and suboptimal outcomes for many patients.
  • To address this shortcoming, the European Society of Medical Oncology (ESMO) and the Chordoma Foundation, the global chordoma patient advocacy group, convened a multi-disciplinary group of chordoma specialists to define by consensus evidence-based best practices for the optimal approach to chordoma.
  • This meeting involved over 60 specialists from Europe, the United States and Japan with expertise in treatment of patients with chordoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
  • (PMID = 28184416.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; chemotherapy / chordoma / radiotherapy / relapse / sarcoma / surgery
  •  go-up   go-down


16. Huang X, Li H, Meyers K, Xia W, Meng Z, Li C, Bai J, He S, Cai W, Huang C, Liu S, Wang H, Ling X, Ma P, Tan D, Wang F, Ruan L, Zhao H, Wei H, Liu Y, Yu J, Lu H, Wang M, Zhang T, Chen H, Wu H: Burden of sleep disturbances and associated risk factors: A cross-sectional survey among HIV-infected persons on antiretroviral therapy across China. Sci Rep; 2017 Jun 16;7(1):3657
HIV InSite. treatment guidelines - Adherence to HIV Antiretroviral Therapy .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study evaluated the prevalence and factors associated with sleep disturbance in a large cohort of HIV-infected patients across China.
  • A cross-sectional study was conducted among HIV-infected patients on antiretroviral therapy at 20 AIDS clinics.
  • 4103 patients had complete data for analysis.
  • Sleep disturbances were observed in 43.1% of patients.
  • Health workers may consider routinely assessing sleep disturbances among HIV-infected patients, especially in the first three months after HIV diagnosis, and referring for mental health services, which may positively impact adherence to treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Neurophysiol. 2012 Dec;123(12):2402-5 [22727712.001]
  • [Cites] J Clin Sleep Med. 2012 Feb 15;8(1):67-75 [22334812.001]
  • [Cites] Front Psychol. 2016 Aug 08;7:1126 [27551270.001]
  • [Cites] Sleep. 1991 Dec;14(6):540-5 [1798888.001]
  • [Cites] Psychosom Med. 2005 Mar-Apr;67(2):260-9 [15784792.001]
  • [Cites] Sleep. 2008 Dec;31(12):1655-62 [19090321.001]
  • [Cites] Am J Psychiatry. 1995 Dec;152(12):1776-81 [8526245.001]
  • [Cites] PLoS One. 2013 Nov 25;8(11):e81261 [24282576.001]
  • [Cites] J Psychosom Res. 2012 Jun;72(6):439-42 [22656440.001]
  • [Cites] J Assoc Nurses AIDS Care. 2016 Jan-Feb;27(1):5-16 [26547298.001]
  • [Cites] J Int AIDS Soc. 2014 Nov 02;17(4 Suppl 3):19576 [25394083.001]
  • [Cites] AIDS Behav. 2013 Oct;17(8):2808-15 [23299876.001]
  • [Cites] Clin Infect Dis. 2012 Nov 15;55(10):1429-30; author reply 1430-1 [22893581.001]
  • [Cites] AIDS Care. 2016;28(4):465-70 [26689341.001]
  • [Cites] Sleep. 2012 Oct 01;35(10):1367-75 [23024435.001]
  • [Cites] J Assoc Nurses AIDS Care. 2014 Nov-Dec;25(6):638-45 [24759056.001]
  • [Cites] Sleep Med. 2006 Mar;7(2):123-30 [16459140.001]
  • [Cites] J Assoc Nurses AIDS Care. 2013 Jan-Feb;24(1 Suppl):S72-85 [23290379.001]
  • [Cites] Nat Rev Neurosci. 2009 Mar;10(3):199-210 [19209176.001]
  • [Cites] AIDS Behav. 2016 Feb;20(2):339-44 [26271816.001]
  • [Cites] AIDS. 1995 Sep;9(9):1043-50 [8527076.001]
  • [Cites] Psychoneuroendocrinology. 2013 Nov;38(11):2647-53 [23850225.001]
  • [Cites] Holist Nurs Pract. 1996 Jul;10(4):33-43 [8717996.001]
  • [Cites] AIDS Patient Care STDS. 2011 Sep;25(9):517-24 [21770763.001]
  • [Cites] Am J Psychiatry. 1992 Apr;149(4):514-20 [1554037.001]
  • [Cites] Clin Infect Dis. 2004 Feb 1;38(3):430-2 [14727217.001]
  • [Cites] AIDS Rev. 2014 Jan-Mar;16(1):3-13 [24522778.001]
  • [Cites] J Assoc Nurses AIDS Care. 2015 Jul-Aug;26(4):454-63 [26066696.001]
  • [Cites] Int J Nurs Stud. 2012 Jan;49(1):102-8 [21924421.001]
  • [Cites] J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):609-16 [23722610.001]
  • [Cites] Sleep. 1999 May 1;22 Suppl 2:S347-53 [10394606.001]
  • [Cites] Sleep. 2011 Dec 01;34(12):1723-6 [22131611.001]
  • [Cites] Clin Infect Dis. 2012 May;54(10):1485-94 [22431801.001]
  • [Cites] AIDS Care. 2016;28 Suppl 1:124-31 [26886415.001]
  • [Cites] HIV Med. 2006 May;7(4):243-7 [16630036.001]
  • [Cites] Arq Neuropsiquiatr. 2008 Dec;66(4):817-20 [19099118.001]
  • [Cites] Clin Infect Dis. 2015 Feb 1;60(3):473-80 [25362201.001]
  • [Cites] PLoS One. 2014 Jun 10;9(6):e98962 [24915530.001]
  • [Cites] AIDS Patient Care STDS. 2016 Feb;30(2):70-7 [26784360.001]
  • [Cites] J Assoc Nurses AIDS Care. 2001 Jan-Feb;12(1):17-22 [11211669.001]
  • [Cites] J Affect Disord. 2014;167:93-7 [24953480.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 1;28(4):399-400 [11707679.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Nov 1;19(3):260-5 [9803968.001]
  • [Cites] Sleep Med. 2015 Aug;16(8):901-7 [26188954.001]
  • [Cites] Lancet HIV. 2014 Oct;1(1):e32-40 [26423814.001]
  • [Cites] Neurol Res Int. 2014;2014:298703 [24876959.001]
  • [Cites] Psychiatry Res. 1989 May;28(2):193-213 [2748771.001]
  • [Cites] Psychiatriki. 2010 Oct-Dec;21(4):279-86 [21914610.001]
  • [Cites] JAMA. 1989 Sep 15;262(11):1479-84 [2769898.001]
  • [Cites] JAMA. 1988 Aug 19;260(7):922 [3398189.001]
  • [Cites] Sleep Med Rev. 2016 Feb;25:52-73 [26163057.001]
  • [Cites] Asian J Psychiatr. 2016 Aug;22:182-9 [26617385.001]
  • (PMID = 28623361.001).
  • [ISSN] 2045-2322
  • [Journal-full-title] Scientific reports
  • [ISO-abbreviation] Sci Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


17. Budin-Ljøsne I, Teare HJ, Kaye J, Beck S, Bentzen HB, Caenazzo L, Collett C, D'Abramo F, Felzmann H, Finlay T, Javaid MK, Jones E, Katić V, Simpson A, Mascalzoni D: Dynamic Consent: a potential solution to some of the challenges of modern biomedical research. BMC Med Ethics; 2017 Jan 25;18(1):4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: An interdisciplinary workshop jointly organised by the University of Oxford and the COST Action CHIP ME gathered clinicians, researchers, ethicists, lawyers, research participants and patient representatives to discuss experiences of using Dynamic Consent, and how such use may facilitate the conduct of specific research tasks.
  • [MeSH-major] Biomedical Research / methods. Data Collection / methods. Informed Consent. Professional-Patient Relations
  • [MeSH-minor] Communication. Ethics, Research. Follow-Up Studies. Humans. Information Dissemination. Patient Selection. Research Design. Research Personnel. Research Subjects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nurs Sci Q. 2011 Apr;24(2):146-51 [21471039.001]
  • [Cites] Orphanet J Rare Dis. 2016 Nov 8;11(1):150 [27825362.001]
  • [Cites] Public Health Genomics. 2015 ;18(3):160-72 [25790760.001]
  • [Cites] Am J Bioeth. 2015 ;15(9):34-42 [26305750.001]
  • [Cites] BMC Med Ethics. 2016 Aug 24;17(1):51 [27553007.001]
  • [Cites] BMC Med Genomics. 2013 May 23;6:19 [23702358.001]
  • [Cites] J Epidemiol Community Health. 2015 Nov;69(11):1125-8 [25669218.001]
  • [Cites] Appl Transl Genom. 2012 Dec 1;1:25-29 [24772384.001]
  • [Cites] Nat Rev Genet. 2012 Apr 03;13(5):371-6 [22473380.001]
  • [Cites] Med Health Care Philos. 2006;9(1):81-6 [16645800.001]
  • [Cites] Tidsskr Nor Laegeforen. 2015 Dec 01;135(22):2031-2 [26627287.001]
  • [Cites] PLoS Med. 2008 Sep 16;5(9):e192 [18798689.001]
  • [Cites] BMJ Open. 2012 Jan 06;2(1):e000496 [22228729.001]
  • [Cites] Nat Rev Genet. 2008 May;9(5):406-11 [18379574.001]
  • [Cites] BMJ. 2014 Feb 05;348:g1294 [24500352.001]
  • [Cites] J Transl Med. 2015 Nov 05;13:348 [26541195.001]
  • [Cites] Nature. 2015 Oct 15;526(7573):361-70 [26469047.001]
  • [Cites] J Biomed Inform. 2013 Jun;46(3):541-62 [23305810.001]
  • [Cites] Contemp Clin Trials. 2011 May;32(3):353-62 [21276876.001]
  • [Cites] J Clin Epidemiol. 1999 Dec;52(12):1143-56 [10580777.001]
  • [Cites] Public Health Genomics. 2015;18(1):26-39 [25359560.001]
  • [Cites] Cureus. 2016 Mar 16;8(3):e535 [27096135.001]
  • [Cites] Stroke. 2015 Aug;46(8):2232-7 [26185186.001]
  • [Cites] J Adv Nurs. 2008 Apr;62(1):107-15 [18352969.001]
  • [Cites] Public Health Genomics. 2011;14(6):319-24 [21430368.001]
  • [Cites] BMC Med Res Methodol. 2014 Jan 23;14:10 [24456229.001]
  • [Cites] AJOB Prim Res. 2012 Jul 1;3(3):3-11 [23493836.001]
  • [Cites] Nat Biotechnol. 2016 Apr;34(4):377-9 [26939011.001]
  • [Cites] Eur J Cancer Care (Engl). 2016 Aug 10;:null [27507437.001]
  • [Cites] Am J Med Genet A. 2012 Jun;158A(6):1310-9 [22532433.001]
  • [Cites] Genet Med. 2015 Mar;17(3):226-33 [25144889.001]
  • [Cites] BMC Med Ethics. 2003 Jan 03;4:E1 [12513704.001]
  • [Cites] Lancet Oncol. 2006 Mar;7(3):266-9 [16510336.001]
  • [Cites] J Med Internet Res. 2016 Apr 15;18(4):e66 [27083521.001]
  • [Cites] Genet Med. 2010 Aug;12(8):486-95 [20535021.001]
  • [Cites] Contemp Clin Trials. 2013 Sep;36(1):25-31 [23747986.001]
  • [Cites] Genome Med. 2014 Feb 28;6(2):10 [24713084.001]
  • [Cites] Bioethics. 2016 Sep;30(7):471-8 [26990222.001]
  • [Cites] Life Sci Soc Policy. 2015;11:3 [26085313.001]
  • [Cites] BMC Med Ethics. 2013 Jul 23;14:28 [23879694.001]
  • [Cites] J Pers Med. 2016 Jun 09;6(2):null [27294961.001]
  • [Cites] JMIR Med Inform. 2015 Jan 13;3(1):e3 [25586934.001]
  • [Cites] Am J Bioeth. 2015;15(9):44-6 [26305752.001]
  • [Cites] EGEMS (Wash DC). 2016 Mar 31;4(2):1207 [27141520.001]
  • [Cites] Eur J Hum Genet. 2015 Feb;23(2):141-6 [24801761.001]
  • [Cites] Eur J Hum Genet. 2013 Sep;21(9):897-902 [23299918.001]
  • [Cites] Eur J Hum Genet. 2016 Oct;24(10):1403-8 [27049302.001]
  • [Cites] Genome Biol. 2012 May 29;13(5):158 [22647613.001]
  • [Cites] Pediatrics. 2014 Apr;133(4):690-7 [24616359.001]
  • [Cites] J Empir Res Hum Res Ethics. 2010 Sep;5(3):9-16 [20831417.001]
  • [Cites] Life Sci Soc Policy. 2014;10:16 [26573981.001]
  • [Cites] J Med Ethics. 2005 Jul;31(7):385-92 [15994356.001]
  • [Cites] J Med Ethics. 2009 Feb;35(2):125-9 [19181887.001]
  • [Cites] BMC Med Ethics. 2015 Sep 09;16:60 [26354520.001]
  • [Cites] Nat Rev Drug Discov. 2016 Nov;15(11):731-732 [27444223.001]
  • [Cites] Eur J Hum Genet. 2010 Nov;18(11):1261-4 [20648060.001]
  • (PMID = 28122615.001).
  • [ISSN] 1472-6939
  • [Journal-full-title] BMC medical ethics
  • [ISO-abbreviation] BMC Med Ethics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Biobank / Clinical research / Clinical trials / Dynamic consent / Ethics / Participant engagement / Research communication / Software tools
  •  go-up   go-down


18. Naseem R, Adam AM, Khan F, Dossal A, Khan I, Khan A, Paul H, Jawed H, Aslam A, Syed FM, Niazi MA, Nadeem S, Khan A, Zia A, Arshad MH: Prevalence and characteristics of resistant hypertensive patients in an Asian population. Indian Heart J; 2017 Jul - Aug;69(4):442-446

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and characteristics of resistant hypertensive patients in an Asian population.
  • These patients are subjected to a higher risk of developing hypertensive complications.
  • The objective of our study was to evaluate the prevalence and determinants of resistant hypertension in an Asian cohort of hypertensive patients.
  • METHODS: This cross-sectional study was carried out among hypertensive patients visiting a tertiary care hospital in Karachi from September-December 2015.
  • Patient data and characteristics were recorded using a pre-coded questionnaire.
  • Pearson's chi-square test was used to analyze statistical differences between hypertensive patients and related factors.
  • RESULTS: A total of 515 patients were included in the study.
  • Overall, 12% of the total patients (n=62) were resistant hypertensives and 25% (n=129) had pseudo-resistant hypertension.
  • Resistant patients were more often females, older and had a higher body mass index (all P<0.001).
  • Prevalence of comorbid conditions, including diabetes (p=0.33), hyperlipidemia (p=0.46), and chronic kidney disease (p=0.23), was not significantly higher in patients with resistant hypertension.
  • CONCLUSION: Nearly one in ten hypertensive patients had true resistant hypertension, and twenty-five percent of patients had pseudo-resistance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017. Published by Elsevier B.V.
  • [Cites] Hypertension. 2000 Sep;36(3):461-5 [10988282.001]
  • [Cites] J Hypertens. 2001 Dec;19(12):2271-7 [11725173.001]
  • [Cites] JAMA. 2003 Apr 23-30;289(16):2073-82 [12709465.001]
  • [Cites] BMC Res Notes. 2013 Sep 21;6:373 [24053215.001]
  • [Cites] Hypertension. 2002 Nov;40(5):604-8; discussion 601-3 [12411450.001]
  • [Cites] Hypertension. 2005 Sep;46(3):500-7 [16103274.001]
  • [Cites] Hypertension. 2000 Oct;36(4):594-9 [11040241.001]
  • [Cites] Cochrane Database Syst Rev. 2013 Apr 30;(4):CD004937 [23633321.001]
  • [Cites] Int J Antimicrob Agents. 2005 Jul;26(1):56-61 [15961289.001]
  • [Cites] Rev Esp Cardiol (Engl Ed). 2014 Apr;67(4):270-6 [24774589.001]
  • [Cites] Am J Hypertens. 2004 Oct;17(10):904-10 [15485752.001]
  • [Cites] Yonsei Med J. 2015 Sep;56(5):1258-65 [26256968.001]
  • [Cites] Br J Gen Pract. 2010 Jun;60(575):449-50 [20529498.001]
  • [Cites] J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404 [12461301.001]
  • [Cites] JAMA. 1981 Mar 27;245(12):1225-9 [7206111.001]
  • [Cites] Hypertens Res. 2012 Jun;35(6):574-81 [22476227.001]
  • [Cites] Hypertension. 1988 Feb;11(2 Pt 2):I229-32 [2894358.001]
  • [Cites] JAMA. 2003 Jul 9;290(2):199-206 [12851274.001]
  • [Cites] Circulation. 2011 Aug 30;124(9):1046-58 [21824920.001]
  • [Cites] Arq Bras Cardiol. 2007 Jun;88(6):683-92 [17664996.001]
  • [Cites] Hypertension. 2003 Mar;41(3 Pt 2):625-33 [12623970.001]
  • [Cites] Circulation. 2008 Jun 24;117(25):e510-26 [18574054.001]
  • [Cites] J Hypertens. 2013 Oct;31(10):2018-24 [23838657.001]
  • [Cites] JAMA. 1988 May 6;259(17):2561-5 [3357230.001]
  • [Cites] Curr Hypertens Rep. 2016 Aug;18(8):62 [27372446.001]
  • [Cites] J Clin Hypertens (Greenwich). 2008 Mar;10(3):239-44 [18326968.001]
  • [Cites] J Community Health. 2014 Aug;39(4):732-6 [24452406.001]
  • [Cites] Clin Exp Hypertens. 2013;35(6):412-7 [23148480.001]
  • [Cites] J Hypertens. 1999 Jan;17(1):61-6 [10100095.001]
  • [Cites] J Hum Hypertens. 1993 Dec;7(6):581-3 [8114053.001]
  • [Cites] Arch Intern Med. 2001 Feb 26;161(4):589-93 [11252120.001]
  • [Cites] Eur J Heart Fail. 2005 Jan;7(1):5-17 [15642526.001]
  • [Cites] Lancet. 2005 Oct 1;366(9492):1197-209 [16198769.001]
  • [Cites] Annu Rev Public Health. 2006;27:465-90 [16533126.001]
  • [Cites] Ann Intern Med. 1987 Nov;107(5):628-35 [2889416.001]
  • [Cites] Hypertension. 2011 Jun;57(6):1076-80 [21502568.001]
  • [Cites] Mayo Clin Proc. 2013 Oct;88(10):1099-107 [24079679.001]
  • [Cites] Circulation. 2012 Apr 3;125(13):1635-42 [22379110.001]
  • [Cites] Patient Educ Couns. 2005 Jul;58(1):63-70 [15950838.001]
  • [Cites] CMAJ. 2008 May 20;178(11):1441-9 [18490640.001]
  • [Cites] Circulation. 2000 Jan 25;101(3):329-35 [10645931.001]
  • (PMID = 28822508.001).
  • [ISSN] 0019-4832
  • [Journal-full-title] Indian heart journal
  • [ISO-abbreviation] Indian Heart J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Keywords] NOTNLM ; Pakistan / Prevalence / Resistant hypertension
  •  go-up   go-down


19. Cadilhac DA, Andrew NE, Lannin NA, Middleton S, Levi CR, Dewey HM, Grabsch B, Faux S, Hill K, Grimley R, Wong A, Sabet A, Butler E, Bladin CF, Bates TR, Groot P, Castley H, Donnan GA, Anderson CS, Australian Stroke Clinical Registry Consortium: Quality of Acute Care and Long-Term Quality of Life and Survival: The Australian Stroke Clinical Registry. Stroke; 2017 Apr;48(4):1026-1032
MedlinePlus Health Information. consumer health - Stroke.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of Acute Care and Long-Term Quality of Life and Survival: The Australian Stroke Clinical Registry.
  • Multivariable regression was used to determine associations between 3 interventions: received acute stroke unit (ASU) care and in various combinations with prescribed antihypertensive medication at discharge, provision of a discharge care plan, and outcomes of survival and HRQoL (EuroQoL 5-dimensional questionnaire visual analogue scale) at 180 days, by stroke type.
  • An assessment was also made of outcomes related to the number of processes patients received.
  • Cumulative benefits on outcomes related to the number of care processes received by patients.
  • ASU care was associated with a reduced likelihood of death (hazard ratio, 0.49; 95% confidence interval, 0.43-0.56) and better HRQoL (coefficient, 21.34; 95% confidence interval, 15.50-27.18) within 180 days.
  • For those discharged from hospital, receiving ASU+antihypertensive medication provided greater 180-day survival (hazard ratio, 0.45; 95% confidence interval, 0.38-0.52) compared with ASU care alone (hazard ratio, 0.64; 95% confidence interval, 0.54-0.76).
  • HRQoL gains were greatest for patients with intracerebral hemorrhage who received care bundles involving discharge processes (range of increase, 11%-19%).
  • CONCLUSIONS: Patients with stroke who receive best practice recommended hospital care have improved long-term survival and HRQoL.
  • [MeSH-major] Critical Care / standards. Outcome Assessment (Health Care) / standards. Patient Discharge / standards. Practice Guidelines as Topic / standards. Quality Indicators, Health Care / standards. Quality of Life. Registries / statistics & numerical data. Stroke / mortality. Stroke / therapy

  • MedlinePlus Health Information. consumer health - Critical Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • (PMID = 28258253.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; hospitals / quality of health care / quality of life / stroke / survival
  •  go-up   go-down


20. Ferguson S, Ahmad S, Chen Y, Ferreira C, Islam M, Keeling V, Lau A, Jin H: SU-F-T-143: Implementation of a Correction-Based Output Model for a Compact Passively Scattered Proton Therapy System. Med Phys; 2016 Jun;43(6):3494-3495

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A previously published output prediction model (Sahoo et al, Med Phys, 35, 5088-5097, 2008) was commissioned for our Mevion S250 proton therapy system.
  • To minimize fluence perturbation, scattered dose from range compensator and patient was not considered.
  • However, great care should be taken when the field-size is less than 5×5 cm<sup>2</sup> where a direct output measurement is required due to substantial output change by irregular block shape.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2016 American Association of Physicists in Medicine.
  • (PMID = 28047467.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Computer modeling / Interpolation / Proton therapy
  •  go-up   go-down


21. Funk M, Fennie KP, Stephens KE, May JL, Winkler CG, Drew BJ, PULSE Site Investigators: Association of Implementation of Practice Standards for Electrocardiographic Monitoring With Nurses' Knowledge, Quality of Care, and Patient Outcomes: Findings From the Practical Use of the Latest Standards of Electrocardiography (PULSE) Trial. Circ Cardiovasc Qual Outcomes; 2017 Feb;10(2)
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of Implementation of Practice Standards for Electrocardiographic Monitoring With Nurses' Knowledge, Quality of Care, and Patient Outcomes: Findings From the Practical Use of the Latest Standards of Electrocardiography (PULSE) Trial.
  • We evaluated implementation of American Heart Association practice standards for ECG monitoring on nurses' knowledge, quality of care, and patient outcomes.
  • Nurses' knowledge (N=3013 nurses) was measured by a validated 20-item online test, quality of care related to ECG monitoring (N=4587 patients) by on-site observation, and patient outcomes (mortality, in-hospital myocardial infarction, and not surviving a cardiac arrest; N=95 884 hospital admissions) by review of administrative, laboratory, and medical record data.
  • For most measures of quality of care (accurate electrode placement, accurate rhythm interpretation, appropriate monitoring, and ST-segment monitoring when indicated), the intervention was associated with significant improvement, which was sustained 15 months later.
  • Of the 3 patient outcomes, only in-hospital myocardial infarction declined significantly after the intervention and was sustained.
  • CONCLUSIONS: Online ECG monitoring education and strategies to change practice can lead to improved nurses' knowledge, quality of care, and patient outcomes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • (PMID = 28174175.001).
  • [ISSN] 1941-7705
  • [Journal-full-title] Circulation. Cardiovascular quality and outcomes
  • [ISO-abbreviation] Circ Cardiovasc Qual Outcomes
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT01269736
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL081642
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; electrocardiography / nursing / outcome assessment (health care) / quality of health care / randomized controlled trial
  • [Investigator] Borman B; Calcasola S; Carey M; Currie L; Davis L; Fitzpatrick E; Fleischman R; Hawkins D; Hazlewood E; Henry R; Honess C; Kalowes P; Ann Kearns S; Leeper B; Liggett J; Lusardi P; Lynn C; Man M; McCauley K; Hing M; Pang A; Parkosewich J; Phillips J; Robinson A; Salazar N; Sandau K; Piper Sandoval C; Sangkachand P; Shaffer R; Sherrard H; Smith M; Stamm R; Strang V; Tee N; Wells K; White P
  •  go-up   go-down


22. Arabi YM, Al-Omari A, Mandourah Y, Al-Hameed F, Sindi AA, Alraddadi B, Shalhoub S, Almotairi A, Al Khatib K, Abdulmomen A, Qushmaq I, Mady A, Solaiman O, Al-Aithan AM, Al-Raddadi R, Ragab A, Al Mekhlafi GA, Al Harthy A, Kharaba A, Ahmadi MA, Sadat M, Mutairi HA, Qasim EA, Jose J, Nasim M, Al-Dawood A, Merson L, Fowler R, Hayden FG, Balkhy HH, Saudi Critical Care Trial Group: Critically Ill Patients With the Middle East Respiratory Syndrome: A Multicenter Retrospective Cohort Study. Crit Care Med; 2017 10;45(10):1683-1695

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Critically Ill Patients With the Middle East Respiratory Syndrome: A Multicenter Retrospective Cohort Study.
  • OBJECTIVES: To describe patient characteristics, clinical manifestations, disease course including viral replication patterns, and outcomes of critically ill patients with severe acute respiratory infection from the Middle East respiratory syndrome and to compare these features with patients with severe acute respiratory infection due to other etiologies.
  • SETTING: Patients admitted to ICUs in 14 Saudi Arabian hospitals.
  • PATIENTS: Critically ill patients with laboratory-confirmed Middle East respiratory syndrome severe acute respiratory infection (n = 330) admitted between September 2012 and October 2015 were compared to consecutive critically ill patients with community-acquired severe acute respiratory infection of non-Middle East respiratory syndrome etiology (non-Middle East respiratory syndrome severe acute respiratory infection) (n = 222).
  • MEASUREMENTS AND MAIN RESULTS: Although Middle East respiratory syndrome severe acute respiratory infection patients were younger than those with non-Middle East respiratory syndrome severe acute respiratory infection (median [quartile 1, quartile 3] 58 yr [44, 69] vs 70 [52, 78]; p < 0.001), clinical presentations and comorbidities overlapped substantially.
  • Patients with Middle East respiratory syndrome severe acute respiratory infection had more severe hypoxemic respiratory failure (PaO2/FIO2: 106 [66, 160] vs 176 [104, 252]; p < 0.001) and more frequent nonrespiratory organ failure (nonrespiratory Sequential Organ Failure Assessment score: 6 [4, 9] vs 5 [3, 7]; p = 0.002), thus required more frequently invasive mechanical ventilation (85.2% vs 73.0%; p < 0.001), oxygen rescue therapies (extracorporeal membrane oxygenation 5.8% vs 0.9%; p = 0.003), vasopressor support (79.4% vs 55.0%; p < 0.001), and renal replacement therapy (48.8% vs 22.1%; p < 0.001).
  • CONCLUSIONS: Substantial overlap exists in the clinical presentation and comorbidities among patients with Middle East respiratory syndrome severe acute respiratory infection from other etiologies; therefore, a high index of suspicion combined with diagnostic testing is essential component of severe acute respiratory infection investigation for at-risk patients.
  • [MeSH-minor] Adult. Age Factors. Aged. Alanine Transaminase / analysis. Aspartate Aminotransferases / analysis. Cohort Studies. Community-Acquired Infections / epidemiology. Community-Acquired Infections / therapy. Extracorporeal Membrane Oxygenation / statistics & numerical data. Female. Humans. Hypoxia / epidemiology. Intensive Care Units. Leukopenia / epidemiology. Male. Middle Aged. Renal Insufficiency / epidemiology. Renal Insufficiency / therapy. Renal Replacement Therapy / statistics & numerical data. Respiration, Artificial / statistics & numerical data. Respiratory Insufficiency / epidemiology. Respiratory Tract Infections / epidemiology. Respiratory Tract Infections / therapy. Retrospective Studies. Saudi Arabia / epidemiology. Shock / epidemiology. Shock / therapy. Thrombocytopenia / epidemiology. Vasoconstrictor Agents / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28787295.001).
  • [ISSN] 1530-0293
  • [Journal-full-title] Critical care medicine
  • [ISO-abbreviation] Crit. Care Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vasoconstrictor Agents; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  • [Investigator] Arabi Y; Aldawood A; Balkhy H; Al Ahmadi M; Sadat M; Al Mutairi H; Al Qasim E; Deeb A; Aldorzi H; Jose J; Naseem M; Shihab M; Abdukahil SA; Toledo A; Afesh L; Sohail MR; Al Shankeety O; Al Motairi A; Almekhlafi GA; Mandourah Y; Hassan S; Alwan A; Cabal R; Mahamed RE; Harbi KM; Ala Haidary A; Al-Harthy A; Mady AF; Ramadan OE; Rana MA; Huwait BR; Al-Odat MA; Al-Atreeby WT; Solaiman O; Mommin AA; Fares M; Barry M; Al Omari A; Al-Hameed F; Al Refai J; Shalhoub S; Alraddadi BM; Alrehaili RE; Batawi S; Sindi A; Al-Raddadi R; Rajab A; Shabouni O; Housa AM; Turkistani AA; Almarashi AA; Sarraj AA; Own SA; AlJeaid SM; Baeshen WA; Al Khatib K; Badr H; Azzo M; Alaithan A; Kharaba A; Noor N; Merson L; Fowler R; Hayden F
  •  go-up   go-down


23. Chanpimol S, Seamon B, Hernandez H, Harris-Love M, Blackman MR: Using Xbox kinect motion capture technology to improve clinical rehabilitation outcomes for balance and cardiovascular health in an individual with chronic TBI. Arch Physiother; 2017;7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Further studies appear warranted to determine the potential therapeutic utility of commercial VR games in this patient population.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 2012 Nov 13;79(20):2056-60 [23115212.001]
  • [Cites] Brain Inj. 2002 Sep;16(9):789-97 [12217204.001]
  • [Cites] Gait Posture. 2010 Oct;32(4):641-4 [20888770.001]
  • [Cites] Disabil Rehabil. 2012;34(9):788-94 [22149161.001]
  • [Cites] Disabil Rehabil. 2001 Jan 15;23(1):1-8 [11213316.001]
  • [Cites] J Sci Med Sport. 2016 Mar;19(3):267-271 [25824058.001]
  • [Cites] Phys Ther. 2016 Dec;96(12 ):1955-1964 [27417165.001]
  • [Cites] J Neurol Phys Ther. 2006 Jun;30(2):74-81 [16796772.001]
  • [Cites] Cyberpsychol Behav Soc Netw. 2013 May;16(5):385-401 [23713844.001]
  • [Cites] Disabil Rehabil. 2017 Apr;39(7):721-726 [27008348.001]
  • [Cites] Neurorehabil Neural Repair. 2014 Jan;28(1):56-65 [23897906.001]
  • [Cites] J Rehabil Med. 2011 May;43(6):527-33 [21533334.001]
  • [Cites] Disabil Rehabil Assist Technol. 2012 May;7(3):205-10 [22117107.001]
  • [Cites] Brain Inj. 2014;28(11):1417-24 [24946127.001]
  • [Cites] J Vasc Interv Neurol. 2016 Oct;9(2):21-29 [27829967.001]
  • [Cites] Physiotherapy. 2014 Jun;100(2):162-8 [24703891.001]
  • [Cites] Clin Rehabil. 2010 Nov;24(11):979-87 [20719820.001]
  • [Cites] Brain Inj. 2013;27(12):1402-8 [24102295.001]
  • [Cites] Arch Gen Psychiatry. 1973 Sep;29(3):319-25 [4724141.001]
  • [Cites] J Phys Ther Sci. 2015 Jul;27(7):2057-60 [26311925.001]
  • [Cites] J Phys Ther Sci. 2015 Sep;27(9):2863-5 [26504312.001]
  • [Cites] J Vestib Res. 2000;10(2):99-105 [10939685.001]
  • [Cites] J Rehabil Res Dev. 2012;49(7):985-94 [23341274.001]
  • [Cites] Brain Inj. 1997 Sep;11(9):661-75 [9376834.001]
  • [Cites] Arch Phys Med Rehabil. 2001 Feb;82(2):174-82 [11239307.001]
  • [Cites] NeuroRehabilitation. 2013;32(3):463-72 [23648601.001]
  • [Cites] Acta Med Port. 2012 Nov-Dec;25(6):414-21 [23534593.001]
  • [Cites] Int J Environ Res Public Health. 2013 Oct 31;10(11):5697-710 [24185843.001]
  • [Cites] Hum Mov Sci. 2014 Feb;33:404-18 [24444657.001]
  • [Cites] Games Health J. 2015 Feb;4(1):31-7 [26181678.001]
  • [Cites] J Vestib Res. 1996 Sep-Oct;6(5):343-53 [9004971.001]
  • [Cites] Arch Phys Med Rehabil. 2015 Mar;96(3):418-425.e2 [25448245.001]
  • [Cites] Brain Inj. 2014;28(4):486-95 [24702281.001]
  • [Cites] Stud Health Technol Inform. 2012;181:108-12 [22954838.001]
  • [Cites] J Head Trauma Rehabil. 2010 May-Jun;25(3):173-83 [20473091.001]
  • [Cites] J Athl Train. 2011 Nov-Dec;46(6):600-6 [22488184.001]
  • [Cites] Respir Care. 2015 Aug;60(8):1172-9 [25899477.001]
  • [Cites] Games Health J. 2016 Feb;5(1):68-74 [26625306.001]
  • [Cites] Parkinsonism Relat Disord. 2005 Jan;11(1):19-24 [15619458.001]
  • [Cites] Phys Ther. 2015 Mar;95(3):426-40 [25256741.001]
  • [Cites] J Rehabil Res Dev. 2007;44(7):975-82 [18075954.001]
  • (PMID = 28824816.001).
  • [ISSN] 2057-0082
  • [Journal-full-title] Archives of physiotherapy
  • [ISO-abbreviation] Arch Physiother
  • [Language] eng
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR001409
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Intervention / Physical therapy / Traumatic brain injury / Virtual reality / Xbox kinect
  •  go-up   go-down


24. Højgaard L, Löwenberg B, Selby P, Lawler M, Banks I, Law K, Albreht T, Armand JP, Barbacid M, Barzach M, Bergh J, Cameron D, Conte P, de Braud F, de Gramont A, De Lorenzo F, Diehl V, Diler S, Erdem S, Geissler J, Gore-Booth J, Henning G, Horgan D, Jassem J, Johnson P, Kaasa S, Kapitein P, Karjalainen S, Kelly J, Kienesberger A, La Vecchia C, Lacombe D, Lindahl T, Luzzatto L, Malby R, Mastris K, Meunier F, Murphy M, Naredi P, Nurse P, Oliver K, Pearce J, Pelouchov J, Piccart M, Pinedo B, Spurrier-Bernard G, Sullivan R, Tabernero J, Van de Velde C, van Herk B, Vedsted P, Waldmann A, Weller D, Wilking N, Wilson R, Yared W, Zielinski C, Zur Hausen H, Le Chevalier T, Johnston P: The European Cancer Patient's Bill of Rights, update and implementation 2016. ESMO Open; 2016;1(6):e000127

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The European Cancer Patient's Bill of Rights, update and implementation 2016.
  • In this implementation phase of the European Cancer Patient's Bill of Rights (BoR), we confirm the following three patient-centred principles that underpin this initiative:The right of every European citizen to receive the most accurate information and to be proactively involved in his/her care.The right of every European citizen to optimal and timely access to a diagnosis and to appropriate specialised care, underpinned by research and innovation.The right of every European citizen to receive care in health systems that ensure the best possible cancer prevention, the earliest possible diagnosis of their cancer, improved outcomes, patient rehabilitation, best quality of life and affordable health care.
  • The vision of 70% long-term survival for patients with cancer in 2035, promoting cancer prevention and cancer control and the associated progress in ensuring good patient experience and quality of life.Establish the major mechanisms to underpin its delivery. (1) The systematic and rigorous sharing of best practice between and across European cancer healthcare systems and (2) the active promotion of Research and Innovation focused on improving outcomes;.
  • (3) Improving access to new and established cancer care by sharing best practice in the development, approval, procurement and reimbursement of cancer diagnostic tests and treatments.Work with other organisations to bring into being a Europe based centre that will (1) systematically identify, evaluate and validate and disseminate best practice in cancer management for the different countries and regions and (2) promote Research and Innovation and its translation to maximise its impact to improve outcomes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncologist. 2014 Mar;19(3):217-24 [24493667.001]
  • [Cites] Lancet Oncol. 2014 Mar;15(3):258-60 [24503530.001]
  • [Cites] Oncologist. 2014 Mar;19(3):225-7 [24567282.001]
  • (PMID = 28848664.001).
  • [ISSN] 2059-7029
  • [Journal-full-title] ESMO open
  • [ISO-abbreviation] ESMO Open
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Keywords] NOTNLM ; Bill of Rights / Cancer Concord / Cancer outcomes
  •  go-up   go-down


25. Fink AM, Bahlo J, Robrecht S, Al-Sawaf O, Aldaoud A, Hebart H, Jentsch-Ullrich K, Dörfel S, Fischer K, Wendtner CM, Nösslinger T, Ghia P, Bosch F, Kater AP, Döhner H, Kneba M, Kreuzer KA, Tausch E, Stilgenbauer S, Ritgen M, Böttcher S, Eichhorst B, Hallek M: Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol; 2017 Oct;4(10):e475-e486

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The combined use of genetic markers and detectable minimal residual disease identifies patients with chronic lymphocytic leukaemia with poor outcome after first-line chemoimmunotherapy.
  • We aimed to assess lenalidomide maintenance therapy in these high-risk patients.
  • METHODS: In this randomised, double-blind, phase 3 study (CLLM1; CLL Maintenance 1 of the German CLL Study Group), patients older than 18 years and diagnosed with immunophenotypically confirmed chronic lymphocytic leukaemia with active disease, who responded to chemoimmunotherapy 2-5 months after completion of first-line therapy and who were assessed as having a high risk for an early progression with at least a partial response after four or more cycles of first-line chemoimmunotherapy, were eligible if they had high minimal residual disease levels or intermediate levels combined with an unmutated IGHV gene status or TP53 alterations.
  • Patients were randomly assigned (2:1) to receive either lenalidomide (5 mg) or placebo.
  • FINDINGS: Between July 5, 2012, and March 15, 2016, 468 previously untreated patients with chronic lymphocytic leukaemia were screened for the study; 379 (81%) were not eligible.
  • Recruitment was closed prematurely due to poor accrual after 89 of 200 planned patients were randomly assigned: 60 (67%) enrolled patients were assigned to the lenalidomide group and 29 (33%) to the placebo group, of whom 56 (63%) received lenalidomide and 29 (33%) placebo, with a median of 11·0 (IQR 4·5-20·5) treatment cycles at data cutoff.
  • The most frequent adverse events were skin disorders (35 patients [63%] in the lenalidomide group vs eight patients [28%] in the placebo group), gastrointestinal disorders (34 [61%] vs eight [28%]), infections (30 [54%] vs 19 [66%]), haematological toxicity (28 [50%] vs five [17%]), and general disorders (28 [50%] vs nine [31%]).
  • One fatal adverse event was reported in each of the treatment groups (one [2%] patient with fatal acute lymphocytic leukaemia in the lenalidomide group and one patient (3%) with fatal multifocal leukoencephalopathy in the placebo group).
  • INTERPRETATION: Lenalidomide is an efficacious maintenance therapy reducing the relative risk of progression in first-line patients with chronic lymphocytic leukaemia who do not achieve minimal residual disease negative disease state following chemoimmunotherapy approaches.
  • The toxicity seems to be acceptable considering the poor prognosis of the eligible patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28916311.001).
  • [ISSN] 2352-3026
  • [Journal-full-title] The Lancet. Haematology
  • [ISO-abbreviation] Lancet Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. Moradi S, Sahebi Z, Ebrahim Valojerdi A, Rohani F, Ebrahimi H: The association between the number of office visits and the control of cardiovascular risk factors in Iranian patients with type2 diabetes. PLoS One; 2017;12(6):e0179190

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association between the number of office visits and the control of cardiovascular risk factors in Iranian patients with type2 diabetes.
  • INTRODUCTION: Patients with diabetes type2 should receive regular medical care.
  • METHODS: Four hundred and ninety patients with type 2 diabetes mellitus who were followed in a tertiary center were enrolled in this longitudinal study.
  • Patient data were extracted from manual or electronic records.
  • The association between changes in these parameters and the number of patients' office visits per year were not statistically significant.
  • In patients with disease duration less than 5 years, each additional office visits by one visit per year was associated with a decrease in serum total cholesterol by 6.94 mg/dl.
  • The mean number of office visits per year in patients older than 60 years old was more than younger patient (p = 0.001).
  • Yet, these changes were not related to the mean number of patients' office visits per year, which may reflect the poor compliance of patients to treatment regardless of the number of their office visits.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diabetes Care. 2015 Jan;38 Suppl:S33-40 [25537705.001]
  • [Cites] Diabetes Care. 2008 Jan;31(1):81-6 [17934153.001]
  • [Cites] Am J Med. 2013 Sep;126(9 Suppl 1):S38-48 [23953078.001]
  • [Cites] Diabetes Care. 2000 Sep;23(9):1272-7 [10977018.001]
  • [Cites] Diabet Med. 2013 Mar;30(3):338-44 [23075262.001]
  • [Cites] Ann Fam Med. 2006 Jan-Feb;4(1):32-9 [16449394.001]
  • [Cites] Arch Intern Med. 2011 Sep 26;171(17):1542-50 [21949161.001]
  • [Cites] Hypertension. 2010 Jul;56(1):68-74 [20497991.001]
  • [Cites] N Engl J Med. 2005 Aug 4;353(5):487-97 [16079372.001]
  • [Cites] Endocr Pract. 2009 Sep-Oct;15(6):540-59 [19858063.001]
  • [Cites] Diabetes Care. 2004 May;27(5):1047-53 [15111519.001]
  • [Cites] Diabetes Care. 2013 Mar;36(3):543-9 [23193208.001]
  • [Cites] Arch Intern Med. 2000 Nov 27;160(21):3278-85 [11088090.001]
  • [Cites] Eur J Cardiovasc Nurs. 2003 Dec;2(4):323 [14667488.001]
  • [Cites] Diabetes Metab Syndr Obes. 2014 Dec 16;8:1-8 [25565873.001]
  • [Cites] Diabetologia. 2006 Feb;49(2):271-8 [16362814.001]
  • [Cites] J Gen Intern Med. 1997 Sep;12(9):567-80 [9294791.001]
  • [Cites] Int J Circumpolar Health. 2011;70(5):552-63 [22067097.001]
  • [Cites] Diabetes Care. 2010 Jan;33 Suppl 1:S11-61 [20042772.001]
  • [Cites] Pediatrics. 1999 May;103(5 Pt 1):948-51 [10224170.001]
  • [Cites] NCHS Data Brief. 2014 Jul;(161):1-8 [25077512.001]
  • (PMID = 28666031.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Giustiniano E, Procopio F, Costa G, Rocchi L, Ruggieri N, Cantoni S, Zito PC, Gollo Y, Torzilli G, Raimondi F: Serum lactate in liver resection with intermittent Pringle maneuver: the "square-root" shape. J Hepatobiliary Pancreat Sci; 2017 Sep 08;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A total of 133 patients who underwent liver resection were enrolled.
  • More than 76 min of cumulative Pringle Time (cPT) exposed patients to a worse cLac at the end of the resection phase (P < 0.0001).
  • Normal liver may expose the patient to the risk of hyperlactatemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Japanese Society of Hepato-Biliary-Pancreatic Surgery.
  • (PMID = 28884958.001).
  • [ISSN] 1868-6982
  • [Journal-full-title] Journal of hepato-biliary-pancreatic sciences
  • [ISO-abbreviation] J Hepatobiliary Pancreat Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Hepatic resection / Lactate clearance / Pringle maneuver
  •  go-up   go-down


28. Gelfand JM, Bradshaw MJ, Stern BJ, Clifford DB, Wang Y, Cho TA, Koth LL, Hauser SL, Dierkhising J, Vu N, Sriram S, Moses H, Bagnato F, Kaufmann JA, Ammah DJ, Yohannes TH, Hamblin MJ, Venna N, Green AJ, Pawate S: Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series. Neurology; 2017 Oct 13;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Investigators at 6 US centers retrospectively identified patients with CNS sarcoidosis treated with infliximab, including only patients with definite or probable neurosarcoidosis following rigorous exclusion of other causes.
  • RESULTS: Of 66 patients with CNS sarcoidosis (27 definite, 39 probable) treated with infliximab for a median of 1.5 years, the mean age was 47.5 years at infliximab initiation (SD 11.7, range 24-71 years); 56.1% were female; 62.1% were white, 37.0% African American, and 3% Hispanic.
  • Using infliximab doses ranging from 3 to 7 mg/kg every 4-8 weeks, MRI evidence of a favorable treatment response was observed in 82.1% of patients with imaging follow-up (n = 56), with complete remission of active disease in 51.8% and partial MRI improvement in 30.1%; MRI worsened in 1 patient (1.8%).
  • There was clinical improvement in 77.3% of patients, with complete neurologic recovery in 28.8%, partial improvement in 48.5%, clinical stability in 18.2%, worsening in 3%, and 1 lost to follow-up.
  • In 16 patients in remission when infliximab was discontinued, the disease recurred in 9 (56%), typically in the same neuroanatomic location.
  • CONCLUSIONS: Most patients with CNS sarcoidosis treated with infliximab exhibit favorable imaging and clinical treatment responses, including some previously refractory to other immunosuppressive treatments.
  • CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with CNS sarcoidosis infliximab is associated with favorable imaging and clinical responses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Academy of Neurology.
  • (PMID = 29030454.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Smith MA, Weiss JM, Potvien A, Schumacher JR, Gangnon RE, Kim DH, Weeth-Feinstein LA, Pickhardt PJ: Insurance Coverage for CT Colonography Screening: Impact on Overall Colorectal Cancer Screening Rates. Radiology; 2017 Sep;284(3):717-724
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Purpose To compare overall colorectal cancer (CRC) screening rates for patients who were eligible and due for CRC screening and who were with and without insurance coverage for computed tomographic (CT) colonography for CRC screening.
  • This study used longitudinal electronic health record data from 2005 through 2010 for patients managed by one of the largest multispecialty physician groups in the United States.
  • It included 33 177 patients under age 65 who were eligible and due for CRC screening and managed by the participating health system.
  • Results After adjustment, patients who had insurance coverage for CT colonography and were due for CRC screening had a 48% greater likelihood of being screened for CRC by any method compared with those without coverage who were due for CRC screening (HR, 1.48; 95% CI: 1.41, 1.55).
  • Similarly, patients with CT colonography coverage had a greater likelihood of being screened with CT colonography (HR, 8.35; 95% CI: 7.11, 9.82) and with colonoscopy (HR, 1.38; 95% CI: 1.31, 1.45) but not with fecal occult blood test (HR, 1.00; 95% CI: 0.91, 1.10) than those without such insurance coverage.
  • Conclusion Insurance coverage of CT colonography for CRC screening was associated with a greater likelihood of a patient being screened and a greater likelihood of being screened with a test that helps both to detect cancer and prevent cancer from developing (CT colonography or colonoscopy).

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Care. 2008 Oct;46(10):1033-40 [18815524.001]
  • [Cites] Radiology. 2006 Nov;241(2):417-25 [16982816.001]
  • [Cites] J Gen Intern Med. 2009 Nov;24(11):1228-35 [19763699.001]
  • [Cites] J Gen Intern Med. 2008 Feb;23(2):169-74 [18157581.001]
  • [Cites] Lancet Oncol. 2012 Jan;13(1):55-64 [22088831.001]
  • [Cites] J Gen Intern Med. 2012 Oct;27(10 ):1349-60 [22700393.001]
  • [Cites] Am J Gastroenterol. 2004 Jun;99(6):1145-51 [15180739.001]
  • [Cites] Value Health. 2007 Sep-Oct;10(5):415-30 [17888107.001]
  • [Cites] Patient Educ Couns. 2012 Oct;89(1):116-21 [22705250.001]
  • [Cites] J Gen Intern Med. 2012 Sep;27(9):1150-8 [22539065.001]
  • [Cites] Am J Prev Med. 2009 Jul;37(1):8-16 [19442479.001]
  • [Cites] N Engl J Med. 2012 Mar 1;366(9):780-1 [22375967.001]
  • [Cites] Am J Gastroenterol. 2013 Jul;108(7):1159-67 [23670114.001]
  • [Cites] CA Cancer J Clin. 2008 May-Jun;58(3):130-60 [18322143.001]
  • [Cites] WMJ. 2004;103(3):45-8 [15217113.001]
  • [Cites] Med Care. 1998 Jan;36(1):8-27 [9431328.001]
  • [Cites] Arch Intern Med. 2012 Apr 9;172(7):575-82 [22493463.001]
  • [Cites] Stat Med. 2014 Mar 30;33(7):1242-58 [24122911.001]
  • [Cites] J Natl Cancer Inst. 2015 Dec 30;108(2):null [26719225.001]
  • [Cites] J Gen Intern Med. 2005 Jun;20(6):531-5 [15987329.001]
  • [Cites] Am J Gastroenterol. 2014 Jul;109(7):1072-9 [24935273.001]
  • [Cites] J Gen Intern Med. 2012 Oct;27(10):1361-7 [22618581.001]
  • [Cites] Annu Rev Public Health. 1997;18:507-28 [9143729.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2013 Nov 8;62(44):881-8 [24196665.001]
  • [Cites] CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 [24399786.001]
  • [Cites] Patient Educ Couns. 2012 Feb;86(2):137-46 [21640543.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2011 Mar;20(3):509-21 [21239688.001]
  • [Cites] Abdom Radiol (NY). 2017 Apr;42(4):1268-1275 [27864601.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):347-57 [15741571.001]
  • [Cites] Cancer Causes Control. 2008 May;19(4):339-59 [18085415.001]
  • [Cites] AJR Am J Roentgenol. 2012 Jun;198(6):1361-6 [22623549.001]
  • [Cites] AJR Am J Roentgenol. 2010 Nov;195(5):1118-23 [20966316.001]
  • [Cites] Am J Prev Med. 2008 Sep;35(3):194-202 [18619761.001]
  • [Cites] Med Care. 2001 Sep;39(9):934-44 [11502951.001]
  • (PMID = 28696184.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA014520; United States / NCI NIH HHS / CA / R01 CA144835; United States / NCATS NIH HHS / TR / UL1 TR000427
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Dreyer RP, Dharmarajan K, Kennedy KF, Jones PG, Vaccarino V, Murugiah K, Nuti SV, Smolderen KG, Buchanan DM, Spertus JA, Krumholz HM: Sex Differences in 1-Year All-Cause Rehospitalization in Patients After Acute Myocardial Infarction: A Prospective Observational Study. Circulation; 2017 Feb 07;135(6):521-531
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex Differences in 1-Year All-Cause Rehospitalization in Patients After Acute Myocardial Infarction: A Prospective Observational Study.
  • METHODS: We recruited 3536 patients (33% women) ≥18 years of age hospitalized with AMI from 24 US centers into the TRIUMPH study (Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status).
  • Data were obtained by medical record abstraction and patient interviews, and a physician panel adjudicated hospitalizations within the first year after AMI.
  • [MeSH-minor] Acute Disease. Female. Humans. Male. Middle Aged. Patient Readmission. Prospective Studies. Sex Factors

  • Genetic Alliance. consumer health - Myocardial infarction 1.
  • MedlinePlus Health Information. consumer health - Heart Attack.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • [Cites] J Gen Intern Med. 2001 Sep;16(9):606-13 [11556941.001]
  • [Cites] Circulation. 2015 Jul 21;132(3):158-66 [26085455.001]
  • [Cites] Heart. 2009 Jan;95(1):20-6 [18463200.001]
  • [Cites] Stat Methods Med Res. 2013 Jun;22(3):278-95 [21220355.001]
  • [Cites] Circ Cardiovasc Qual Outcomes. 2011 Jul;4(4):467-76 [21772003.001]
  • [Cites] J Health Soc Behav. 1983 Dec;24(4):385-96 [6668417.001]
  • [Cites] Psychosom Med. 2005 Nov-Dec;67(6):879-88 [16314592.001]
  • [Cites] Am Heart J. 2006 Mar;151(3):589-97 [16504619.001]
  • [Cites] Am Heart J. 2008 Feb;155(2):375-81 [18215611.001]
  • [Cites] N Engl J Med. 2013 Jan 10;368(2):100-2 [23301730.001]
  • [Cites] JAMA. 2003 Jul 9;290(2):215-21 [12851276.001]
  • [Cites] Ann Intern Med. 2001 Feb 6;134(3):173-81 [11177329.001]
  • [Cites] PLoS Med. 2014 Sep 30;11(9):e1001737 [25268126.001]
  • [Cites] Circ Cardiovasc Qual Outcomes. 2009 Jan;2(1):33-40 [20031810.001]
  • [Cites] Am J Cardiol. 1994 Dec 15;74(12):1240-4 [7977097.001]
  • [Cites] JAMA Intern Med. 2013 Jun 10;173(11):997-1004 [23471421.001]
  • [Cites] J Am Heart Assoc. 2016 Jan 25;5(1):null [26811163.001]
  • [Cites] JAMA. 2009 Nov 18;302(19):2095-103 [19918088.001]
  • [Cites] Psychosom Med. 2005 Nov-Dec;67(6):869-78 [16314591.001]
  • [Cites] Heart. 2004 May;90(5):523-7 [15084550.001]
  • [Cites] J Am Coll Cardiol. 1995 Feb;25(2):333-41 [7829785.001]
  • [Cites] J Am Coll Cardiol. 2005 Nov 15;46(10):1838-44 [16286168.001]
  • [Cites] J Am Coll Cardiol. 2005 Nov 15;46(10):1845-51 [16286169.001]
  • [Cites] Am Heart J. 2000 Jan;139(1 Pt 1):1-9 [10618555.001]
  • [Cites] N Engl J Med. 1999 Jul 22;341(4):217-25 [10413733.001]
  • [Cites] Circ Cardiovasc Qual Outcomes. 2010 Mar;3(2):143-50 [20160162.001]
  • [Cites] Med Care. 1996 Mar;34(3):220-33 [8628042.001]
  • [Cites] Circulation. 2015 Jun 2;131(22):1971-80 [25862743.001]
  • [Cites] Am J Cardiol. 2006 Aug 1;98(3):282-8 [16860010.001]
  • [Cites] Health Qual Life Outcomes. 2004 May 13;2:24 [15142277.001]
  • [Cites] Arch Intern Med. 2006 Apr 24;166(8):876-83 [16636213.001]
  • [Cites] J Am Heart Assoc. 2015 Nov 03;4(11):null [26534862.001]
  • [Cites] Circ Cardiovasc Qual Outcomes. 2009 Sep;2(5):500-7 [20031883.001]
  • [Cites] Circ Cardiovasc Qual Outcomes. 2014 Jan;7(1):2-4 [24425704.001]
  • [Cites] Qual Life Res. 2005 Mar;14(2):285-95 [15892420.001]
  • [Cites] Circ Cardiovasc Qual Outcomes. 2009 Jan;2(1):25-32 [20031809.001]
  • [Cites] Stat Med. 1999 Apr 15;18(7):855-88 [10327531.001]
  • [Cites] JAMA. 2008 Nov 26;300(20):2379-88 [19033588.001]
  • [Cites] BMJ. 2015 Feb 05;350:h411 [25656852.001]
  • (PMID = 28153989.001).
  • [ISSN] 1524-4539
  • [Journal-full-title] Circulation
  • [ISO-abbreviation] Circulation
  • [Language] eng
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR001863; United States / NIA NIH HHS / AG / P30 AG021342; United States / NHLBI NIH HHS / HL / U01 HL105270; United States / NHLBI NIH HHS / HL / P50 HL077113; United States / NIA NIH HHS / AG / K23 AG048331
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; acute myocardial infarction / readmission / sex differences / women
  •  go-up   go-down


31. Sauser Zachrison K, Levine DA, Fonarow GC, Bhatt DL, Cox M, Schulte P, Smith EE, Suter RE, Xian Y, Schwamm LH: Timely Reperfusion in Stroke and Myocardial Infarction Is Not Correlated: An Opportunity for Better Coordination of Acute Care. Circ Cardiovasc Qual Outcomes; 2017 Mar;10(3)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Timely Reperfusion in Stroke and Myocardial Infarction Is Not Correlated: An Opportunity for Better Coordination of Acute Care.
  • The degree to which hospital performance is correlated on emergent STEMI and AIS care is unknown.
  • Primary objective of this study was to determine whether there was a positive correlation between hospital performance on door-to-balloon (D2B) time for STEMI and door-to-needle (DTN) time for AIS, with and without controlling for patient and hospital differences.
  • METHODS AND RESULTS: Prospective study of all hospitals in both Get With The Guidelines-Stroke and Get With The Guidelines-Coronary Artery Disease from 2006 to 2009 and treating ≥10 patients.
  • There were 43 hospitals with 1976 AIS and 59 823 STEMI patients.
  • There was no correlation between hospitals' proportion of eligible patients treated within target time windows for AIS and STEMI (median DTN time <60 minutes: 21% [interquartile range, 11-30]; median D2B time <90 minutes: 68% [interquartile range, 62-79]; ρ=-0.14; <i>P</i>=0.36).
  • Opportunities exist to improve hospitals' performance of time-critical care processes for AIS and STEMI in a coordinated approach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • [Cites] Lancet. 2004 Mar 6;363(9411):768-74 [15016487.001]
  • [Cites] J Am Coll Cardiol. 2011 Aug 2;58(6):637-44 [21798428.001]
  • [Cites] J Stroke Cerebrovasc Dis. 2013 Feb;22(2):154-60 [22155116.001]
  • [Cites] Circulation. 1999 Jul 6;100(1):14-20 [10393675.001]
  • [Cites] Neurology. 2000 Dec 12;55(11):1649-55 [11113218.001]
  • [Cites] Am Heart J. 2004 Nov;148(5 Suppl):S46-8 [15514634.001]
  • [Cites] JAMA Neurol. 2014 Sep;71(9):1155-61 [25023407.001]
  • [Cites] Stroke. 2010 Jul;41(7):1431-9 [20522809.001]
  • [Cites] Circulation. 2009 Jan 6;119(1):107-15 [19075103.001]
  • [Cites] Circulation. 2014 Mar 11;129(10):1152-60 [24615963.001]
  • [Cites] JAMA. 2013 Jun 19;309(23):2480-8 [23780461.001]
  • [Cites] Circulation. 2004 Mar 16;109(10):1223-5 [15007008.001]
  • [Cites] Circulation. 2011 Aug 30;124(9):1038-45 [21859971.001]
  • [Cites] Lancet. 2010 May 15;375(9727):1695-703 [20472172.001]
  • [Cites] Crit Pathw Cardiol. 2006 Dec;5(4):179-86 [18340235.001]
  • [Cites] Am Heart J. 2010 Feb;159(2):207-14 [20152218.001]
  • [Cites] J Am Coll Cardiol. 2006 Jun 6;47(11):2180-6 [16750682.001]
  • [Cites] JAMA. 2014 Apr 23-30;311(16):1632-40 [24756513.001]
  • [Cites] Stroke. 2009 Nov;40(11):3580-4 [19797701.001]
  • [Cites] Stroke. 2013 Mar;44(3):870-947 [23370205.001]
  • [Cites] Am Heart J. 2009 Oct;158(4):546-53 [19781413.001]
  • (PMID = 28283469.001).
  • [ISSN] 1941-7705
  • [Journal-full-title] Circulation. Cardiovascular quality and outcomes
  • [ISO-abbreviation] Circ Cardiovasc Qual Outcomes
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / K23 AG040278
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; American Heart Association / fibrinolysis / myocardial infarction / stroke / tissue-type plasminogen activator
  •  go-up   go-down


32. Berlowitz DR, Foy CG, Kazis LE, Bolin LP, Conroy MB, Fitzpatrick P, Gure TR, Kimmel PL, Kirchner K, Morisky DE, Newman J, Olney C, Oparil S, Pajewski NM, Powell J, Ramsey T, Simmons DL, Snyder J, Supiano MA, Weiner DE, Whittle J, SPRINT Research Group: Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes. N Engl J Med; 2017 08 24;377(8):733-744
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.
  • Whether such intensive treatment affected patient-reported outcomes was uncertain; those results from the trial are reported here.
  • Patient-reported outcome measures included the scores on the Physical Component Summary (PCS) and Mental Component Summary (MCS) of the Veterans RAND 12-Item Health Survey, the Patient Health Questionnaire 9-item depression scale (PHQ-9), patient-reported satisfaction with their blood-pressure care and blood-pressure medications, and adherence to blood-pressure medications.
  • Satisfaction with blood-pressure care was high in both treatment groups, and we found no significant difference in adherence to blood-pressure medications.
  • CONCLUSIONS: Patient-reported outcomes among participants who received intensive treatment, which targeted a systolic blood pressure of less than 120 mm Hg, were similar to those among participants who received standard treatment, including among participants with decreased physical or cognitive function. (Funded by the National Institutes of Health; SPRINT ClinicalTrials.gov number, NCT01206062 .).
  • [MeSH-major] Antihypertensive Agents / administration & dosage. Cardiovascular Diseases / prevention & control. Hypertension / drug therapy. Patient Reported Outcome Measures
  • [MeSH-minor] Aged. Blood Pressure / drug effects. Drug Therapy, Combination. Female. Health Status. Humans. Male. Medication Adherence. Middle Aged. Patient Outcome Assessment. Patient Satisfaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28834483.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT01206062
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000439; United States / NCRR NIH HHS / RR / UL1 RR025755; United States / NCRR NIH HHS / RR / UL1 RR024134; United States / NCATS NIH HHS / TR / UL1 TR000003; United States / NCRR NIH HHS / RR / UL1 RR025771; United States / NCATS NIH HHS / TR / UL1 TR000093; United States / NCRR NIH HHS / RR / UL1 RR025752; United States / NCATS NIH HHS / TR / UL1 TR000073; United States / NCATS NIH HHS / TR / UL1 TR001064; United States / NCATS NIH HHS / TR / UL1 TR000050; United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCATS NIH HHS / NCATS NIH HHS / U54 TR0000017 UNIVERSITY OF TEXAS SOUTHWESTERN; United States / NCATS NIH HHS / TR / UL1 TR000105; United States / NCATS NIH HHS / TR / UL1 TR000445; United States / NCATS NIH HHS / TR / UL1 TR000075; United States / NCATS NIH HHS / TR / UL1 TR000002; United States / NCATS NIH HHS / TR / UL1 TR000064; United States / NCATS NIH HHS / TR / UL1 TR000433; United States / NIGMS NIH HHS / GM / P30 GM103337
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antihypertensive Agents
  • [Investigator] Whelton P; Johnson KC; Fine L; Bild D; Bonds D; Cook N; Cutler J; Kaufmann P; Launer L; Moy C; Riley W; Ryan L; Tolunay E; Yang S; Wright JT Jr; Rahman M; Lerner AJ; Still C; Wiggers A; Zamanian S; Bee A; Dancie R; Cushman W; Wall B; Nichols L; Burns R; Martindale-Adams J; Clark E; Walsh S; Geraci T; Huff C; Shaw L; Lewis CE; Bradley V; Calhoun D; Glasser S; Jenkins K; Cheung AK; Beddhu S; Chelune G; Childs J; Gren L; Randall A; Rocco M; Goff D; Rodriguez C; Coker L; Hawfield A; Yeboah J; Crago L; Summerson J; Hege A; Reboussin D; Williamson J; Ambrosius W; Applegate W; Evans G; Freedman BI; Kitzman D; Lyles M; Rapp S; Rushing S; Shah N; Sink KM; Vitolins M; Wagenknecht L; Wilson V; Perdue L; Woolard N; Craven T; Garcia K; Gaussoin S; Lovato L; Amoroso B; Davis P; Griffin J; Harris D; King M; Lane K; Roberson W; Steinberg D; Ashford D; Babcock P; Chamberlain D; Christensen V; Cloud L; Collins C; Cook D; Currie K; Felton D; Harpe S; Howard M; Lewis M; Nance P; Puccinelli-Ortega N; Russell L; Walker J; Craven B; Goode C; Troxler M; Davis J; Hutchens S; Killeen AA; Lukkari AM; Ringer R; Dillard B; Archibeque N; Warren S; Sather M; Pontzer J; Taylor Z; Soliman EZ; Zhang ZM; Li Y; Campbell C; Hensley S; Hu J; Keasler L; Barr M; Taylor T; Bryan RN; Davatzikos C; Nasarallah I; Desiderio L; Elliott M; Borthakur A; Battapady H; Erus G; Smith A; Wang Z; Doshi J; Townsend R; Cohen D; Huan Y; Duckworth M; Ford V; Sexton K; Lerner A; Stokes DL; Smith S; Sunshine J; Clampitt M; Smith S; Welch B; Donahue M; Dagley A; Pennell D; Cannistraci C; Merkle K; Lewis J; Sika M; Wright C; Sabati M; Campuzano E; Martin H; Roman A; Cruz J; Nagornaya N; Maldjian J; Kaminsky S; Fuller D; Jung Y; Lewis B; Wadley V; Evanochko W; Roberson G; Corbitt T; Fisher W; Clements C; Wells A; Civiletto A; Aurigemma GP; Bodkin N; Norbash A; Lavoye M; Ellison A; Killiany R; Sakai O; Cheung A; Sink K; Thomas G; Schreiber M Jr; Navaneethan SD; Hickner J; Lioudis M; Lard M; Marczewski S; Maraschky J; Colman M; Aaby A; Payne S; Ramos M; Horner C; Drawz P; Raghavendra PP; Ober S; Mourad R; Pallaki M; Russo P; Raghavendra P; Fantauzzo P; Tucker L; Schwing B; Sedor JR; Horwitz EJ; Schellling JR; O’Toole JF; Humbert L; Tutolo W; White S; Gay A; Clark W Jr; Hughes R; Dobre M; Still CH; Williams M; Bhatt U; Hebert L; Agarwal A; Murphy MB; Ford N; Stratton C; Baxter J; Lykins AA; Neal AM; Hirmath L; Kwame O; Soe K; Miser WF; Sagrilla C; Johnston J; Anaya A; Mintos A; Howell AA; Rogers K; Taylor S; Ebersbacher D; Long L; Bednarchik B; Schnall A; Smith J; Peysha L; Leach L; Tribout M; Harwell C; Ellington P; Banerji MA; Ghody P; Rambaud MV; Leshner J; Davison A; Vander Veen S; Gadegbeku CA; Gillespie A; Paranjape A; Amoroso S; Pfeffer Z; Quinn SB; He J; Chen J; Lustigova E; Malone E; Krousel-Wood M; Deichmann R; Ronney P; Muery S; Trapani D; Diamond M; Mulloy L; Hodges M; Collins M; Weathers C; Anderson H; Stone E; Walker W; McWilliams A; Dulin M; Kuhn L; Standridge S; Lowe L; Everett K; Preston K; Norton S; Gaines S; Rizvi AA; Sides AW; Herbert D; Hix MM; Whitmire M; Arnold B; Hutchinson P; Espiritu J; Feinglos M; Kovalik E; Gedon-Lipscomb G; Evans K; Thacker C; Zimmer R; Furst M; Mason M; Bolin P; Zhang J; Pinion M; Davis G; Bryant W; Phelps P; Garris-Sutton C; Atkinson B; Contreras G; Suarez M; Schulman I; Koggan D; Vassallo J; Peruyera G; Bethea C; Mayer S; Gilliam L; Pedley C; Zurek G; Baird M; Herring C; Smoak MM; Williams J; Rogers S; Gordon L; Kennedy E; Belle B; McCorkle-Doomy J; Adams J; Lopez R; Janavs J; Rahbari-Oskoui F; Chapman A; Dollar A; Williams O; Han Y; Haley W; Blackshear J; Shapiro B; Harrell A; Palaj A; Henderson K; Johnson A; Gonzalez H; Robinson J; Tamariz L; Denizard J; Barakat R; Krishnamoorthy D; Greenway F; Monce R; Church T; Hendrick C; Yoches A; Sones L; Baltazar M; Pemu P; Jones C; Akpalu D; Dember L; Soares D; Yee J; Umanath K; Ogletree N; Thaxton S; Campana K; Sheldon D; MacArthur K; Muhlestein JB; Allred N; Clements B; Dhar R; Meredith K; Le V; Miner E; Orford J; Riessen ER; Ballantyne B; Chisum B; Johnson K; Peeler D; Chertow G; Tamura M; Chang T; Erickson K; Shen J; Stafford RS; Zaharchuk G; Del Cid M; Dentinger M; Sabino J; Sahay R; Telminova E; Sarnak M; Chan L; Heath A; Kantor A; Jain P; Kirkpatrick B; Well A; Yuen B; Chonchol M; Farmer B; Farmer H; Greenwald C; Malaczewski M; Lash J; Porter A; Ricardo A; Rosman RT; Cohan J; Lopez Barrera N; Meslar D; Meslar P; Conroy M; Unruh M; Hess R; Jhamb M; Thomas H; Fazio P; Klixbull E; Komlos-Weimer M; Mandich L; Vita T; Toto R; Van Buren P; Inrig J; Cruz M; Lightfoot T; Wang N; Webster L; Raphael K; Stults B; Zaman T; Lavasani T; Filipowicz R; Wei G; Miller GM; Harerra J; Christensen J; Giri A; Chen X; Anderton N; Jensen A; Lewis J; Burgner A; Dwyer JP; Schulman G; Herrud T; Leavell E; McCray T; McNeil-Simaan E; Poudel M; Reed M; Woods D; Zirkenbach JL; Raj DS; Cohen S; Patel S; Velasquez M; Bastian RS; Wing M; Roy-Chaudhury A; Depner T; Dalyrymple L; Kaysen G; Anderson S; Nord J; Ix JH; Goldenstein L; Miracle CM; Forbang N; Mircic M; Thomas B; Tran T; Rastogi A; Kim M; Rashid M; Lizarraga B; Hocza A; Sarmosyan K; Norris J; Sharma T; Chioy A; Bernard E; Cabrera E; Lopez C; Nunez S; Riad J; Schweitzer S; Sirop S; Thomas S; Wada L; Kramer H; Bansal V; Taylor CE; Segal MS; Hall KL; Kazory A; Gilbert L; Owens L; Poulton D; Whidden E; Wiggins J; Blaum C; Nyquist L; Min L; Lewis R; Mawby J; Robinson E; Qureshi N; Ferguson K; Haider S; James M; Jones C; Renfroe K; Seay A; Weigart C; Thornley-Brown D; Rizik D; Cotton B; Fitz-Gerald M; Grimes T; Johnson C; Kennedy S; Mason C; Rosato-Burson L; Willingham R; Judd E; Breaux-Shropshire T; Cook F; Medina J; Lewis J; Brantley R; Brouilette J; Glaze J; Hall S; Hiott N; Tharpe D; Boddy S; Mack C; Womack C; Griffin B; Hendrix C; Johnson K; Jones L; Towers C; Punzi H; Cassidy K; Schumacher K; Irizarry C; Colon I; Colon-Ortiz P; Colon-Hernandez P; Carrasquillo M; Vazquez N; Sosa-Padilla M; Cintron-Pinero A; Ayala M; Pacheco O; Rivera C; Sotomayor-Gonzalez I; Claudio J; Lazaro J; Arce M; Heres L; Perez A; Tavarez-Valle J; Arocho F; Torres M; Vazquez M; Takis-Smith R; Andrieni J; Chaudhary K; Hu P; Kostis J; Kostis WJ; Cosgrove N; Bankowski D; Boleyn M; Casazza L; Giresi V; Patel T; Squindo E; Wu Y; Wofford M; Flessner M; Adair C; Asher J; Loope D; Cobb R; Venegas R; Bigger T; Donovan D; Lopez-Jimenez C; Tirado A; Getaneh A; Tang R; Durant S; Maurer M; Teruya S; Helmke S; Alvarez J; Campbell R; Pisoni R; Sturdivant R; Counts C; Hunt V; Spillers L; Brautigam D; Kitchen T; Gorman T; Sayers J; Button S; Chiarot J; Fischer R; Lyon M; Resnick M; Servilla K; Vigil D; Barrett T; Sweeney ME; Johnson R; McConnell S; Salles KS; Watson F; Schenk C; Whittington L; Maher M; Williams J; Swartz S; Conlin P; Alexis G; Lamkin R; Underwood P; Gomes H; Peters JJ; Rosendorff C; Atlas S; Kwon L; Matar M; Johnson RH; Basile J; John J; Ham D; Baig H; Saklayen M; Yap J; Neff H; Miller C; Zheng-Phelan L; Dingell JD; Gappy S; Rau S; Raman A; Berchou V; Jones E; Olgren E; Yudd M; Sastrasinh S; Michaud J; Fiore J; Kutza M; Randall M; Shorr R; Mount R; Thoms J; Dunn H; Stinson S; Hunter J; DeBakey ME; Taylor A; Bates J; Anderson C; Montgomery GV; Stubbs J; Hinton A; Spencer A; City K; Sharma S; Wiegmann T; Mehta S; Krause M; Dishongh K; Childress R; Gyamlani G; Niakan A; Thompson C; Moody J; Zablocki CJ; Barnas G; Wolfgram D; Cortese H; Johnson J; Roumie C; Hung A; Wharton J; Niesner K; Katz L; Richardson E; Brock G; Holland J; Dixon T; Zias A; Spiller C; Baker P; Felicetta J; Rehman S; Bingham K; Watnick S; Weiss J; Johnston T; Giddings S; Klein A; Rowe C; Vargo K; Waidmann K; Papademetriou V; Elkhoury JP; Gregory B; Amodeo S; Bloom M; Goldfarb-Waysman D; Treger R; Knibloe K; Ishani A; Slinin Y; Rust J; Fanti P; Bansal S; Dunnam M; Dyer C; Hu LL; Zarate-Abbott P
  •  go-up   go-down


33. Rubenstein R, Chang B, Yue JK, Chiu A, Winkler EA, Puccio AM, Diaz-Arrastia R, Yuh EL, Mukherjee P, Valadka AB, Gordon WA, Okonkwo DO, Davies P, Agarwal S, Lin F, Sarkis G, Yadikar H, Yang Z, Manley GT, Wang KKW, and the TRACK-TBI Investigators, Cooper SR, Dams-O'Connor K, Borrasso AJ, Inoue T, Maas AIR, Menon DK, Schnyer DM, Vassar MJ: Comparing Plasma Phospho Tau, Total Tau, and Phospho Tau-Total Tau Ratio as Acute and Chronic Traumatic Brain Injury Biomarkers. JAMA Neurol; 2017 Sep 01;74(9):1063-1072

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To date, the presence of the hypophosphorylated tau protein (P-tau) in plasma from patients with acute TBI and chronic TBI has not been investigated.
  • Objective: To examine the associations between plasma P-tau and total-tau (T-tau) levels and injury presence, severity, type of pathoanatomic lesion (neuroimaging), and patient outcomes in acute and chronic TBI.
  • Design, Setting, and Participants: In the TRACK-TBI Pilot study, plasma was collected at a single time point from 196 patients with acute TBI admitted to 3 level I trauma centers (<24 hours after injury) and 21 patients with TBI admitted to inpatient rehabilitation units (mean [SD], 176.4 [44.5] days after injury).
  • Results: In the 217 patients with TBI, 161 (74.2%) were men; mean (SD) age was 42.5 (18.1) years.
  • The P-tau and T-tau levels and P-tau-T-tau ratio in patients with acute TBI were higher than those in healthy controls.
  • Acute P-tau levels and P-tau-T-tau ratio weakly distinguished patients with TBI who had good outcomes (Glasgow Outcome Scale-Extended GOS-E, 7-8) (AUC = 0.663 and 0.658, respectively) and identified those with poor outcomes (GOS-E, ≤4 vs >4) (AUC = 0.771 and 0.777, respectively).
  • Plasma samples from patients with chronic TBI also showed elevated P-tau levels and a P-tau-T-tau ratio significantly higher than that of healthy controls, with both P-tau indices strongly discriminating patients with chronic TBI from healthy controls (AUC = 1.000 and 0.963, respectively).
  • Compared with T-tau levels alone, P-tau levels and P-tau-T-tau ratios show more robust and sustained elevations among patients with chronic TBI.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28738126.001).
  • [ISSN] 2168-6157
  • [Journal-full-title] JAMA neurology
  • [ISO-abbreviation] JAMA Neurol
  • [Language] eng
  • [Grant] United States / RRD VA / RX / I01 RX001859; United States / NINDS NIH HHS / NS / U01 NS086090
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / tau Proteins
  •  go-up   go-down


34. Finnegan MA, Shaffer R, Remington A, Kwong J, Curtin C, Hernandez-Boussard T: Emergency Department Visits Following Elective Total Hip and Knee Replacement Surgery: Identifying Gaps in Continuity of Care. J Bone Joint Surg Am; 2017 Jun 21;99(12):1005-1012
MedlinePlus Health Information. consumer health - Knee Replacement.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emergency Department Visits Following Elective Total Hip and Knee Replacement Surgery: Identifying Gaps in Continuity of Care.
  • BACKGROUND: Major joint replacement surgical procedures are common, elective procedures with a care episode that includes both inpatient readmissions and postoperative emergency department (ED) visits.
  • Factors associated with increased risk of an ED visit were estimated using hierarchical regression models controlling for patient variables with a fixed hospital effect.
  • RESULTS: Among the 152,783 patients who underwent major joint replacement, 5,229 (3.42%) returned to the inpatient setting and 8,883 (5.81%) presented to the ED for care within 30 days.
  • Patients presenting to the ED for subsequent care had more comorbidities and were more frequently non-white with public insurance relative to those not returning to the ED (p < 0.001).
  • There was a significantly increased risk (p < 0.05) of isolated ED visits with regard to type of insurance when patients with Medicaid (odds ratio [OR], 2.28 [95% confidence interval (CI), 2.04 to 2.55]) and those with Medicare (OR, 1.38 [95% CI, 1.29 to 1.47]) were compared with patients with private insurance and with regard to race when black patients (OR, 1.38 [95% CI, 1.25 to 1.53]) and Hispanic patients (OR, 1.12 [95% CI, 1.03 to 1.22]) were compared with white patients.
  • These increases in risk were stronger for isolated ED visits for patients with a pain diagnosis.
  • Medicaid patients had almost double the risk of an ED or pain-related ED visit following a surgical procedure.
  • The future of U.S. health-care insurance coverage expansions are uncertain; however, there are ongoing attempts to improve quality across the continuum of care.
  • It is therefore essential to ensure that all patients, particularly vulnerable populations, receive appropriate postoperative care, including pain management.
  • [MeSH-minor] California. Continuity of Patient Care. Elective Surgical Procedures / statistics & numerical data. Female. Florida. Humans. Male. Middle Aged. New York. Pain, Postoperative / etiology. Postoperative Care / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Hip Replacement.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28632589.001).
  • [ISSN] 1535-1386
  • [Journal-full-title] The Journal of bone and joint surgery. American volume
  • [ISO-abbreviation] J Bone Joint Surg Am
  • [Language] eng
  • [Grant] United States / AHRQ HHS / HS / R01 HS024096
  • [Publication-type] Journal Article; Multicenter Study; Observational Study
  • [Publication-country] United States
  •  go-up   go-down


35. Dawes TJW, de Marvao A, Shi W, Fletcher T, Watson GMJ, Wharton J, Rhodes CJ, Howard LSGE, Gibbs JSR, Rueckert D, Cook SA, Wilkins MR, O'Regan DP: Machine Learning of Three-dimensional Right Ventricular Motion Enables Outcome Prediction in Pulmonary Hypertension: A Cardiac MR Imaging Study. Radiology; 2017 May;283(2):381-390
MedlinePlus Health Information. consumer health - Pulmonary Hypertension.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Purpose To determine if patient survival and mechanisms of right ventricular failure in pulmonary hypertension could be predicted by using supervised machine learning of three-dimensional patterns of systolic cardiac motion.
  • Two hundred fifty-six patients (143 women; mean age ± standard deviation, 63 years ± 17) with newly diagnosed pulmonary hypertension underwent cardiac magnetic resonance (MR) imaging, right-sided heart catheterization, and 6-minute walk testing with a median follow-up of 4.0 years.
  • Results At the end of follow-up, 36% of patients (93 of 256) died, and one underwent lung transplantation.
  • Conclusion A machine-learning survival model that uses three-dimensional cardiac motion predicts outcome independent of conventional risk factors in patients with newly diagnosed pulmonary hypertension.

  • Genetic Alliance. consumer health - Pulmonary Hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Crit Care Med. 2006 Nov 1;174(9):1034-41 [16888289.001]
  • [Cites] Circulation. 2013 Jan 15;127(2):197-206 [23224059.001]
  • [Cites] J Cardiovasc Magn Reson. 2014 Feb 03;16:16 [24490638.001]
  • [Cites] J Am Coll Cardiol. 2011 Dec 6;58(24):2511-9 [22133851.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7 [12091180.001]
  • [Cites] IEEE Trans Med Imaging. 2016 Sep 13;:null [28113656.001]
  • [Cites] Circ Res. 2015 Mar 27;116(7):1115-9 [25814682.001]
  • [Cites] PLoS Biol. 2004 Apr;2(4):E108 [15094809.001]
  • [Cites] Interface Focus. 2016 Apr 6;6(2):20150083 [27051509.001]
  • [Cites] J Cardiovasc Magn Reson. 2012 Jan 11;14:4 [22236389.001]
  • [Cites] J Cardiovasc Magn Reson. 2013 May 01;15:35 [23634753.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Sep;136(3):578-89, 589.e1-11 [18805255.001]
  • [Cites] Neuroimage. 2009 Jul 1;46(3):726-38 [19245840.001]
  • [Cites] Bioinformatics. 2011 Aug 15;27(16):2288-95 [21737439.001]
  • [Cites] Med Image Comput Comput Assist Interv. 2014;17(Pt 1):348-55 [25333137.001]
  • [Cites] J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D22-33 [24355638.001]
  • [Cites] PLoS One. 2014 Oct 31;9(10):e110243 [25360520.001]
  • [Cites] J Cardiovasc Magn Reson. 2013 Oct 08;15:91 [24103764.001]
  • [Cites] Circulation. 2010 Jul 13;122(2):164-72 [20585012.001]
  • [Cites] J Cardiovasc Magn Reson. 2014 Jul 30;16:56 [25160814.001]
  • [Cites] Brief Bioinform. 2011 May;12(3):203-14 [21324971.001]
  • [Cites] Eur Respir J. 2015 Oct;46(4):903-75 [26318161.001]
  • [Cites] J Cardiovasc Magn Reson. 2010 Jun 04;12:35 [20525337.001]
  • [Cites] Med Image Anal. 2015 Dec;26(1):133-45 [26387054.001]
  • [Cites] Phys Med Biol. 2001 Mar;46(3):R1-45 [11277237.001]
  • [Cites] J Am Coll Cardiol. 2007 Jun 26;49(25):2450-6 [17599609.001]
  • [Cites] Med Image Anal. 2012 Jan;16(1):201-15 [21920797.001]
  • [Cites] Eur Respir J. 2015 Jan;45(1):33-5 [25552736.001]
  • [Cites] IEEE Trans Med Imaging. 2017 Jan;36(1):332-342 [28055830.001]
  • [Cites] Nature. 2015 May 28;521(7553):436-44 [26017442.001]
  • [Cites] Med Image Anal. 2015 Jan;19(1):187-202 [25461337.001]
  • [Cites] Circulation. 2015 Nov 17;132(20):1920-30 [26572668.001]
  • [Cites] Biometrics. 2000 Jun;56(2):337-44 [10877287.001]
  • (PMID = 28092203.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / ; United Kingdom / Wellcome Trust / / 100211; United Kingdom / British Heart Foundation / / PG/12/27/29489; United Kingdom / British Heart Foundation / / SP/10/10/28431
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Fogel MA, Li C, Elci OU, Pawlowski T, Schwab PJ, Wilson F, Nicolson SC, Montenegro LM, Diaz L, Spray TL, Gaynor JW, Fuller S, Mascio C, Keller MS, Harris MA, Whitehead KK, Bethel J, Vossough A, Licht DJ: Neurological Injury and Cerebral Blood Flow in Single Ventricles Throughout Staged Surgical Reconstruction. Circulation; 2017 Feb 14;135(7):671-682
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Patients with a single ventricle experience a high rate of brain injury and adverse neurodevelopmental outcome; however, the incidence of brain abnormalities throughout surgical reconstruction and their relationship with cerebral blood flow, oxygen delivery, and carbon dioxide reactivity remain unknown.
  • METHODS: Patients with a single ventricle were studied with magnetic resonance imaging scans immediately prior to bidirectional Glenn (pre-BDG), before Fontan (BDG), and then 3 to 9 months after Fontan reconstruction.
  • Nonacute ischemic white matter changes on T2-weighted imaging, focal tissue loss, and ventriculomegaly were all more commonly detected in BDG and Fontan compared with pre-BDG patients (<i>P</i><0.05).
  • BDG patients had significantly higher cerebral blood flow than did Fontan patients.
  • The odds of discovering brain injury with adjustment for surgical stage as well as ≥2 coexisting lesions within a patient decreased (63%-75% and 44%, respectively) with increasing amount of cerebral blood flow (<i>P</i><0.05).
  • In general, there was no association of oxygen delivery (except for ventriculomegaly in the BDG group) or carbon dioxide reactivity with neurological injury.
  • CONCLUSIONS: Significant brain abnormalities are commonly present in patients with a single ventricle, and detection of these lesions increases as children progress through staged surgical reconstruction, with multiple coexisting lesions more common earlier than later.
  • In addition, this study demonstrated that BDG patients had greater cerebral blood flow than did Fontan patients and that an inverse association exists of various indexes of cerebral blood flow with these brain lesions.
  • However, CO<sub>2</sub> reactivity and oxygen delivery (with 1 exception) were not associated with brain lesion development.

  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2016 American Heart Association, Inc.
  • [Cites] J Pediatr. 2013 Feb;162(2):250-6.e2 [22939929.001]
  • [Cites] Magn Reson Med. 1995 Sep;34(3):293-301 [7500865.001]
  • [Cites] Pediatrics. 2007 Sep;120(3):584-93 [17766532.001]
  • [Cites] Ann Thorac Surg. 2014 Jul;98 (1):125-32 [24820395.001]
  • [Cites] Pediatrics. 2006 Jan;117(1):1-8 [16396853.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Mar;127(3):692-704 [15001897.001]
  • [Cites] J Thorac Cardiovasc Surg. 2009 Mar;137(3):529-36; discussion 536-7 [19258059.001]
  • [Cites] J Thorac Cardiovasc Surg. 2006 Jan;131(1):190-7 [16399311.001]
  • [Cites] Early Hum Dev. 2009 May;85(5):279-84 [19141366.001]
  • [Cites] Arch Dis Child Fetal Neonatal Ed. 2005 May;90(3):F257-61 [15846019.001]
  • [Cites] Magn Reson Imaging. 1994;12(8):1205-25 [7854027.001]
  • [Cites] Neuroradiology. 2003 Apr;45(4):253-8 [12687311.001]
  • [Cites] Gerontology. 1994;40(5):279-85 [7959085.001]
  • [Cites] Ann Neurol. 1983 Feb;13(2):155-9 [6830175.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Dec;128(6):841-9 [15573068.001]
  • [Cites] J Thorac Cardiovasc Surg. 2010 Mar;139(3):543-56 [19909994.001]
  • [Cites] Intern Med. 2015 ;54(9):1027-33 [25948342.001]
  • [Cites] Circulation. 2000 Aug 22;102(8):883-9 [10952957.001]
  • [Cites] Brain Dev. 2008 Oct;30(9):589-94 [18367356.001]
  • [Cites] Circulation. 2013 Mar 5;127(9):971-9 [23371931.001]
  • [Cites] Heart. 2015 Aug;101(16):1325-31 [26048877.001]
  • [Cites] Magn Reson Med. 2002 Aug;48(2):242-54 [12210932.001]
  • [Cites] J Thorac Cardiovasc Surg. 2014 Apr;147(4):1312-8 [23879933.001]
  • [Cites] Circulation. 2002 Sep 24;106(12 Suppl 1):I95-102 [12354716.001]
  • [Cites] J Pediatr. 2004 Nov;145(5):588-92 [15520755.001]
  • [Cites] Acta Paediatr. 2008 Oct;97(10):1426-32 [18624991.001]
  • [Cites] Circulation. 2002 Sep 24;106(12 Suppl 1):I109-14 [12354718.001]
  • [Cites] Ultrasound Obstet Gynecol. 2010 Aug;36(2):178-85 [20503251.001]
  • [Cites] N Engl J Med. 2007 Nov 8;357(19):1928-38 [17989385.001]
  • [Cites] Blood. 1990 Nov 1;76(9):1680-97 [2224118.001]
  • [Cites] Stroke. 2007 Feb;38(2 Suppl):736-41 [17261728.001]
  • [Cites] Pediatrics. 2000 May;105(5):1082-9 [10790466.001]
  • [Cites] Acta Paediatr Scand Suppl. 1989;360:72-82 [2484464.001]
  • [Cites] N Engl J Med. 2010 May 27;362(21):1980-92 [20505177.001]
  • [Cites] BMC Neurol. 2014 Mar 06;14 :43 [24602446.001]
  • [Cites] Ann Thorac Surg. 2014 Nov;98(5):1693-8 [25149046.001]
  • [Cites] J Thorac Cardiovasc Surg. 2010 Sep;140(3):550-7 [20434174.001]
  • [Cites] Circulation. 2008 Jan 1;117(1):85-92 [18071068.001]
  • [Cites] Pediatr Neurol. 1985 Mar-Apr;1(2):85-90 [3880396.001]
  • [Cites] Ultrasound Obstet Gynecol. 2008 Dec;32(7):894-9 [19035538.001]
  • [Cites] Chest. 2008 Jun;133(6 Suppl):887S-968S [18574281.001]
  • (PMID = 28031423.001).
  • [ISSN] 1524-4539
  • [Journal-full-title] Circulation
  • [ISO-abbreviation] Circulation
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT02135081
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL090615; United States / NINDS NIH HHS / NS / R01 NS060653; United States / NINDS NIH HHS / NS / R01 NS072338; United States / NICHD NIH HHS / HD / U01 HD087180
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Fontan procedure / cerebral infarction / cerebrovascular circulation / heart ventricles / magnetic resonance imaging
  •  go-up   go-down


37. Frisoli TM, Nowak R, Evans KL, Harrison M, Alani M, Varghese S, Rahman M, Noll S, Flannery KR, Michaels A, Tabaku M, Jacobsen G, McCord J: Henry Ford HEART Score Randomized Trial: Rapid Discharge of Patients Evaluated for Possible Myocardial Infarction. Circ Cardiovasc Qual Outcomes; 2017 Oct;10(10)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Henry Ford HEART Score Randomized Trial: Rapid Discharge of Patients Evaluated for Possible Myocardial Infarction.
  • BACKGROUND: Hospital evaluation of patients with chest pain is common and costly.
  • The HEART score risk stratification tool that merges troponin testing into a clinical risk model for evaluation emergency department patients with possible acute myocardial infarction (AMI) has been shown to effectively identify a substantial low-risk subset of patients possibly safe for early discharge without stress testing, a strategy that could have tremendous healthcare savings implications.
  • METHOD AND RESULTS: A total of 105 patients evaluated for AMI in the emergency departments of 2 teaching hospitals in the Henry Ford Health System (Detroit and West Bloomfield, MI), between February 2014 and May 2015, with a modified HEART score ≤3 (which includes cardiac troponin I <0.04 ng/mL at 0 and 3 hours) were randomized to immediate discharge (n=53) versus management in an observation unit with stress testing (n=52).
  • Patients randomized to early discharge, compared with those who were admitted for observation and cardiac testing, spent less time in the hospital (median 6.3 hours versus 25.9 hours; <i>P</i><0.001) with an associated reduction in median total charges of care ($2953 versus $9616; <i>P</i><0.001).
  • One patient in each group was lost to follow-up.
  • CONCLUSIONS: Among patients evaluated for possible AMI in the emergency department with a modified HEART score ≤3, early discharge without stress testing as compared with transfer to an observation unit for stress testing was associated with significant reductions in length of stay and total charges, a finding that has tremendous potential national healthcare expenditure implications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • (PMID = 28954802.001).
  • [ISSN] 1941-7705
  • [Journal-full-title] Circulation. Cardiovascular quality and outcomes
  • [ISO-abbreviation] Circ Cardiovasc Qual Outcomes
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; acute coronary syndrome / chest pain / length of stay / myocardial infarction / troponin
  •  go-up   go-down


38. Mohammed MF, Marais O, Min A, Ferguson D, Jalakhan S, Khosa F, OʼKeeffe M, OʼConnell T, Schmiedeskamp H, Krauss B, Rohr A, Nicolaou S: Unenhanced Dual-Energy Computed Tomography: Visualization of Brain Edema. Invest Radiol; 2017 Sep 14;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: This was a retrospective, single-center study of 40 patients who presented to the emergency department (ED) of a major, acute care, teaching center with signs and symptoms of acute stroke.
  • Only those patients who presented to the ED within 4 hours of symptom onset were included in this study.
  • All 40 patients received a noncontrast DECT of the head at the time of presentation.
  • Each patient also received standard noncontrast CT of the head 24 hours after their initial presentation to the ED.
  • RESULTS: Of the 40 patients, 28 (70%) were diagnosed with an acute infarction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28915161.001).
  • [ISSN] 1536-0210
  • [Journal-full-title] Investigative radiology
  • [ISO-abbreviation] Invest Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Grubbs SS, Go RS, Berger MZ, Gonzalez M, Thompson MA, Enos R, St Germain DC, Denicoff A, Servididio C, Bearden JD, Zaren H, Wilkinson K, Krasna M, McCaskill-Stevens W, Bell M, Freeman RK, Miesfeldt S, Ravikumar TS, Nair SG, Bashey A: Early success in narrowing age, gender, and racial disparities in clinical trial accrual: Targeted screening efforts through the National Cancer Institute Community Cancer Centers Program (NCCCP). J Clin Oncol; 2011 May 20;29(15_suppl):6110

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The data included patient demographics, trial eligibility, trial enrollment, and reasons for non-enrollment.
  • This abstract addresses patient demographics.
  • RESULTS: Of the 1,589 patients screened during this period, 359 were enrolled, for an overall accrual rate of 23%.
  • No disparity based on gender, ethnicity, or race between Whites and African Americans (P value for the latter comparison 0.59) was found and the disparity gap between the young and elderly appears narrowed when compared to historical data (3-fold difference; Murthy VH, et al JAMA 2004).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28022513.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Fordyce CB, Al-Khalidi HR, Jollis JG, Roettig ML, Gu J, Bagai A, Berger PB, Corbett CC, Dauerman HL, Fox K, Garvey JL, Henry TD, Rokos IC, Sherwood MW, Wilson BH, Granger CB, STEMI Systems Accelerator Project: Association of Rapid Care Process Implementation on Reperfusion Times Across Multiple ST-Segment-Elevation Myocardial Infarction Networks. Circ Cardiovasc Interv; 2017 Jan;10(1)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of Rapid Care Process Implementation on Reperfusion Times Across Multiple ST-Segment-Elevation Myocardial Infarction Networks.
  • BACKGROUND: The Mission: Lifeline STEMI Systems Accelerator program, implemented in 16 US metropolitan regions, resulted in more patients receiving timely reperfusion.
  • We assessed whether implementing key care processes was associated with system performance improvement.
  • METHODS AND RESULTS: Hospitals (n=167 with 23 498 ST-segment-elevation myocardial infarction patients) were surveyed before (March 2012) and after (July 2014) program intervention.
  • Data were merged with patient-level clinical data over the same period.
  • For reperfusion, hospitals were grouped by whether a specific process of care was implemented, preexisting, or never implemented.
  • Uptake of 4 key care processes increased after intervention: prehospital catheterization laboratory activation (62%-91%; P<0.001), single call transfer protocol from an outside facility (45%-70%; P<0.001), and emergency department bypass for emergency medical services direct presenters (48%-59%; P=0.002) and transfers (56%-79%; P=0.001).
  • Similarly, patients treated at hospitals implementing single call transfer protocols had shorter median first medical contact-to-device times (112 versus 128 versus 152 minutes; P<0.001).
  • CONCLUSIONS: The Accelerator program increased uptake of key care processes, which were associated with improved system performance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • (PMID = 28082714.001).
  • [ISSN] 1941-7632
  • [Journal-full-title] Circulation. Cardiovascular interventions
  • [ISO-abbreviation] Circ Cardiovasc Interv
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; ST-segment–elevation myocardial infarction / percutaneous coronary intervention / quality improvement / reperfusion times / systems of care
  •  go-up   go-down


41. Anderson BR, Wallace AS, Hill KD, Gulack BC, Matsouaka R, Jacobs JP, Bacha EA, Glied SA, Jacobs ML: Association of Surgeon Age and Experience With Congenital Heart Surgery Outcomes. Circ Cardiovasc Qual Outcomes; 2017 Jul;10(7)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Relationships between surgeon seniority and patient outcomes are often assumed, yet there are little data.
  • Sensitivity analyses explored the effects of patient characteristics, institutional/surgeon volumes, and various measures of institutional surgeon team experience.
  • CONCLUSIONS: In this study of >200 congenital heart surgeons, we found patient outcomes for surgeons with the fewest years of experience to be comparable to those of their midcareer and senior colleagues, within the context of existing referral and support practices.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • (PMID = 28710297.001).
  • [ISSN] 1941-7705
  • [Journal-full-title] Circulation. Cardiovascular quality and outcomes
  • [ISO-abbreviation] Circ Cardiovasc Qual Outcomes
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; health care quality, access, and evaluation / heart defects, congenital / mentoring / surgeons
  •  go-up   go-down


42. Kavakli K, Demartis F, Karimi M, Eshghi P, Neme D, Chambost H, Sommer L, Zak M, Benson G: Safety and effectiveness of room temperature stable recombinant factor VIIa in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study. Haemophilia; 2017 Jul;23(4):575-582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and effectiveness of room temperature stable recombinant factor VIIa in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study.
  • Although no confirmed cases of neutralising antibodies to rFVIIa in patients with haemophilia A or B have been observed with the original formulation, changes in formulation or storage condition may alter immunogenicity.
  • AIM: SMART-7™ was designed to investigate the safety of NovoSeven<sup>®</sup> in a real-world setting in patients with haemophilia A or B with inhibitors.
  • Patient baseline information was collected at enrolment.
  • RESULTS: Fifty-one patients were enrolled and 31 completed the study.
  • Forty-one adverse events (AEs) were reported in 23 patients; 25 AEs in 14 patients were serious.
  • Forty-eight patients experienced 618 bleeding episodes and 93.4% of 609 evaluated bleeds were stopped by treatment.
  • CONCLUSION: Data collected during the SMART-7™ study revealed no treatment-related safety issues and no FVII-binding antibodies for patients treated with NovoSeven<sup>®</sup> under real-world conditions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 John Wiley & Sons Ltd.
  • (PMID = 28440004.001).
  • [ISSN] 1365-2516
  • [Journal-full-title] Haemophilia : the official journal of the World Federation of Hemophilia
  • [ISO-abbreviation] Haemophilia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; antibodies / haemophilia A / haemophilia B / real world / recombinant FVIIa
  •  go-up   go-down


43. PRISM Investigators, Rowan KM, Angus DC, Bailey M, Barnato AE, Bellomo R, Canter RR, Coats TJ, Delaney A, Gimbel E, Grieve RD, Harrison DA, Higgins AM, Howe B, Huang DT, Kellum JA, Mouncey PR, Music E, Peake SL, Pike F, Reade MC, Sadique MZ, Singer M, Yealy DM: Early, Goal-Directed Therapy for Septic Shock - A Patient-Level Meta-Analysis. N Engl J Med; 2017 06 08;376(23):2223-2234
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early, Goal-Directed Therapy for Septic Shock - A Patient-Level Meta-Analysis.
  • This meta-analysis of individual patient data from the three recent trials was designed prospectively to improve statistical power and explore heterogeneity of treatment effect of EGDT.
  • We tested for treatment-by-subgroup interactions for 16 patient characteristics and 6 care-delivery characteristics.
  • RESULTS: We studied 3723 patients at 138 hospitals in seven countries.
  • Mortality at 90 days was similar for EGDT (462 of 1852 patients [24.9%]) and usual care (475 of 1871 patients [25.4%]); the adjusted odds ratio was 0.97 (95% confidence interval, 0.82 to 1.14; P=0.68).
  • EGDT was associated with greater mean (±SD) use of intensive care (5.3±7.1 vs. 4.9±7.0 days, P=0.04) and cardiovascular support (1.9±3.7 vs. 1.6±2.9 days, P=0.01) than was usual care; other outcomes did not differ significantly, although average costs were higher with EGDT.
  • Subgroup analyses showed no benefit from EGDT for patients with worse shock (higher serum lactate level, combined hypotension and hyperlactatemia, or higher predicted risk of death) or for hospitals with a lower propensity to use vasopressors or fluids during usual resuscitation.
  • CONCLUSIONS: In this meta-analysis of individual patient data, EGDT did not result in better outcomes than usual care and was associated with higher hospitalization costs across a broad range of patient and hospital characteristics. (Funded by the National Institute of General Medical Sciences and others; PRISM ClinicalTrials.gov number, NCT02030158 .).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] N Engl J Med. 2017 Sep 7;377(10 ):995 [28877021.001]
  • [CommentIn] N Engl J Med. ;377(10 ):994 [28880501.001]
  • (PMID = 28320242.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT02030158
  • [Grant] United States / NIGMS NIH HHS / GM / P50 GM076659
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cardiotonic Agents; 0 / Vasoconstrictor Agents
  • [Investigator] Eaton TL; Keener C; Landis K; Stapleton DK; Weissfeld LA; Willochell M; Wofford KA; Kulstad E; Watts H; Venkat A; Hou PC; Massaro A; Parmar S; Limkakeng AT Jr; Brewer K; Delbridge TR; Mainhart A; Chawla LS; Miner JR; Allen TL; Grissom CK; Swadron S; Conrad SA; Carlson R; LoVecchio F; Bajwa EK; Filbin MR; Parry BA; Ellender TJ; Sama AE; Fine J; Nafeei S; Terndrup T; Wojnar M; Pearl RG; Wilber ST; Sinert R; Orban DJ; Wilson JW; Ufberg JW; Albertson T; Panacek EA; Parekh S; Gunn SR; Rittenberger JS; Wadas RJ; Edwards AR; Kelly M; Wang HE; Holmes TM; McCurdy MT; Weinert C; Harris ES; Self WH; Dubinski D; Phillips CA; Migues RM; Cameron PA; Holdgate A; Webb SA; Williams P; Cooper DJ; Cross A; Gomersall C; Graham C; Jacobs I; Johanson S; Jones P; Kruger P; McArthur C; Myburgh J; Nichol A; Pettilä V; Rajbhandari D; Williams A; Williams J; Bives G; Jovanovska A; Lam L; Little L; Newby L; Bennett V; Board J; McCracken P; McGloughlin S; Nanjayya V; Teo A; Hill E; O’Brien E; Sawtell F; Schimanski K; Wilson D; Bolch S; Eastwood G; Kerr F; Peak L; Young H; Edington J; Fletcher J; Smith J; Ghelani D; Nand K; Sara T; Flemming D; Grummisch M; Purdue A; Fulton E; Grove K; Harney A; Milburn K; Millar R; Mitchell I; Rodgers H; Scanlon S; Coles T; Connor H; Dennett J; Van Berkel A; Barrington S; Henderson S; Mehrtens J; Dryburgh J; Tankel A; Braitberg G; O’Bree B; Shepherd K; Vij S; Allsop S; Haji D; Haji K; Vuat J; Bone A; Elderkin T; Orford N; Ragg M; Kelly S; Stewart D; Woodward N; Harjola VP; Okkonen M; Sutinen S; Wilkman E; Fratzia J; Halkhoree J; Treloar S; Ryan K; Sandford T; Walsham J; Jenkins C; Williamson D; Burrows J; Hawkins D; Tang C; Dimakis A; Micallef S; Parr M; White H; Morrison L; Sosnowski K; Ramadoss R; Soar N; Wood J; Franks M; Hogan C; Song R; Tilsley A; Rainsford D; Wells R; Dowling J; Galt P; Lamac T; Lightfoot D; Walker C; Braid K; DeVillecourt T; Tan HS; Seppelt I; Chang LF; Cheung WS; Fok SK; Lam PK; Lam SM; So HM; Yan WW; Altea A; Lancashire B; Gomersall CD; Graham CA; Leung P; Arora S; Bass F; Shehabi Y; Isoardi J; Isoardi K; Powrie D; Lawrence S; Ankor A; Chester L; Davies M; O’Connor S; Poole A; Soulsby T; Sundararajan K; Greenslade JH; MacIsaac C; Gorman K; Jordan A; Moore L; Ankers S; Bird S; Fogg T; Hickson E; Jewell T; Kyneur K; O’Connor A; Townsend J; Yarad E; Brown S; Chamberlain J; Cooper J; Jenkinson E; McDonald E; Webb S; Buhr H; Coakley J; Cowell J; Hutch D; Gattas D; Keir M; Rees C; Baker S; Roberts B; Farone E; Holmes J; Santamaria J; Winter C; Finckh A; Knowles S; McCabe J; Nair P; Reynolds C; Ahmed B; Barton D; Meaney E; Harris R; Shields L; Thomas K; Karlsson S; Kuitunen A; Kukkurainen A; Tenhunen J; Varila S; Ryan N; Trethewy C; Crosdale J; Smith JC; Vellaichamy M; Furyk J; Gordon G; Jones L; Senthuran S; Bates S; Butler J; French C; Tippett A; Kelly J; Kwans J; Murphy M; O’Flynn D; Kurenda C; Otto T; Raniga V; Ho HF; Leung A; Wu H; Bell D; Bion J; Hodgetts T; Young D; Harvey S; Jahan R; Osborn T; Power S; Tan J; Corlett S; Muskett H; Scott R; Ahmed V; Boyle A; Scott-Donkin A; Black H; Smalley C; Jacob R; Wooten A; Humphrey J; Pearson SA; Griffiths J; Subramanyam D; Niblett D; Krishnanankutty S; Gao-Smith F; Melody T; Couper K; Nichani R; Brennan E; Tucker S; Benger J; Edwards J; Pollock K; Arawwawala D; Hieatt A; McNeela F; Weldring T; Carungcong J; MacNaughton P; McMillan H; Tantam K; Doyle T; Moreton S; Jones S; Kendall J; Worner R; Gilbertson A; Borland C; Boys S; Ranjan S; Smith I; Smith N; Mendham V; Smith P; Farras-Araya R; Vallance D; Watt P; Raymode P; Hollos L; Hopkins P; Riozzi P; Couper H; Helyar S; Thompson J; Hales D; Essat Z; Andreou P; Gilby S; Chilton P; Miller R; Butler J; Jefferies A; Clark R; Sanders G; Pinto N; Plowright C; Innes R; Bayford D; Richards P; Gopal S; Pooni JS; Spencer H; Napier J; Warrington E; Kevern L; Hunt J; Barrett C; Sykes E; Connelly K; Yates B; Carle C; Croft T; Jenkins N; Reschreiter H; Camsooksai J; Barcraft-Barnes H; Snelson C; Bergin C; Keats F; Linnett V; Ritzema J; Christian S; Harvey D; Miller P; Woodford C; Bolland A; Keating L; Mossop D; Jones C; Martin D; Willett E; Swallow P; McBride S; Ijaz A; Datta J; Craig J; Owen T; Williams A; McMullan S; Baldwin J; Zuleika M; Carvalho P; Agranoff D; Ingoldby F; Ortiz-Ruiz De Gordoa L; Ridley C; Clement I; Higham C; Martin B; Clayton K; Chadwick J; Frey C; Miller D; Laverick P; Iftikhar K; Higgins D; Katsande V; Chikungwa M; Jackson C; Watters M; Liddiard P; Gannon K; Howard-Griffin R; Bell S; Blaylock H; Gonzalez I; Cirstea E; Bonner S; Moondi P; Wong K; Carter J; Hartley S; Crossingham I; Hinchcliffe J; Phoenix L; Harris T; Pott J; Bellhouse G; Mercer M; Mercer P; Robinson H; Brealey D; Ryu J; Becardes G; Morris AM; Poulson M; Barnett L; Massey I; Skene I; Nee P; Dowling S; McCairn A; Duckitt R; Venn R; Margalef J; Redman J; Milner H; Ma S
  •  go-up   go-down


44. Nag N, Millar J, Davis ID, Costello S, Duthie JB, Mark S, Delprado W, Smith D, Pryor D, Galvin D, Sullivan F, Murphy ÁC, Roder D, Elsaleh H, Currow D, White C, Skala M, Moretti KL, Walker T, De Ieso P, Brooks A, Heathcote P, Frydenberg M, Thavaseelan J, Evans SM: Development of Indicators to Assess Quality of Care for Prostate Cancer. Eur Urol Focus; 2016 Feb 20;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of Indicators to Assess Quality of Care for Prostate Cancer.
  • BACKGROUND: The development, monitoring, and reporting of indicator measures that describe standard of care provide the gold standard for assessing quality of care and patient outcomes.
  • A standard set, defining numerator, denominator, and risk adjustments, will enable global benchmarking of quality of care.
  • OBJECTIVE: To develop a set of indicators to enable assessment and reporting of quality of care for men with localised prostate cancer (PCa).
  • The set includes indicators covering pre-, intra-, and post-treatment of PCa care, within the limits of the data captured by PCOR-ANZ.
  • CONCLUSIONS: The 12 endorsed quality measures enable international benchmarking on the quality of care of men with localised PCa.
  • Reporting on these indicators enhances safety and efficacy of treatment, reduces variation in care, and can improve patient outcomes.
  • PATIENT SUMMARY: PCa has the highest incidence of all cancers in men.
  • Early diagnosis and relatively high survival rates mean issues of quality of care and best possible health outcomes for patients are important.
  • This paper identifies 12 important measurable quality indicators in PCa care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • (PMID = 28753751.001).
  • [ISSN] 2405-4569
  • [Journal-full-title] European urology focus
  • [ISO-abbreviation] Eur Urol Focus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Clinical registries / Population health / Prostate cancer / Quality indicators / Quality measures
  •  go-up   go-down


45. Razmjou H, Boljanovic D, Lincoln S, Holtby R, Gallay S, Henry P, Macritchie I, WCP Consortium, Borthwick C, Mayer L, Roknic C, Shore D, Kamino A, Grossman J, Hill J, Singh G, Travers N, Yanofsky L, Wilson M, Sumar S, Savona A, De Medeiros F, Mann H, Champsi A, Chau S, Medeiros D, Richards RR: Outcome of Expedited Rotator Cuff Surgery in Injured Workers: Determinants of Successful Recovery. Orthop J Sports Med; 2017 May;5(5):2325967117705319

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: One hundred forty-six patients (43 women [29%], 103 men [71%]; mean age, 52 years; SD, 8 years) completed the study.
  • Sixty-seven (46%) patients underwent rotator cuff repair.
  • The mean time between the date the patient consented to have surgery and the date of surgery was 82 (SD, 44) days.
  • Eighty-four percent (n = 122) of patients exceeded the MCID of 17 points.
  • Individual factors that affected patient overall disability were preoperative ASES, work status prior to surgery, access to care, and autonomy at work.
  • Achieving a minimal clinically meaningful change was influenced by perceived access to care, autonomy and stress at work, and overall satisfaction with the job.
  • Successful recovery after work-related shoulder injuries may further be facilitated by improving the psychosocial work environment and increasing access to care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 2013 Jul 17;95(14 ):1249-55 [23864172.001]
  • [Cites] BMC Musculoskelet Disord. 2006 Mar 13;7:26 [16533405.001]
  • [Cites] Occup Environ Med. 2003 Apr;60(4):244-53 [12660372.001]
  • [Cites] Physiother Can. 2008 Winter;60(1):72-9 [20145743.001]
  • [Cites] Occup Environ Med. 2002 Dec;59(12):807-15 [12468746.001]
  • [Cites] Physiother Can. 2012 Spring;64(2):135-44 [23450087.001]
  • [Cites] Pain. 2006 Feb;120(3):276-85 [16426760.001]
  • [Cites] J Shoulder Elbow Surg. 2001 May-Jun;10 (3):199-203 [11408898.001]
  • [Cites] BMC Musculoskelet Disord. 2011 Apr 01;12:66 [21457534.001]
  • [Cites] J Shoulder Elbow Surg. 2010 Dec;19(8):1191-8 [21030274.001]
  • [Cites] J Bone Joint Surg Am. 2010 Feb;92 (2):296-303 [20124055.001]
  • [Cites] J Clin Epidemiol. 2003 Mar;56(3):221-9 [12725876.001]
  • [Cites] Occup Environ Med. 2016 Apr;73(4):246-53 [26740688.001]
  • [Cites] J Bone Joint Surg Am. 2014 Jan 15;96(2):106-12 [24430409.001]
  • [Cites] Am J Epidemiol. 1989 Mar;129(3):483-94 [2916541.001]
  • [Cites] Clin Orthop Relat Res. 1999 Oct;(367 ):243-55 [10546622.001]
  • [Cites] Clin Orthop Relat Res. 1983 May;(175):18-24 [6839586.001]
  • [Cites] Pain. 2004 Jun;109(3):420-31 [15157703.001]
  • [Cites] Scand J Rheumatol. 2004;33(2):73-81 [15163107.001]
  • [Cites] J Shoulder Elbow Surg. 2002 Nov-Dec;11(6):587-94 [12469084.001]
  • [Cites] BMC Musculoskelet Disord. 2009 Feb 24;10:26 [19239706.001]
  • [Cites] Eur J Appl Physiol Occup Physiol. 1989;58(4):353-60 [2920713.001]
  • [Cites] Rheumatol Int. 2013 Dec;33(12):2975-83 [23934521.001]
  • [Cites] Oper Tech Orthop. 2015 Mar 1;25(1):2-9 [26726288.001]
  • [Cites] J Shoulder Elbow Surg. 2010 Jan;19(1):157-64 [19559630.001]
  • [Cites] Knee Surg Sports Traumatol Arthrosc. 2011 Oct;19(10 ):1766-70 [21258779.001]
  • [Cites] Int Arch Occup Environ Health. 2016 Jul;89(5):719-28 [26715494.001]
  • [Cites] Ann Rheum Dis. 2003 Aug;62(8):755-60 [12860731.001]
  • [Cites] Healthc Pap. 2008;8(3):16-20; discussion 52-4 [18493171.001]
  • [Cites] J Bone Joint Surg Am. 1984 Apr;66(4):563-7 [6707035.001]
  • [Cites] Healthc Pap. 2008;8(3):6-14 [18493170.001]
  • [Cites] J Bone Joint Surg Am. 2015 Dec 16;97(24):1999-2003 [26677233.001]
  • [Cites] J Shoulder Elbow Surg. 2006 Mar-Apr;15(2):148-53 [16517356.001]
  • [Cites] Appl Ergon. 2014 Nov;45(6):1610-21 [24934982.001]
  • [Cites] Health Econ. 2012 Feb;21(2):83-100 [22223554.001]
  • [Cites] J Shoulder Elbow Surg. 2011 Jan;20(1):62-8 [20675154.001]
  • (PMID = 28589156.001).
  • [ISSN] 2325-9671
  • [Journal-full-title] Orthopaedic journal of sports medicine
  • [ISO-abbreviation] Orthop J Sports Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; expedited surgery / rotator cuff / workers’ compensation
  •  go-up   go-down


46. Goobie SM, Cladis FP, Glover CD, Huang H, Reddy SK, Fernandez AM, Zurakowski D, Stricker PA, Gries, the Pediatric Craniofacial Collaborative Group: Safety of antifibrinolytics in cranial vault reconstructive surgery: a report from the pediatric craniofacial collaborative group. Paediatr Anaesth; 2017 03;27(3):271-281

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No significant difference was detected in the incidence of postoperative seizures between patients receiving tranexamic acid and those receiving aminocaproic acid [the odds ratio for seizures being 0.34 (95% confidence interval: 0.07-1.85) controlling for American Society of Anesthesia (ASA) physical class] nor in patients receiving antifibrinolytics compared to those not administered antifibrinolytics (the odds ratio for seizures being 1.02 (confidence interval 0.29-3.63) controlling for ASA physical class).
  • One complicated patient in the antifibrinolytic group with a femoral venous catheter had a postoperative deep venous thrombosis.
  • There was no significant difference in postoperative seizures or seizure-like events in those patients who received the tranexamic acid or aminocaproic acid vs those that did not.
  • Caution should prevail however in using antifibrinolytic in high-risk patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 John Wiley & Sons Ltd.
  • [ErratumIn] Paediatr Anaesth. 2017 Jun;27(6):670. Gries, Heike [added]; Meier, Petra [added]; Haberkern, Charlie [added]; Nguyen, Thanh [added]; Benzon, Hubert [added] [28474812.001]
  • (PMID = 28211198.001).
  • [ISSN] 1460-9592
  • [Journal-full-title] Paediatric anaesthesia
  • [ISO-abbreviation] Paediatr Anaesth
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antifibrinolytic Agents; 6T84R30KC1 / Tranexamic Acid; U6F3787206 / Aminocaproic Acid
  • [Keywords] NOTNLM ; aminocaproic acid (major topic) / antifibrinolytics (major topic) / craniofacial surgery (major topic) / craniosynostosis (major topic) / safety (major topic) / tranexamic acid (major topic)
  • [Investigator] Fiadjoe J; Soneru C; Falcon R; Petersen T; Kowalczyk-Derderian C; Dalesio N; Budac S; Groenewald N; Rubens D; Thompson D; Watts R; Gentry K; Ivanova I; Hetmaniuk M; Hsieh V; Collins M; Wong K; Binstock W; Reid R; Poteet-Schwartz K; Gries H; Hall R; Koh J; Colpitts K; Scott L; Bannister C; Sung W; Jain R; Chaudhry R; Tuite GF; Ruas E; Drozhinin O; Tetreault L; Muldowney B; Ricketts K; Fernandez P; Sohn L; Hajduk J; Taicher B; Burkhart J; Wright A; Kugler J; Barajas-DeLoa L; Gangadharan M; Busso V; Stallworth K; Staudt S; Labovsky K; Glover C; Karlberg-Hippard H; Capehart S; Streckfus C; Nguyen KP; Manyang P; Martinez JL; Hansen J; Mitzel H; Brzenski A; Chiao F; Ingelmo P; Mujallid R; Bosenberg A; Meier P; Haberkern Ch; Nguyen T; Benzon H
  •  go-up   go-down


47. Matsushita K, Ballew SH, Coresh J, Arima H, Ärnlöv J, Cirillo M, Ebert N, Hiramoto JS, Kimm H, Shlipak MG, Visseren FLJ, Gansevoort RT, Kovesdy CP, Shalev V, Woodward M, Kronenberg F, Chronic Kidney Disease Prognosis Consortium: Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol; 2017 Sep;5(9):718-728
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In this collaborative meta-analysis of international cohorts included in the Chronic Kidney Disease Prognosis Consortium (baseline measurements obtained between 1972 and 2014) with baseline measurements of eGFR and albuminuria, at least 1000 participants (this criterion not applied to cohorts exclusively enrolling patients with chronic kidney disease), and at least 50 peripheral artery disease events, we analysed adult participants without peripheral artery disease at baseline at the individual patient level with Cox proportional hazards models to quantify associations of creatinine-based eGFR, urine albumin-to-creatinine ratio (ACR), and dipstick proteinuria with the incidence of peripheral artery disease (including hospitalisation with a diagnosis of peripheral artery disease, intermittent claudication, leg revascularisation, and leg amputation).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28716631.001).
  • [ISSN] 2213-8595
  • [Journal-full-title] The lancet. Diabetes & endocrinology
  • [ISO-abbreviation] Lancet Diabetes Endocrinol
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / U01 HL080295; United States / NCATS NIH HHS / TR / UL1 TR001079; United States / NHLBI NIH HHS / HC / N01 HC095164; United States / NHLBI NIH HHS / HC / N01 HC095166; United States / NIA NIH HHS / AG / R01 AG007181; United States / NIDDK NIH HHS / DK / R01 DK031801; United States / NHLBI NIH HHS / HC / N01 HC095165; United States / NCATS NIH HHS / TR / UL1 TR000040; United States / NHLBI NIH HHS / HC / N01 HC095163; United States / NIDDK NIH HHS / DK / R01 DK100446; United States / NIA NIH HHS / AG / R01 AG023629
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Investigator] Chalmers J; Arima H; Perkovic V; Grams ME; Sang Y; Schaeffner E; Martus P; Levin A; Djurdjev O; Tang M; Heine G; Seiler S; Zawada A; Emrich I; Sarnak M; Katz R; Brenner H; Schöttker B; Rothenbacher D; Saum KU; Köttgen A; Schneider M; Eckardt KU; Green J; Kirchner HL; Chang AR; Black C; Marks A; Prescott G; Clark L; Fluck N; Jee SH; Mok Y; Chodick G; Shalev V; Wetzels JFM; Blankestijn PJ; van Zuilen AD; Bots M; Peralta C; Hiromoto J; Katz R; Sarnak M; Bottinger E; Nadkarni GN; Ellis SB; Nadukuru R; Kenealy T; Elley CR; Collins JF; Drury PL; Bakker SJ; Heerspink HJL; Jassal SK; Bergstrom J; Ix JH; Barrett-Connor E; Kalantar-Zadeh K; Carrero JJ; Gasparini A; Qureshi AR; Barany P; Algra A; van der Graaf Y; Evans M; Segelmark M; Stendahl M; Schön S; Tangri N; Sud M; Naimark D; Lannfelt L; Larsson A; Hallan S; Levey AS; Chen J; Kwak L; Grams ME; Sang Y
  •  go-up   go-down


48. Ueda K, Maeno Y, Miyoshi T, Inamura N, Kawataki M, Taketazu M, Nii M, Hagiwara A, Horigome H, Shozu M, Shimizu W, Yasukochi S, Yoda H, Shiraishi I, Sakaguchi H, Katsuragi S, Sago H, Ikeda T, ; on behalf of Japan Fetal Arrhythmia Group: The impact of intrauterine treatment on fetal tachycardia: a nationwide survey in Japan. J Matern Fetal Neonatal Med; 2017 Jul 19;:1-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To investigate the clinical course of fetal tachycardia and analyze the impact of intrauterine treatment on the postnatal treatment and patient outcomes.
  • Data were collected from questionnaires that were sent to all 750 secondary or tertiary perinatal care centers in Japan.
  • Intrauterine treatment significantly reduced the incidence of cesarean delivery (29.3 vs. 70.7%, p < .01), preterm birth (12.2 vs. 41.5%, p = .02) and neonatal arrhythmias (48.8 vs. 78.0%, p = .01) in comparison to untreated fetuses.
  • CONCLUSIONS: This nationwide survey revealed that intrauterine treatment was performed for approximately half of the cases of fetal tachycardia and was associated with lower rates of cesarean delivery, premature birth and neonatal arrhythmias in comparison to untreated fetuses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28720014.001).
  • [ISSN] 1476-4954
  • [Journal-full-title] The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
  • [ISO-abbreviation] J. Matern. Fetal. Neonatal. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Antiarrhythmic drugs / fetal tachycardia / intrauterine treatment / prenatal diagnosis
  •  go-up   go-down


49. Nguyen KT, Olgin JE, Pletcher MJ, Ng M, Kaye L, Moturu S, Gladstone RA, Malladi C, Fann AH, Maguire C, Bettencourt L, Christensen MA, Marcus GM: Smartphone-Based Geofencing to Ascertain Hospitalizations. Circ Cardiovasc Qual Outcomes; 2017 Mar;10(3)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Ascertainment of hospitalizations is critical to assess quality of care and the effectiveness and adverse effects of various therapies.
  • An in-person study included consecutive consenting patients scheduled for electrophysiology and cardiac catheterization procedures.
  • Of 22 eligible in-person patients, 17 hospitalizations were detected (sensitivity 77%; 95% confidence interval, 55%-92%).
  • This first proof of concept may ultimately be applicable to geofencing other types of prespecified locations to facilitate healthcare research and patient care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • [Cites] J Biomed Inform. 2009 Apr;42(2):377-81 [18929686.001]
  • [Cites] Telemed J E Health. 2016 Aug;22(8):655-65 [26958742.001]
  • [Cites] J Am Coll Cardiol. 2012 Aug 14;60(7):569-80 [22796257.001]
  • [Cites] J Vasc Surg. 2014 Jul;60(1):98-105 [24636641.001]
  • [Cites] Am J Epidemiol. 1998 May 15;147(10):969-77 [9596475.001]
  • [Cites] Med Care Res Rev. 2006 Apr;63(2):217-35 [16595412.001]
  • [Cites] J Clin Epidemiol. 1990;43(1):87-91 [2319285.001]
  • [Cites] Gerontologist. 2016 Oct;56(5):807-16 [26035900.001]
  • [Cites] Patient Prefer Adherence. 2016 Jan 27;10:99-106 [26869773.001]
  • [Cites] Am J Hypertens. 2007 Sep;20(9):942-8 [17765133.001]
  • [Cites] JMIR Mhealth Uhealth. 2016 Apr 19;4(2):e41 [27095507.001]
  • [Cites] Soc Sci Med. 2008 Jul;67(1):128-36 [18396367.001]
  • [Cites] AIDS. 2006 Jan 9;20(2):253-60 [16511419.001]
  • [Cites] Lancet. 2012 Dec 15;380(9859):2197-223 [23245608.001]
  • [Cites] Am J Epidemiol. 2004 Dec 15;160(12):1152-8 [15583367.001]
  • [Cites] Biotechnol Adv. 2016 May-Jun;34(3):291-304 [26952640.001]
  • [Cites] Lancet. 2014 Jul 5;384(9937):45-52 [24996589.001]
  • [Cites] Heart Rhythm. 2016 Jan;13(1):3-9 [26340844.001]
  • [Cites] JMIR Mhealth Uhealth. 2014 May 01;2(2):e19 [25099179.001]
  • [Cites] BMJ Open. 2015 Dec 23;5(12):e008896 [26700275.001]
  • [Cites] Health Serv Res. 2002 Jun;37(3):751-74 [12132604.001]
  • (PMID = 28325751.001).
  • [ISSN] 1941-7705
  • [Journal-full-title] Circulation. Cardiovascular quality and outcomes
  • [ISO-abbreviation] Circ Cardiovasc Qual Outcomes
  • [Language] eng
  • [Grant] United States / NIMHD NIH HHS / MD / R25 MD006832; United States / NCATS NIH HHS / TR / TL1 TR000144; United States / NIBIB NIH HHS / EB / U2C EB021881
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; fast food / hospitalization / internet / pharmacies / smartphone
  •  go-up   go-down


50. Burjek NE, Nishisaki A, Fiadjoe JE, Adams HD, Peeples KN, Raman VT, Olomu PN, Kovatsis PG, Jagannathan N, Hunyady A, Bosenberg A, Tham S, Low D, Hopkins P, Glover C, Olutoye O, Szmuk P, McCloskey J, Dalesio N, Koka R, Greenberg R, Watkins S, Patel V, Reynolds P, Matuszczak M, Jain R, Khalil S, Polaner D, Zieg J, Szolnoki J, Sathyamoorthy K, Taicher B, Riveros Perez NR, Bhattacharya S, Bhalla T, Stricker P, Lockman J, Galvez J, Rehman M, Von Ungern-Sternberg B, Sommerfield D, Soneru C, Chiao F, Richtsfeld M, Belani K, Sarmiento L, Mireles S, Bilen Rosas G, Park R, Peyton J, PeDI Collaborative Investigators: Videolaryngoscopy versus Fiber-optic Intubation through a Supraglottic Airway in Children with a Difficult Airway: An Analysis from the Multicenter Pediatric Difficult Intubation Registry. Anesthesiology; 2017 Sep;127(3):432-440
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patient age, intubation technique, success per attempt, use of continuous ventilation, and complications were recorded for each case.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28650415.001).
  • [ISSN] 1528-1175
  • [Journal-full-title] Anesthesiology
  • [ISO-abbreviation] Anesthesiology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Observational Study
  • [Publication-country] United States
  •  go-up   go-down


51. Al Ashgar H, Peedikayil MC, Al Quaiz M, Al Sohaibani F, Al Fadda A, Khan MQ, Thoralsson E, Al Thawadi S, Al Jedai A, Al Kahtani K: HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study. Saudi J Gastroenterol; 2017 May-Jun;23(3):190-198

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study.
  • We investigated the role of adding PEGylated interferon (PEG IFN) to ongoing tenofovir treatment in chronic HBV patients for achieving HBsAg clearance.
  • PATIENTS AND METHODS: In this randomized controlled trial, chronic HBV patients who have been receiving tenofovir for >6 months with HBV viral load <2000 IU/ml were randomized into two groups.
  • Patients in the other group received only tenofovir 300 mg orally on a daily basis.
  • Patients in both groups were followed up for a total of two years, and patients in both groups were given tenofovir 300 mg daily indefinitely until they developed HBsAg clearance.
  • RESULTS: Twenty-three patients were allocated to the PEG IFN and tenofovir (add-on therapy) group, and another 25 patients were recruited to the tenofovir monotherapy group.
  • Before randomization, patients had received tenofovir for 1135 mean days (range203 to 1542 days).
  • One patient (4.3%) in add-on therapy lost HBsAg and seroconverted.
  • More patients in the add-on group developed serious side effects, with treatment discontinuation, and dose reductions (P = 0.3).
  • CONCLUSION: PEG IFN and tenofovir add-on therapy was successful in achieving HBsAg clearance and seroconversion in 4.3% of the patients.
  • Add-on therapy patients had a significant decrease in HBsAg levels in two years; and no significant decrease in HBsAg levels with the tenofovir monotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2016 Jan;150(1):134-144.e10 [26453773.001]
  • [Cites] J Hepatol. 2013 Feb;58(2):205-9 [23159772.001]
  • [Cites] World J Gastroenterol. 2014 Jul 7;20(25):8195-200 [25009392.001]
  • [Cites] Antivir Ther. 2009;14 (8):1165-74 [20032546.001]
  • [Cites] J Clin Virol. 2013 Dec;58(4):713-7 [24183313.001]
  • [Cites] Gut. 2015 Apr;64(4):667-72 [24833635.001]
  • [Cites] Hepatology. 2015 May;61(5):1459-61 [25645624.001]
  • [Cites] Hepatology. 2015 May;61(5):1512-22 [25348661.001]
  • [Cites] Annu Rev Immunol. 1995;13:29-60 [7612225.001]
  • [Cites] Hepatology. 2016 Jan;63(1):261-83 [26566064.001]
  • [Cites] Hepatol Int. 2016 Jan;10 (1):1-98 [26563120.001]
  • [Cites] Liver Int. 2014 Feb;34 Suppl 1:97-107 [24373085.001]
  • [Cites] Aliment Pharmacol Ther. 2010 Dec;32(11-12):1323-31 [21050234.001]
  • [Cites] Liver Int. 2015 Jan;35 Suppl 1:82-90 [25529092.001]
  • [Cites] J Hepatol. 2014 Oct;61(4):777-84 [24915612.001]
  • [Cites] Aliment Pharmacol Ther. 2015 May;41(9):867-76 [25752878.001]
  • [Cites] J Dig Dis. 2013 Aug;14 (8):446-50 [23615131.001]
  • [Cites] Ann Intern Med. 2005 Feb 15;142(4):240-50 [15710957.001]
  • [Cites] J Hepatol. 2009 Jun;50(6):1084-92 [19376603.001]
  • [Cites] Hepatology. 2001 Apr;33(4):963-71 [11283861.001]
  • [Cites] J Hepatol. 2012 Jul;57(1):167-85 [22436845.001]
  • [Cites] Liver Int. 2015 Jan;35 Suppl 1:114-20 [25529096.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2682-95 [15987917.001]
  • [Cites] J Viral Hepat. 2014 Dec;21(12):825-34 [25402543.001]
  • [Cites] J Clin Virol. 2012 May;54(1):93-5 [22365367.001]
  • [Cites] Lancet. 2005 Jan 8-14;365(9454):123-9 [15639293.001]
  • [Cites] N Engl J Med. 2004 Sep 16;351(12 ):1206-17 [15371578.001]
  • [Cites] Hepatology. 2009 Apr;49(4):1141-50 [19338056.001]
  • [Cites] Liver Int. 2013 Apr;33(4):580-5 [23311449.001]
  • (PMID = 28611343.001).
  • [ISSN] 1998-4049
  • [Journal-full-title] Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
  • [ISO-abbreviation] Saudi J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


52. Erek E, Aydın S, Suzan D, Yıldız O, Altın F, Kırat B, Demir IH, Ödemiş E: Extracorporeal cardiopulmonary resuscitation for refractory cardiac arrest in children after cardiac surgery. Anatol J Cardiol; 2017 Apr;17(4):328-333

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Medical records of all the patients who experienced cardiac arrest and ECPR in an early postoperative period (n=25; 4%) were analyzed.
  • Sixteen patients had palliative procedures.
  • In 88% of the patients, cardiac arrest episodes occurred in the first 24 h after operation.
  • RESULTS: The CPR duration until commencing mechanical support was <20 min in two patients, 20-40 min in 11 patients, and >40 min in 12 patients.
  • Eleven patients (44%) were weaned successfully from ECMO and survived more than 7 days.
  • While four patients were observed to have normal neuromotor development, one patient died of cerebral bleeding 6 months after discharge.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cardiothorac Surg. 2014 Feb;45(2):276-7 [23828848.001]
  • [Cites] Resuscitation. 2009 Oct;80(10):1124-9 [19695762.001]
  • [Cites] Ann Thorac Surg. 2013 Jun;95(6):2140-6; discussion 2146-7 [23506632.001]
  • [Cites] World J Pediatr Congenit Heart Surg. 2012 Apr 1;3(2):229-35 [23804779.001]
  • [Cites] Ann Thorac Surg. 2012 Sep;94(3):874-9; discussion 879-80 [22698774.001]
  • [Cites] Circulation. 1994 Nov;90(5 Pt 2):II280-4 [7955266.001]
  • [Cites] Circulation. 2010 Sep 14;122(11 Suppl):S241-8 [20837920.001]
  • [Cites] Resuscitation. 2012 Jun;83(6):710-4 [22306256.001]
  • [Cites] Circulation. 1999 Nov 9;100(19 Suppl):II194-9 [10567303.001]
  • [Cites] ARYA Atheroscler. 2013 Mar;9(2):145-9 [23690815.001]
  • [Cites] Circulation. 1992 Nov;86(5 Suppl):II300-4 [1424017.001]
  • [Cites] J Intensive Care. 2014 Dec 31;2(1):68 [25705425.001]
  • [Cites] Resuscitation. 2013 Mar;84(3):326-30 [22800860.001]
  • [Cites] Circulation. 2010 Nov 2;122(18 Suppl 3):S876-908 [20956230.001]
  • [Cites] Artif Organs. 2013 Jan;37(1):E29-34 [23305584.001]
  • [Cites] Eur J Cardiothorac Surg. 2008 Mar;33(3):409-17 [18206379.001]
  • [Cites] Pediatr Crit Care Med. 2009 Jul;10(4):445-51 [19451851.001]
  • [Cites] Ann Thorac Surg. 2001 Dec;72(6):2095-101; discussion 2101-2 [11789800.001]
  • [Cites] Crit Care Med. 1997 Dec;25(12):1951-5 [9403741.001]
  • [Cites] Eur J Cardiothorac Surg. 2009 Jul;36(1):3-28 [19297185.001]
  • [Cites] Circulation. 2007 Oct 9;116(15):1693-700 [17893278.001]
  • [Cites] Eur J Cardiothorac Surg. 2014 Feb;45(2):268-75 [23818569.001]
  • (PMID = 28045013.001).
  • [ISSN] 2149-2271
  • [Journal-full-title] Anatolian journal of cardiology
  • [ISO-abbreviation] Anatol J Cardiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


53. Schober A, Sterz F, Herkner H, Wallmueller C, Weiser C, Hubner P, Testori C: Emergency extracorporeal life support and ongoing resuscitation: a retrospective comparison for refractory out-of-hospital cardiac arrest. Emerg Med J; 2017 May;34(5):277-281

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extracorporeal cardiopulmonary resuscitation (ECPR) is an option for certain patients with cardiac arrest.
  • The aim of this study was to evaluate characteristics of patients selected for ECPR.
  • METHODS: Anonymised data of adult patients suffering refractory cardiac arrest, transported with ongoing CPR to an ED of a tertiary care centre between 2002 and 2012 were analysed.
  • RESULTS: Overall, 239 patients fulfilled the inclusion criteria.
  • ECPR was initiated in seven patients.
  • Patients treated with ECPR were younger (46 vs 60 years; p=0.04), had shorter intervals before CPR was started (0 vs 1 min; p=0.013), faster admissions at the ED (38 vs 56 min; p=0.31) and lower blood glucose levels on admission (14 vs 21 mmol/L; p=0.018).
  • Survival to discharge in good neurological condition was achieved in 14 (6%) of all patients.
  • One patient in the ECPR group survived in excellent neurological condition.
  • CONCLUSIONS: Emergency extracorporeal life support was used for a highly selected group of patients in refractory cardiac arrest.
  • The patient selection resulting in a survival of one patient out of seven treated seems reasonable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
  • (PMID = 28213587.001).
  • [ISSN] 1472-0213
  • [Journal-full-title] Emergency medicine journal : EMJ
  • [ISO-abbreviation] Emerg Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Cardiac arrest / ECLS / ECPR / Extracorporeal life support / Resuscitation / Ventricular fibrillation
  •  go-up   go-down


54. Hofland J, Ouattara A, Fellahi JL, Gruenewald M, Hazebroucq J, Ecoffey C, Joseph P, Heringlake M, Steib A, Coburn M, Amour J, Rozec B, Liefde I, Meybohm P, Preckel B, Hanouz JL, Tritapepe L, Tonner P, Benhaoua H, Roesner JP, Bein B, Xenon-CABG Study Group: Effect of Xenon Anesthesia Compared to Sevoflurane and Total Intravenous Anesthesia for Coronary Artery Bypass Graft Surgery on Postoperative Cardiac Troponin Release: An International, Multicenter, Phase 3, Single-blinded, Randomized Noninferiority Trial. Anesthesiology; 2017 09 05;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated whether xenon anesthesia could limit myocardial damage in coronary artery bypass graft surgery patients, as has been reported for animal ischemia models.
  • METHODS: In 17 university hospitals in France, Germany, Italy, and The Netherlands, low-risk elective, on-pump coronary artery bypass graft surgery patients were randomized to receive xenon, sevoflurane, or propofol-based total intravenous anesthesia for anesthesia maintenance.
  • RESULTS: The first patient included at each center received xenon anesthesia for practical reasons.
  • For all other patients, anesthesia maintenance was randomized (intention-to-treat: n = 492; per-protocol/without major protocol deviation: n = 446).
  • CONCLUSIONS: In postoperative cardiac troponin I release, xenon was noninferior to sevoflurane in low-risk, on-pump coronary artery bypass graft surgery patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28872484.001).
  • [ISSN] 1528-1175
  • [Journal-full-title] Anesthesiology
  • [ISO-abbreviation] Anesthesiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Investigator] Hanouz L; Tenbrinck R; Bogers AJJC; Mik BG; Coiffic A; Renner J; Steinfath M; Francksen H; Broch O; Haneya A; Schaller M; Guinet P; Daviet L; Brianchon C; Rosier S; Lehot JJ; Paarmann H; Schön J; Hanke T; Ettel J; Olsson S; Klotz S; Samet A; Laurinenas G; Thibaud A; Cristinar M; Collanges O; Levy F; Rossaint R; Stevanovic A; Schaelte G; Stoppe C; Hamou NA; Hariri S; Quessard A; Carillion A; Morin H; Silleran J; Robert D; Crouzet AS; Zacharowski K; Reyher C; Iken S; Weber NC; Hollmann M; Eberl S; Carriero G; Collacchi D; Di Persio A; Fourcade O; Bergt S; Alms A
  •  go-up   go-down


55. Horvat N, Marcelino ASZ, Horvat JV, Yamanari TR, Batista Araújo-Filho JA, Panizza P, Seda-Neto J, Antunes da Fonseca E, Carnevale FC, Mendes de Oliveira Cerri L, Chapchap P, Cerri GG: Pediatric Liver Transplant: Techniques and Complications. Radiographics; 2017 Oct;37(6):1612-1631

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liver transplant is considered to be the last-resort treatment approach for pediatric patients with end-stage liver disease.
  • Early diagnosis of complications is crucial for patient survival but is challenging given the lack of specificity in clinical presentation.
  • The authors review surgical techniques, the role of each imaging modality, normal posttransplant imaging features, types of complications after liver transplant, and information required in the radiology report that is critical to patient care.
  • They present an algorithm for an imaging approach for pediatric patients after liver transplant and describe key points that should be included in radiologic reports in the pre- and postoperative settings.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29019744.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Yang K, Downey C, Suter N, Gott L, Naughton L, Aufiero K, Day S, McGovern N, Brock J, Andreou K, Strasser J, Koprowski C, Raben A, Chen H, Mourtada F: SU-F-J-35: Moving Towards Isocentric Prone Breast Setup with Contralateral Leveling Tattoo and Couch Move Assistant (CMA). Med Phys; 2016 Jun;43(6):3413-3414

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Large setup variability has been observed for prone breast patients due to rotation error.
  • METHODS: Daily CBCT is used to evaluate the prone breast patient positioning uncertainty of proposed isocentric technique against our routine manual clinical setup.
  • While the proposed isocentric prone breast method features an additional contralateral leveling tattoo positioned at mid-level of torso during CT simulation to determine correct patient obliqueness, and an automatic couch shift using Elekta CMA to correct both known distance from 2PT to the iso and daily setup uncertainty.
  • Summary statistics were calculated for a cohort of prone breast patients from our clinic (n=5), and will be updated as more patients get administrated.
  • CONCLUSION: Contralateral leveling tattoo is essential to determine correct patient obliqueness.
  • More consistent and accurate isocentric prone breast patient positioning is achievable on Elekta linac with CMA and CBCT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2016 American Association of Physicists in Medicine.
  • (PMID = 28047378.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cone beam computed tomography / Linear accelerators / Medical imaging
  •  go-up   go-down


62. Biegstraaten M, Cox TM, Belmatoug N, Berger MG, Collin-Histed T, Vom Dahl S, Di Rocco M, Fraga C, Giona F, Giraldo P, Hasanhodzic M, Hughes DA, Iversen PO, Kiewiet AI, Lukina E, Machaczka M, Marinakis T, Mengel E, Pastores GM, Plöckinger U, Rosenbaum H, Serratrice C, Symeonidis A, Szer J, Timmerman J, Tylki-Szymańska A, Weisz Hubshman M, Zafeiriou DI, Zimran A, Hollak CEM: Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease. Blood Cells Mol Dis; 2016 Oct 24;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therapy improves the principal manifestations of the condition and, as a consequence, many patients show a modified phenotype which reflects manifestations of their disease that are refractory to treatment.
  • More generally, it is increasingly recognised that information as to how a patient feels and functions [obtained by patient- reported outcome measurements (PROMs)] is critical to any comprehensive evaluation of treatment.
  • Based on a literature review and with input from patients, 65 potential goals were formulated as statements.
  • When applying this set of goals in medical practice, the clinical status of the individual patient should be taken into account.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28274788.001).
  • [ISSN] 1096-0961
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MR/K015338/1; United Kingdom / Medical Research Council / / MR/K025570/1
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Delphi study / Gaucher disease / Management goals / PROMs / Therapy
  •  go-up   go-down


63. Chanques G, Conseil M, Roger C, Constantin JM, Prades A, Carr J, Muller L, Jung B, Belafia F, Cissé M, Delay JM, de Jong A, Lefrant JY, Futier E, Mercier G, Molinari N, Jaber S, SOS-Ventilation study investigators: Immediate interruption of sedation compared with usual sedation care in critically ill postoperative patients (SOS-Ventilation): a randomised, parallel-group clinical trial. Lancet Respir Med; 2017 Oct;5(10):795-805

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immediate interruption of sedation compared with usual sedation care in critically ill postoperative patients (SOS-Ventilation): a randomised, parallel-group clinical trial.
  • BACKGROUND: Avoidance of excessive sedation and subsequent prolonged mechanical ventilation in intensive care units (ICUs) is recommended, but no data are available for critically ill postoperative patients.
  • We hypothesised that in such patients stopping sedation immediately after admission to the ICU could reduce unnecessary sedation and improve patient outcomes.
  • Stratified randomisation with minimisation (1:1 via a restricted web platform) was used to assign eligible patients (aged ≥18 years, admitted to an ICU after abdominal surgery, and expected to require at least 12 h of mechanical ventilation because of a critical illness defined by a Sequential Organ Failure Assessment score >1 for any organ, but without severe acute respiratory distress syndrome or brain injury) to usual sedation care provided according to recommended practices (control group) or to immediate interruption of sedation (intervention group).
  • All patients who underwent randomisation (except for those who were excluded after randomisation) were included in the intention-to-treat analysis.
  • FINDINGS: Between Dec 2, 2011, and Feb 27, 2014, 137 patients were randomly assigned to the control (n=68) or intervention groups (n=69).
  • INTERPRETATION: Immediate interruption of sedation in critically ill postoperative patients with organ dysfunction who were admitted to the ICU after abdominal surgery improved outcomes compared with usual sedation care.
  • These findings support interruption of sedation in these patients following transfer from the operating room.
  • FUNDING: Délégation à la Recherche Clinique et à l'Innovation du Groupement de Coopération Sanitaire de la Mission d'Enseignement, de Recherche, de Référence et d'Innovation (DRCI-GCS-MERRI) de Montpellier-Nîmes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28935558.001).
  • [ISSN] 2213-2619
  • [Journal-full-title] The Lancet. Respiratory medicine
  • [ISO-abbreviation] Lancet Respir Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Investigator] Chanques G; Conseil M; Prades A; Carr J; Jung B; Belafia F; Cissé M; Delay JM; De Jong A; Verzilli D; Clavieras N; Jaber S; Mercier G; Molinari N; Mathieu E; Bertet H; Roger C; Muller L; Lefrant JY; Boutin C; Constantin JM; Futier E; Cayot S; Perbet S; Jabaudon M
  •  go-up   go-down


64. Bouida W, Baccouche H, Sassi M, Dridi Z, Chakroun T, Hellara I, Boukef R, Hassine M, Added F, Razgallah R, Khochtali I, Nouira S, Ramadan Research Group: Effects of Ramadan fasting on platelet reactivity in diabetic patients treated with clopidogrel. Thromb J; 2017;15:15

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of Ramadan fasting on platelet reactivity in diabetic patients treated with clopidogrel.
  • The present study evaluated the influence of RF on platelet reactivity in patients with high cardiovascular risk (CVR) in particular those with type 2 diabetes mellitus (DM).
  • METHODS: A total of 98 stable patients with ≥2 CVR factors were recruited.
  • All patients observed RF and were taking clopidogrel at a maintenance dose of 75 mg.
  • During each patient visit, nutrients intakes were calculated and platelet reactivity assessment using Verify Now P2Y12 assay was performed.
  • RESULTS: In DM patients, the absolute PRU changes from baseline were +27 (<i>p</i> = 0.01) and +16 (<i>p</i> = 0.02) respectively at R and Post-R.
  • In non DM patients there was no significant change in absolute PRU values and metabolic parameters.
  • Clopidogrel resistance rate using 2 cut-off PRU values (235 and 208) did not change significantly in DM and non DM patients.
  • CONCLUSIONS: RF significantly decreased platelet sensitivity to clopidogrel in DM patients during and after Ramadan.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Health Popul Nutr. 2011 Oct;29(5):486-93 [22106754.001]
  • [Cites] Diabetes Care. 2004 Oct;27(10):2306-11 [15451892.001]
  • [Cites] Circulation. 2004 Jun 29;109 (25):3171-5 [15184279.001]
  • [Cites] Thromb Haemost. 2015 Feb;113(2):221-30 [25413597.001]
  • [Cites] Circulation. 2011 Sep 6;124(10):1132-7 [21875913.001]
  • [Cites] Am Heart J. 2009 Nov;158(5):784.e1-6 [19853698.001]
  • [Cites] Br J Haematol. 2014 Sep;166(5):792-4 [24749553.001]
  • [Cites] Vasc Health Risk Manag. 2012;8:65-75 [22371653.001]
  • [Cites] Expert Opin Pharmacother. 2014 Dec;15(17):2553-64 [25297833.001]
  • [Cites] Int Clin Psychopharmacol. 2010 Nov;25(6):323-7 [20827213.001]
  • [Cites] Lancet. 2013 Aug 17;382(9892):614-23 [23890998.001]
  • [Cites] BMJ. 1992 Feb 29;304(6826):521-2 [1559053.001]
  • [Cites] J Am Coll Cardiol. 2014 Sep 9;64(10):1015-8 [25190237.001]
  • [Cites] Thromb Haemost. 1992 Nov 10;68(5):577-82 [1455404.001]
  • [Cites] Circulation. 1999 Sep 28;100(13):1481-92 [10500053.001]
  • [Cites] JAMA. 2010 Feb 24;303(8):754-62 [20179285.001]
  • [Cites] J Diabetes Complications. 2009 Mar-Apr;23(2):89-94 [18358749.001]
  • [Cites] Circulation. 2003 Jun 17;107(23):2908-13 [12796140.001]
  • [Cites] Cardiovasc Diabetol. 2015 Feb 03;14:15 [25645908.001]
  • [Cites] J Thromb Haemost. 2014;12(3):349-54 [24354801.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2009 Jun;23(3):375-88 [19520310.001]
  • [Cites] Diabetes Res Clin Pract. 2006 Aug;73(2):117-25 [16647781.001]
  • [Cites] J Intern Med. 2007 Aug;262(2):157-72 [17645584.001]
  • [Cites] Thromb Res. 2004;113(2):101-13 [15115665.001]
  • [Cites] Eur Heart J. 2008 Apr;29(8):992-1000 [18263931.001]
  • [Cites] J Thromb Haemost. 2004 Aug;2(8):1282-91 [15304032.001]
  • [Cites] Public Health. 1986 Jan;100(1):49-53 [3749438.001]
  • [Cites] JACC Cardiovasc Interv. 2013 Nov;6(11):1111-28 [24262612.001]
  • [Cites] Clin Res Cardiol. 2010 Nov;99(11):743-52 [20526607.001]
  • (PMID = 28588426.001).
  • [ISSN] 1477-9560
  • [Journal-full-title] Thrombosis journal
  • [ISO-abbreviation] Thromb J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Clopidogrel / Diabetes mellitus / Fasting / Platelet activation / Platelet aggregation inhibitors
  •  go-up   go-down


65. Scott JW, Neiman PU, Najjar PA, Tsai TC, Scott KW, Shrime MG, Cutler DM, Salim A, Haider AH: Potential impact of Affordable Care Act-related insurance expansion on trauma care reimbursement. J Trauma Acute Care Surg; 2017 May;82(5):887-895

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential impact of Affordable Care Act-related insurance expansion on trauma care reimbursement.
  • BACKGROUND: Nearly one quarter of trauma patients are uninsured and hospitals recoup less than 20% of inpatient costs for their care.
  • This study examines changes to hospital reimbursement for inpatient trauma care if the full coverage expansion provisions of the Affordable Care Act (ACA) were in effect.
  • Using US census data, we developed a probabilistic microsimulation model to determine the proportion of pre-ACA uninsured trauma patients that would be expected to gain private insurance, Medicaid, or remain uninsured after full implementation of the ACA.
  • RESULTS: There were 145,849 patients (representing 737,852 patients nationwide) included.
  • National inpatient trauma costs for patients aged 18 years to 64 years totaled US $14.8 billion (95% confidence interval [CI], 12.5,17.1).
  • CONCLUSION: Health insurance coverage expansion for uninsured trauma patients has the potential to increase national reimbursement for inpatient trauma care by over one billion dollars and nearly double the proportion of hospitals with a positive margin for trauma care.
  • These data suggest that insurance coverage expansion has the potential to improve trauma centers' financial viability and their ability to provide care for their communities.
  • [MeSH-major] Insurance, Health, Reimbursement / legislation & jurisprudence. Patient Protection and Affordable Care Act / economics. Trauma Centers / legislation & jurisprudence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Trauma. 2011 Apr;70(4):978-84 [21610399.001]
  • [Cites] Br J Surg. 2016 Oct;103(11):1453-61 [27428044.001]
  • [Cites] JAMA Surg. 2014 May;149(5):422-30 [24554059.001]
  • [Cites] Lancet. 2004 May 29;363(9423):1794-801 [15172780.001]
  • [Cites] Arch Surg. 2008 Oct;143(10):945-9 [18936372.001]
  • [Cites] Health Aff (Millwood). 2015 Jan;34(1):125-33 [25561653.001]
  • [Cites] J Trauma Acute Care Surg. 2016 Jun;80(6):1010-4 [27015573.001]
  • [Cites] Lancet Glob Health. 2015 Apr 27;3 Suppl 2:S38-44 [25926319.001]
  • [Cites] J Trauma. 2000 Jan;48(1):25-30; discussion 30-1 [10647561.001]
  • [Cites] J Trauma Acute Care Surg. 2013 May;74(5):1195-205 [23609267.001]
  • [Cites] Health Aff (Millwood). 2014 May;33(5):792-9 [24799576.001]
  • [Cites] Ann Surg. 2015 Jul;262(1):16-7 [26020114.001]
  • [Cites] J Trauma Acute Care Surg. 2015 May;78(5):1026-33 [25909426.001]
  • [Cites] Health Aff (Millwood). 2014 Jun;33(6):988-96 [24889948.001]
  • [Cites] JAMA. 2001 Mar 7;285(9):1164-71 [11231745.001]
  • [Cites] J Trauma Acute Care Surg. 2013 Sep;75(3):512-5 [23823607.001]
  • [Cites] Ann Surg. 2015 Jul;262(1):9-15 [26020113.001]
  • [Cites] Int J Health Serv. 2016;46(1):166-84 [25995304.001]
  • [Cites] Arch Surg. 2012 Jan;147(1):63-70 [21930976.001]
  • [Cites] Bull Am Coll Surg. 2015 Jan;100(1):51-2 [25626271.001]
  • [Cites] Med Care. 2009 Sep;47(9):968-78 [19704354.001]
  • [Cites] Ann Surg. 2013 Oct;258(4):572-9; discussion 579-81 [23979271.001]
  • [Cites] N Engl J Med. 2006 Jan 26;354(4):366-78 [16436768.001]
  • [Cites] J Am Coll Surg. 2010 May;210(5):817-21, 821-3 [20421057.001]
  • [Cites] J Trauma Acute Care Surg. 2012 Nov;73(5):1303-7 [23032805.001]
  • [Cites] J Trauma Acute Care Surg. 2016 Sep;81(3):427-34 [27355684.001]
  • [Cites] Health Aff (Millwood). 2012 May;31(5):909-19 [22566429.001]
  • (PMID = 28431415.001).
  • [ISSN] 2163-0763
  • [Journal-full-title] The journal of trauma and acute care surgery
  • [ISO-abbreviation] J Trauma Acute Care Surg
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / K23 GM093112
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Tokimatsu I, Shigemura K, Kotaki T, Yoshikawa H, Yamamichi F, Tomo T, Arakawa S, Fujisawa M, Kadota JI: A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia. Intern Med; 2017;56(11):1315-1319

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia.
  • Objectives To investigate the efficacy of oral moxifloxacin (MFLX) as a treatment for pneumonia in hemodialysis (HD) patients and the pharmacokinetic (PK) profile of MFLX after oral administration.
  • Methods Thirteen adult patients who required HD due to chronic renal failure were enrolled in the present study, which was performed to investigate the treatment of community-acquired pneumonia in HD patients.
  • Results In total, 13 HD patients with pneumonia (male, n=7; female, n=6) were enrolled in the present study.
  • The evaluation on the 3rd day showed that treatment was successful in 11 patients (84.6%) and that 10 patients were cured (76.9%).
  • In the one case in which MFLX treatment failed, the patient was cured by switching to ceftriaxone (CTRX) (2 g, intravenously) plus levofloxacin (LVFX) (250 mg, orally).
  • The causative bacterium in this male patient was P. aeruginosa.
  • One patient had liver dysfunction due to MFLX.
  • The PK parameters of MFLX among the patients in whom adverse events occurred or in whom a cure was not achieved did not differ from those of the other patients to a statistically significant extent.
  • Conclusion MFLX showed good efficacy and safety in HD patients with community-acquired pneumonia and the results of the PK analysis were favorable.
  • Further prospective studies with larger numbers of patients will be needed to draw definitive conclusions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Antimicrob Agents Chemother. 2004 Mar;48(3):1012-6 [14982797.001]
  • [Cites] Br J Clin Pharmacol. 2007 Dec;64(6):745-9 [17555469.001]
  • [Cites] J Antimicrob Chemother. 2011 Oct;66(10):2330-5 [21729931.001]
  • [Cites] J Infect Chemother. 2014 Jul;20(7):417-22 [24787737.001]
  • [Cites] J Infect Chemother. 2011 Oct;17(5):640-5 [21369775.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416 [15699079.001]
  • [Cites] Drugs R D. 2012 Jun 1;12(2):71-100 [22715866.001]
  • [Cites] Am J Med. 2005 Jul;118 Suppl 7A:29S-38S [15993675.001]
  • [Cites] Respir Investig. 2013 Jun;51(2):103-26 [23790739.001]
  • [Cites] Perit Dial Int. 2009 Sep-Oct;29(5):575-9 [19776053.001]
  • [Cites] Hemodial Int. 2007 Jan;11(1):62-71 [17257358.001]
  • [Cites] J Antimicrob Chemother. 2004 Oct;54(4):780-4 [15347636.001]
  • [Cites] Int J Clin Pract. 2010 Feb;64(3):378-88 [20456176.001]
  • [Cites] Antimicrob Agents Chemother. 1998 Aug;42(8):2060-5 [9687407.001]
  • [Cites] Drugs. 2000 Jan;59(1):115-39 [10718103.001]
  • [Cites] Nephrol Dial Transplant. 2011 Sep;26(9):2899-906 [21273232.001]
  • [Cites] Int J Antimicrob Agents. 2012 Jun;39(6):455-7 [22483562.001]
  • [Cites] J Infect Chemother. 2011 Oct;17(5):678-85 [21847518.001]
  • (PMID = 28566592.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; hemodialysis / moxifloxacin / pharmacokinetics / pneumonia
  •  go-up   go-down


67. Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C: Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet; 2017 Aug 16;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Interim analyses of the phase 3 KEYNOTE-006 study showed superior overall and progression-free survival of pembrolizumab versus ipilimumab in patients with advanced melanoma.
  • METHODS: In this multicentre, open-label, randomised, phase 3 trial, we recruited patients from 87 academic institutions, hospitals, and cancer centres in 16 countries (Australia, Austria, Belgium, Canada, Chile, Colombia, France, Germany, Israel, Netherlands, New Zealand, Norway, Spain, Sweden, UK, and USA).
  • Eligible patients were at least 18 years old, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, at least one measurable lesion per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1), unresectable stage III or IV melanoma (excluding ocular melanoma), and up to one previous systemic therapy (excluding anti-CTLA-4, PD-1, or PD-L1 agents).
  • Patients were excluded if they had active brain metastases or active autoimmune disease requiring systemic steroids.
  • Survival was assessed every 12 weeks, and final analysis occurred after all patients were followed up for at least 21 months.
  • Primary analysis was done on the intention-to-treat population (all randomly assigned patients) and safety analyses were done in the treated population (all randomly assigned patients who received at least one dose of study treatment).
  • FINDINGS: Between Sept 18, 2013, and March 3, 2014, 834 patients with advanced melanoma were enrolled and randomly assigned to receive intravenous pembrolizumab every 2 weeks (n=279), intravenous pembrolizumab every 3 weeks (n=277), or intravenous ipilimumab every 3 weeks (ipilimumab for four doses; n=278).
  • One patient in the pembrolizumab 2 week group and 22 patients in the ipilimumab group withdrew consent and did not receive treatment.
  • A total of 811 patients received at least one dose of study treatment.
  • Median follow-up was 22·9 months; 383 patients died.
  • These conclusions further support the use of pembrolizumab as a standard of care for advanced melanoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28822576.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


68. Sagnelli C, Uberti-Foppa C, Hasson H, Bellini G, Minichini C, Salpietro S, Messina E, Barbanotti D, Merli M, Punzo F, Coppola N, Lazzarin A, Sagnelli E, Rossi F: Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients. PLoS One; 2017;12(7):e0181890
HIV InSite. treatment guidelines - Coinfection with Hepatitis Viruses and HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients.
  • OBJECTIVE: This is the first study to analyze the impact of the rs35761398 variant of the CNR2 gene leading to the substitution of GLN (Q) of codon 63 of the cannabinoid receptor 2 (CB2) with ARG (R) on the clinical presentation of chronic hepatitis in HIV/HCV coinfected patients.
  • METHODS: Enrolled in this study were 166 consecutive HIV/HCV coinfected patients, naïve for HCV treatment.
  • A pathologist unaware of the patients' condition graded liver fibrosis, necroinflammation (Ishak) and steatosis.
  • All patients were screened for the CB2 rs35761398 polymorphism.
  • RESULTS: Of the 166 HIV/HCV coinfected patients, 72.9% were males, 42.5% were infected with HCV-genotype-3 and 60.2% had been intravenous drug users.
  • Thirty-five (21.1%) patients were naive for ART and 131(78.9%) were on ART.
  • The CB2-RR variant was detected in 45.8% of patients, QR in 38.6% and QQ in 15.7%.
  • Patients with CB2-RR showed a necroinflammation score (HAI) ≥9 more frequently than those with CB2-QQ or CB2-QR (32.9% vs. 11.5% and 14.1%, respectively, p≤0.001).
  • CONCLUSION: This study shows interesting interplay between the CB2-RR variant and liver necroinflammation in chronic hepatitis patients with HIV/HCV coinfection, an observation of clinical value that coincides with the interest in the use of the CB2 agonists and antagonists in clinical practice emerging from the literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr HIV Res. 2009 Jul;7(4):447-55 [19601782.001]
  • [Cites] Clin Microbiol Infect. 2016 Apr;22(4):372-8 [26806136.001]
  • [Cites] AIDS Patient Care STDS. 2009 Nov;23(11):915-23 [19877800.001]
  • [Cites] Int Immunopharmacol. 2015 May;26(1):86-91 [25791728.001]
  • [Cites] J Hepatol. 1995 Jun;22(6):696-9 [7560864.001]
  • [Cites] PLoS One. 2014 Jun 18;9(6):e99450 [24940753.001]
  • [Cites] Mol Immunol. 2006 Jul;43(14 ):2169-79 [16503355.001]
  • [Cites] Handb Exp Pharmacol. 2005;(168):385-423 [16596782.001]
  • [Cites] Hepatology. 2009 Apr;49(4):1090-7 [19263473.001]
  • [Cites] Nature. 2009 Oct 8;461(7265):798-801 [19759533.001]
  • [Cites] N Engl J Med. 1992 Dec 31;327(27):1899-905 [1280771.001]
  • [Cites] J Urban Health. 2011 Jun;88(3):507-16 [21302140.001]
  • [Cites] Life Sci. 2014 May 28;104(1-2):15-23 [24742657.001]
  • [Cites] PLoS One. 2012;7(3):e33961 [22448282.001]
  • [Cites] AIDS. 2008 Oct 1;22(15):1979-91 [18784461.001]
  • [Cites] Haematologica. 2011 Dec;96(12):1883-5 [21828121.001]
  • [Cites] Hepatology. 2011 Oct;54(4):1217-26 [21735467.001]
  • [Cites] Hepatology. 2011 Sep 2;54(3):1102; author reply 1102-3 [21608006.001]
  • [Cites] Clin Infect Dis. 2002 Mar 15;34(6):831-7 [11833007.001]
  • [Cites] Aliment Pharmacol Ther. 2014 Apr;39(8):790-801 [24612021.001]
  • [Cites] J Hepatol. 2006 Jan;44(1):47-55 [16182404.001]
  • [Cites] Ann Intern Med. 2014 Mar 18;160(6):369-79 [24723077.001]
  • [Cites] Hepatology. 2005 Jun;41(6):1313-21 [15915461.001]
  • [Cites] Dig Liver Dis. 2016 Nov;48(11):1364-1369 [27476469.001]
  • [Cites] Braz J Infect Dis. 2014 Mar-Apr;18(2):164-9 [24650995.001]
  • [Cites] Pharmacogenet Genomics. 2010 Mar;20(3):157-66 [20124950.001]
  • [Cites] PLoS Med. 2006 Dec;3(12):e492 [17194190.001]
  • [Cites] Hepat Mon. 2011 Jul 1;11(7):525-31 [22706343.001]
  • [Cites] Clin Gastroenterol Hepatol. 2014 Feb;12(2):334-40 [23707465.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2008 Mar;294(3):H1145-55 [18178718.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):63-7 [16340475.001]
  • [Cites] PLoS Pathog. 2009 Oct;5(10):e1000633 [19851458.001]
  • [Cites] Hepatology. 2007 Sep;46(3):622-30 [17659577.001]
  • [Cites] Clin Infect Dis. 2001 Aug 15;33(4):562-9 [11462196.001]
  • [Cites] J Acquir Immune Defic Syndr. 2010 May 1;54(1):107-8 [20418725.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Jan;6(1):69-75 [18166478.001]
  • [Cites] PLoS One. 2010 Jan 14;5(1):e8688 [20098669.001]
  • [Cites] J Hepatol. 2006;44(1 Suppl):S14-8 [16338026.001]
  • [Cites] Hepatology. 2001 Jun;33(6):1358-64 [11391523.001]
  • [Cites] Lancet. 1997 Mar 22;349(9055):825-32 [9121257.001]
  • [Cites] Br J Pharmacol. 2008 Jan;153(2):299-308 [17982478.001]
  • [Cites] World J Clin Cases. 2015 Sep 16;3(9):807-22 [26380828.001]
  • [Cites] Endocr Metab Immune Disord Drug Targets. 2008 Sep;8(3):159-72 [18782012.001]
  • [Cites] Lancet. 2003 Nov 22;362(9397):1708-13 [14643119.001]
  • [Cites] J Neuroimmune Pharmacol. 2013 Jun;8(3):608-20 [23471521.001]
  • [Cites] Hepatology. 1999 Oct;30(4):1054-8 [10498659.001]
  • [Cites] Hepatology. 1998 Sep;28(3):805-9 [9731576.001]
  • [Cites] Pharmacol Res. 2012 Jul;66(1):88-94 [22465144.001]
  • [Cites] Sex Transm Dis. 2011 Mar;38(3):219-20 [20938373.001]
  • [Cites] Nature. 2009 Sep 17;461(7262):399-401 [19684573.001]
  • [Cites] J Leukoc Biol. 2005 Jul;78(1):231-8 [15845647.001]
  • [Cites] World J Gastroenterol. 2016 Oct 14;22(38):8509-8518 [27784963.001]
  • [Cites] J Neuroimmune Pharmacol. 2007 Jun;2(2):178-83 [18040842.001]
  • [Cites] Infection. 2013 Oct;41(5):959-67 [23839212.001]
  • [Cites] Hepatology. 2001 Aug;34(2):283-7 [11481613.001]
  • [Cites] World J Hepatol. 2015 Oct 28;7(24):2510-21 [26523204.001]
  • (PMID = 28759568.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 0 / Receptor, Cannabinoid, CB2
  •  go-up   go-down


69. Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Y Brucker S, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol; 2017 Aug 01;28(8):1700-1712
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
  • Treatments were assessed in light of their intensity, duration and side-effects, seeking where appropriate to escalate or de-escalate therapies based on likely benefits as predicted by tumor stage and tumor biology.
  • The Panel favored several interventions that may reduce surgical morbidity, including acceptance of 2 mm margins for DCIS, the resection of residual cancer (but not baseline extent of cancer) in women undergoing neoadjuvant therapy, acceptance of sentinel node biopsy following neoadjuvant treatment of many patients, and the preference for neoadjuvant therapy in HER2 positive and triple-negative, stage II and III breast cancer.
  • The Panel favored escalating radiation therapy with regional nodal irradiation in high-risk patients, while encouraging omission of boost in low-risk patients.
  • The Panel endorsed gene expression signatures that permit avoidance of chemotherapy in many patients with ER positive breast cancer.
  • However, low-risk patients can avoid these treatments.
  • The Panel recognized that recommendations are not intended for all patients, but rather to address the clinical needs of the majority of common presentations.
  • Individualization of adjuvant therapy means adjusting to the tumor characteristics, patient comorbidities and preferences, and managing constraints of treatment cost and access that may affect care in both the developed and developing world.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
  • (PMID = 28838210.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; St Gallen Consensus / early breast cancer / radiation therapy / surgery / systemic adjuvant therapies
  •  go-up   go-down


70. Moore L, Boukar KM, Tardif PA, Stelfox HT, Champion H, Cameron P, Gabbe B, Yanchar N, Kortbeek J, Lauzier F, Légaré F, Archambault P, Turgeon AF: Low-value clinical practices in injury care: a scoping review protocol. BMJ Open; 2017 Jul 12;7(7):e016024

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-value clinical practices in injury care: a scoping review protocol.
  • Overall, potentially unnecessary medical interventions are estimated to consume up to 30% of healthcare resources and may expose patients to avoidable harm.
  • However, little is known about overuse for acute injury care.
  • We aim to identify low-value clinical practices in injury care.
  • We will search Medline, EMBASE, COCHRANE central, and BIOSIS/Web of Knowledge databases, websites of government agencies, professional societies and patient advocacy organisations, thesis holdings and conference proceedings.
  • This review will contribute new knowledge on low-value clinical practices in acute injury care.
  • Our results will support the development indicators to measure resource overuse and inform policy makers on potential targets for deadoption in injury care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
  • (PMID = 28706101.001).
  • [ISSN] 2044-6055
  • [Journal-full-title] BMJ open
  • [ISO-abbreviation] BMJ Open
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Injury / Low-value clinical practise / Quality in health care / medical overuse
  •  go-up   go-down


71. Yarmolenko PS, Eranki A, Partanen A, Celik H, Kim A, Oetgen M, Beskin V, Santos D, Patel J, Kim PCW, Sharma K: Technical aspects of osteoid osteoma ablation in children using MR-guided high intensity focussed ultrasound. Int J Hyperthermia; 2017 Apr 24;:1-10
figshare. supplemental materials - Supporting Data and Materials for the article .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Magnetic resonance imaging-guided high intensity focussed ultrasound (MR-HIFU) allows non-invasive treatment without ionising radiation exposure, in contrast to the current standard of care treatment with radiofrequency ablation (RFA).
  • This report describes technical aspects of MR-HIFU ablation in the first 8 paediatric OO patients treated in a safety and feasibility clinical trial (total enrolment of up to 12 patients).
  • Detailed treatment workflow, patient positioning and coupling strategies, as well as temperature and tissue perfusion changes were summarised and correlated.
  • Ultrasound standoff pads were shaped to conform to extremity contours providing acoustic coupling and aided patient positioning.
  • Complete pain relief with no medication occurred in 7/8 patients within 28 days following treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28540807.001).
  • [ISSN] 1464-5157
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Clinical trials-thermal ablation / children / high intensity focused ultrasound / osteoid osteoma / thermal ablation
  •  go-up   go-down


72. Wheeler C, Halter M, Drennan VM, de Lusignan S, Grant R, Gabe J, Gage H, Begg P, Ennis J, Parle J: Physician associates working in secondary care teams in England: Interprofessional implications from a national survey. J Interprof Care; 2017 Sep 06;:1-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physician associates working in secondary care teams in England: Interprofessional implications from a national survey.
  • This study investigated the deployment of PAs within secondary care teams in England, through the use of a cross-sectional electronic, self-report survey.
  • Both direct and non-direct patient care activities were reported, with the type of work undertaken varying at times, depending on the presence or absence of other healthcare professionals.
  • PAs reported working within a variety of secondary care team staffing permutations, with the majority of these being interprofessional.
  • Further research is required to understand the nature of PAs' contribution to collaborative care within secondary care teams in England.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28876145.001).
  • [ISSN] 1469-9567
  • [Journal-full-title] Journal of interprofessional care
  • [ISO-abbreviation] J Interprof Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Interprofessional collaboration / physician assistants / physician associates / secondary care / secondary care teams
  •  go-up   go-down


73. Kahan BC, Koulenti D, Arvaniti K, Beavis V, Campbell D, Chan M, Moreno R, Pearse RM, International Surgical Outcomes Study (ISOS) group: Critical care admission following elective surgery was not associated with survival benefit: prospective analysis of data from 27 countries. Intensive Care Med; 2017 Jul;43(7):971-979

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Critical care admission following elective surgery was not associated with survival benefit: prospective analysis of data from 27 countries.
  • PURPOSE: As global initiatives increase patient access to surgical treatments, there is a need to define optimal levels of perioperative care.
  • Our aim was to describe the relationship between the provision and use of critical care resources and postoperative mortality.
  • METHODS: Planned analysis of data collected during an international 7-day cohort study of adults undergoing elective in-patient surgery.
  • We used risk-adjusted mixed-effects logistic regression models to evaluate the association between admission to critical care immediately after surgery and in-hospital mortality.
  • We evaluated hospital-level associations between mortality and critical care admission immediately after surgery, critical care admission to treat life-threatening complications, and hospital provision of critical care beds.
  • RESULTS: 44,814 patients from 474 hospitals in 27 countries were available for analysis.
  • Death was more frequent amongst patients admitted directly to critical care after surgery (critical care: 103/4317 patients [2%], standard ward: 99/39,566 patients [0.3%]; adjusted OR 3.01 [2.10-5.21]; p < 0.001).
  • At hospital level, there was no association between mortality and critical care admission directly after surgery (p = 0.26), critical care admission to treat complications (p = 0.33), or provision of critical care beds (p = 0.70).
  • A sensitivity analysis including only high-risk patients yielded similar findings.
  • CONCLUSIONS: We did not identify any survival benefit from critical care admission following surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 2011 Oct 05;343:d5759 [21976704.001]
  • [Cites] Lancet Glob Health. 2015 Apr 27;3 Suppl 2:S13-20 [25926315.001]
  • [Cites] Nurs Res. 2003 Mar-Apr;52(2):71-9 [12657982.001]
  • [Cites] Lancet Glob Health. 2015 Jun;3(6):e316-23 [25926087.001]
  • [Cites] Lancet. 2015 Apr 27;385 Suppl 2:S11 [26313057.001]
  • [Cites] Med Care. 2011 Apr;49(4):406-14 [21407034.001]
  • [Cites] Br J Anaesth. 2017 Jan;118(1):123-131 [28039249.001]
  • [Cites] Ann Surg. 2012 Apr;255(4):696-702 [22418007.001]
  • [Cites] Lancet. 2008 Jul 12;372(9633):139-44 [18582931.001]
  • [Cites] N Engl J Med. 2009 Apr 2;360(14):1418-28 [19339721.001]
  • [Cites] Br J Anaesth. 2016 Nov;117(5):601-609 [27799174.001]
  • [Cites] Br J Anaesth. 2014 Mar;112(3):491-7 [24148323.001]
  • [Cites] J Nurs Adm. 2004 Jan;34(1):41-5 [14737034.001]
  • [Cites] Lancet. 2012 Sep 22;380(9847):1059-65 [22998715.001]
  • [Cites] Stat Methods Med Res. 2016 Dec;25(6):3069 [27852809.001]
  • [Cites] Intensive Care Med. 2015 Oct;41(10 ):1809-16 [26202040.001]
  • [Cites] Anesthesiology. 2016 Apr;124(4):761-2 [26825150.001]
  • [Cites] JAMA. 2003 Sep 24;290(12):1617-23 [14506121.001]
  • [Cites] Eur J Anaesthesiol. 2015 Feb;32(2):88-105 [25058504.001]
  • [Cites] PLoS One. 2010 May 12;5(5):e10607 [20485549.001]
  • [Cites] Br J Anaesth. 2016 Jan;116(1):54-62 [26675949.001]
  • [Cites] Crit Care. 2006;10 (3):R81 [16749940.001]
  • [Cites] JAMA Surg. 2016 Jun 1;151(6):527-36 [26791112.001]
  • [Cites] Anesthesiology. 2016 Apr;124(4):899-907 [26825149.001]
  • [Cites] Anaesthesia. 2008 Jul;63(7):695-700 [18489613.001]
  • [Cites] N Engl J Med. 2009 Oct 1;361(14):1368-75 [19797283.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):491-507 [9790339.001]
  • [Cites] Anesthesiology. 2010 May;112(5):1105-15 [20418691.001]
  • (PMID = 28439646.001).
  • [ISSN] 1432-1238
  • [Journal-full-title] Intensive care medicine
  • [ISO-abbreviation] Intensive Care Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Critical care/utilisation / Postoperative care/methods / Postoperative care/statistics and numerical data / Surgical procedures, operative/mortality
  • [Investigator] Pearse RM; Beattie S; Clavien PA; Demartines N; Fleisher LA; Grocott M; Haddow J; Hoeft A; Holt P; Moreno R; Pritchard N; Rhodes A; Wijeysundera D; Wilson M; Ahmed T; Everingham K; Hewson R; Januszewska M; Pearse RM; Phull MK; Halliwell R; Shulman M; Myles P; Schmid W; Hiesmayr M; Wouters P; de Hert S; Lobo S; Beattie S; Wijeysundera D; Fang X; Rasmussen L; Futier E; Biais M; Venara A; Slim K; Sander M; Koulenti D; Arvaniti K; Chan M; Kulkarni A; Chandra S; Tantri A; Geddoa E; Abbas M; Della Rocca G; Sivasakthi D; Mansor M; Luna P; Bouwman A; Buhre W; Beavis V; Campbell D; Short T; Osinaike T; Matos R; Grigoras I; Kirov M; Protsenko D; Biccard B; Aldecoa C; Chew M; Hofer C; Hubner M; Ditai J; Szakmany T; Fleisher L; Ferguson M; MacMahon M; Shulman M; Cherian R; Currow H; Kanathiban K; Gillespie D; Pathmanathan E; Phillips K; Reynolds J; Rowley J; Douglas J; Kerridge R; Currow H; Garg S; Bennett M; Jain M; Alcock D; Terblanche N; Cotter R; Leslie K; Stewart M; Zingerle N; Clyde A; Hambidge O; Rehak A; Cotterell S; Binh Quan Huynh W; McCulloch T; Ben-Menachem E; Egan T; Cope J; Halliwell R; Fellinger P; Haselberger S; Holaubek C; Lichtenegger P; Scherz F; Schmid W; Hoffer F; Cakova V; Eichwalder A; Fischbach N; Klug R; Schneider E; Vesely M; Wickenhauser R; Grubmueller KG; Leitgeb M; Lang F; Toro N; Bauer M; Laengle F; Mayrhofer T; Buerkle C; Forstner K; Germann R; Rinoesl H; Schindler E; Trampitsch E; Fritsch G; Szabo C; Bidgoli J; Verdoodt H; Forget P; Kahn D; Lois F; Momeni M; Prégardien C; Pospiech A; Steyaert A; Veevaete L; De Kegel D; De Jongh K; Foubert L; Smitz C; Vercauteren M; Poelaert J; Van Mossevelde V; Abeloos J; Bouchez S; Coppens M; De Baerdemaeker L; Deblaere I; De Bruyne A; De Hert S; Fonck K; Heyse B; Jacobs T; Lapage K; Moerman A; Neckebroek M; Parashchanka A; Roels N; Van Den Eynde N; Vandenheuvel M; Van Limmen J; Vanluchene A; Vanpeteghem C; Wouters P; Wyffels P; Huygens C; Vandenbempt P; Van de Velde M; Dylst D; Janssen B; Schreurs E; Aleixo FB; Candido K; Dias Batista H; Guimarães M; Guizeline J; Hoffmann J; Lobo SM; Lobo FR; Nascimento V; Nishiyama K; Pazetto L; Souza D; Souza Rodrigues R; Vilela Dos Santos AM; Jardim J; Silva J; do Nascimento Junior P; Baio TH; Pereira de Castro GI; Watanabe Oliveira HR; Amendola CP; Cardoso G; Ortega D; Brotto AF; De Oliveira MC; Réa-Neto Á; Dias F; Azambuja P; Knibel MF; Martins A; Almeida W; Neto CN; Tardelli MA; Caser E; Machado M; Aguzzoli C; Baldisserotto S; Beck Tabajara F; Bettega F; Rodrigues Júnior HC; de Gasperi J; Faina L; Nolasco MF; da Costa Fischer BF; de Campos Ferreira MF; Hartmann C; Kliemann M; Ribeiro GLH; Fraga JM; Netto TM; Pozza LV; Wendling PR; Azevedo C; Garcia J; Lopes M; Maia B; Maselli P; Melo R; Mendes W; Neves M; Ney J; Piras C; Applewhaite C; Carr A; Chow L; Duttchen K; Foglia J; Greene M; Hinther A; Houston K; McCormick TJ; Mikhayel J; Montasser S; Ragan A; Suen A; Woolsey A; Yu HC; Funk D; Kowalski S; Legaspi R; McDonald H; Siddiqui F; Pridham J; Rowe B; Sampson S; Thiessen B; Zbitnew G; Bernard A; George R; Jones P; Moor R; Siddiqui N; Wolfer A; Tran D; Winch D; Dobson G; Hinther A; McCormick T; Montasser O; Suen A; Woolsey A; Bernard A; George R; Hall R; Bernard A; George R; Hall R; Applewhaite C; Baghirzada L; McCormick TJ; Suen A; Dai SY; Hare G; Lee E; Shastri U; Tsui A; Yagnik A; Alvares D; Choi S; Dwyer H; Flores K; McCartney C; Somascanthan P; Beattie S; Carroll J; Pazmino-Canizares J; Wijeysundera D; Wolfer A; Ami N; Chan V; Perlas A; Argue R; Lavis K; Mayson K; Cao Y; Gao H; Hu T; Lv J; Yang J; Yang Y; Zhong Y; Zhou J; Zou X; He M; Li X; Luo D; Wang H; Yu T; Chen L; Wang L; Cai Y; Cao Z; Li Y; Lian J; Sun H; Wang S; Wang Z; Wang K; Zhu Y; Du X; Fan H; Fu Y; Huang L; Huang Y; Hwan H; Luo H; Qu PS; Tao F; Wang Z; Wang G; Wang S; Zhang Y; Zhang X; Chen C; Wang W; Liu Z; Fan L; Tang J; Chen Y; Chen Y; Han Y; Huang C; Liang G; Shen J; Wang J; Yang Q; Zhen J; Zhou H; Chen J; Chen Z; Li X; Meng B; Ye H; Zhang X; Bi Y; Cao J; Guo F; Lin H; Liu Y; Lv M; Shi P; Song X; Sun C; Sun Y; Wang Y; Wang S; Zhang M; Chen R; Hou J; Leng Y; Meng QT; Qian L; Shen ZY; Xia ZY; Xue R; Zhang Y; Zhao B; Zhou XJ; Chen Q; Guo H; Guo Y; Qi Y; Wang Z; Wei J; Zhang W; Zheng L; Bao Q; Chen Y; Chen Y; Fei Y; Hu N; Hu X; Lei M; Li X; Lv X; Lv J; Miao F; Ouyang L; Qian L; Shen C; Sun Y; Wang Y; Wang D; Wu C; Xu L; Yuan J; Zhang L; Zhang H; Zhang Y; Zhao J; Zhao C; Zhao L; Zheng T; Zhou D; Zhou H; Zhou C; Lu K; Zhao T; He C; Chen H; Chen S; Cheng B; He J; Jin L; Li C; Li H; Pan Y; Shi Y; Wen XH; Wu S; Xie G; Zhang K; Zhao B; Lu X; Chen F; Liang Q; Lin X; Ling Y; Liu G; Tao J; Yang L; Zhou J; Chen F; Feng Y; Hou B; Lin J; Liu M; Luo F; Shi X; Xiong Y; Xu L; Yang S; Zhang Q; Zhang H; Zhao W; Zhao W; Bai Y; Chen L; Chen S; Dai Q; Geng W; Han K; He X; Huang L; Ji B; Jia D; Jin S; Li Q; Liang D; Luo S; Lwang L; Mo Y; Pan Y; Qi X; Qian M; Qin J; Ren Y; Shi Y; Wang J; Wang J; Wang L; Xie J; Yan Y; Yao Y; Zhang M; Zhao J; Zhuang X; Ai Y; Du F; He L; Huang L; Li Z; Li H; Li Y; Li L; Meng S; Yuan Y; Zhang E; Zhang J; Zhao S; Ji Z; Pei L; Wang L; Chen C; Dong B; Li J; Miao Z; Mu H; Qin C; Su L; Wen Z; Xie K; Yu Y; Yuan F; Hu X; Zhang Y; Xiao W; Zhu Z; Dai Q; Fu K; Hu R; Hu X; Huang S; Li Y; Liang Y; Yu S; Guo Z; Jing Y; Tang N; Wu J; Yuan D; Zhang R; Zhao X; Li Y; Bai HP; Liu CX; Liu FF; Ren W; Wang XL; Xu GJ; Hu N; Li B; Ou Y; Tang Y; Yao S; Zhang S; Kong CC; Liu B; Wang T; Xiao W; Lu B; Xia Y; Zhou J; Cai F; Chen P; Hu S; Wang H; Wu J; Xu Q; Hu L; Jing L; Li J; Li B; Liu Q; Liu Y; Lu X; Peng ZD; Qiu X; Ren Q; Tong Y; Wang Z; Wang J; Wen Y; Wu Q; Xia J; Xie J; Xiong X; Xu S; Yang T; Ye H; Yin N; Yuan J; Zeng Q; Zhang B; Zheng K; Cang J; Chen S; Du F; Fan Y; Fu S; Ge X; Guo B; Huang W; Jiang L; Jiang X; Jin L; Liu Y; Pan Y; Ren Y; Shan Q; Wang J; Wang F; Wu C; Zhang X; Christiansen IC; Granum SN; Rasmussen BS; Daugaard M; Gambhir R; Steingrímsdóttir GE; Jensen-Gadegaard P; Olsen KS; Siegel H; Zwicky Eskildsen K; Gätke MR; Wibrandt I; Heintzelmann SB; Lange KHW; Lundsgaard RS; Amstrup-Hansen L; Hovendal C; Larsen M; Lenstrup M; Kobborg T; Larsen JR; Pedersen AB; Larsen JR; Smith SH; Oestervig RM; Rasmussen L; Afshari A; Andersen C; Ekelund K; Secher EL; Brandsborg B; Beloeil H; Lasocki S; Venara A; Biais M; Ouattara A; Sineus M; Molliex S; Legouge ML; Wallet F; Tesniere A; Gaudin C; Lehur P; Forsans E; de Rudnicki S; Serra Maudet V; Mutter D; Sojod G; Ouaissi M; Regimbeau JM; Futier E; Desbordes J; Comptaer N; El Manser D; Ethgen S; Lebuffe G; Auer P; Härtl C; Deja M; Legashov K; Sonnemann S; Wiegand-Loehnert C; Falk E; Habicher M; Angermair S; Laetsch B; Schmidt K; Sonnemann S; Von Heymann C; Ramminger A; Jelschen F; Pabel S; Weyland A; Czeslick E; Gille J; Malcharek M; Sablotzki A; Lueke K; Wetzel P; Weimann J; Lenhart FP; Reichle F; Schirmer F; Hüppe M; Klotz K; Nau C; Schön J; Mencke T; Wasmund C; Bankewitz C; Baumgarten G; Fleischer A; Guttenthaler V; Hack Y; Hoeft A; Kirchgaessner K; Männer O; Schurig-Urbaniak M; Struck R; van Zyl R; Wittmann M; Goebel U; Harris S; Veit S; Andreadaki E; Souri F; Katsiadramis I; Skoufi A; Vasileiou M; Aimoniotou-Georgiou E; Katsourakis A; Veroniki F; Vlachogianni G; Petra K; Chlorou D; Oloktsidou E; Ourailoglou V; Papapostolou K; Tsaousi G; Daikou P; Dedemadi G; Kalaitzopoulos I; Loumpias C; Bristogiannis S; Dafnios N; Gkiokas G; Kontis E; Kozompoli D; Papailia A; Theodosopoulos T; Bizios C; Koutsikou A; Moustaka A; Plaitakis I; Armaganidis A; Christodoulopoulou T; Lignos M; Theodorakopoulou M; Asimakos A; Ischaki E; Tsagkaraki A; Zakynthinos S; Antoniadou E; Koutelidakis I; Lathyris D; Pozidou I; Voloudakis N; Dalamagka M; Gkonezou E; Chronis C; Manolakaki D; Mosxogiannidis D; Slepova T; Tsakiridou IS; Lampiri CL; Vachlioti AV; Panagiotakis CP; Sfyras DS; Tsimpoukas FT; Tsirogianni A; Axioti E; Filippopoulos A; Kalliafa E; Kassavetis G; Katralis P; Komnos I; Pilichos G; Ravani I; Totis A; Apagaki E; Efthymiadi A; Kampagiannis N; Paraforou T; Tsioka A; Georgiou G; Vakalos A; Bairaktari A; Charitos E; Markou G; Niforopoulou P; Papakonstantinou N; Tsigou E; Xifara A; Zoulamoglou M; Gkioni P; Karatzas S; Kyparissi A; Mainas E; Papapanagiotou I; Papavasilopoulou T; Fragandreas G; Georgopoulou E; Katsika E; Psarras K; Synekidou E; Verroiotou M; Vetsiou E; Zaimi D; Anagnou A; Apostolou K; Melissopoulou T; Rozenberg T; Tsigris C; Boutsikos G; Kalles V; Kotsalas N; Lavdaiou C; Paikou F; Panagou GL; Spring A; Arvaniti K; Botis I; Drimala M; Georgakakis G; Kiourtzieva E; Ntouma P; Prionas A; Xouplidis K; Dalampini E; Giannaki C; Iasonidou C; Ioannidis O; Lavrentieva A; Lavrentieva A; Papageorgiou G; Kokkinoy M; Stafylaraki M; Gaitanakis S; Karydakis P; Paltoglou J; Ponireas P; Chaloulis P; Provatidis A; Sousana A; Gardikou VV; Konstantivelli M; Lataniotou O; Lisari E; Margaroni M; Stamatiou K; Nikolaidis E; Pnevmatikos I; Sertaridou E; Andreou A; Arkalaki E; Athanasakis E; Chaniotaki F; Chatzimichali A; Christofaki M; Dermitzaki D; Fiorentza K; Frantzeskos G; Geromarkaki E; Kafkalaki K; Kalogridaki M; Karydi K; Kokkini S; Kougentakis G; Lefaki T; Lilitsis E; Makatounaki A; Malliotakis P; Michelakis D; Neonaki M; Nyktari V; Palikyra I; Papadakis E; Papaioannou A; Sfakianakis K; Sgouraki M; Souvatzis X; Spartinou A; Stefanidou N; Syrogianni P; Tsagkaraki G; Arnaoutoglou E; Arnaoutoglou C; Bali C; Bouris V; Doumos R; Gkini KP; Kapaktsi C; Koulouras V; Lena A; Lepida D; Michos E; Papadopoulos D; Paschopoulos M; Rompou VA; Siouti I; Tsampalas S; Ververidou O; Zilis G; Charlalampidoy A; Christodoulidis G; Flossos A; Stamoulis K; Chan M; Tsang MSC; Tsang MS; Lai ML; Yip CP; Chan HMH; Law B; Li WS; Chu HM; Koo EGY; Lam CCJ; Cheng KH; Chan M; Lam T; Chu S; Lai ML; Lam WY; Wong KWK; Kwok D; Hung CYJ; Chan WKJ; LamWong W; Chung CKE; Lai ML; Ma SK; Kaushik S; Shah B; Shah D; Shah S; Ar P; Muthuchellappan R; Agarwal V; Divatia J; Kulkarni A; Mishra S; Nimje G; Pande S; Savarkar S; Shrivastava A; Thomas M; Yegnaram S; Hidayatullah R; Chandra S; Tantri A; Puar N; Niman S; Indra I; Hamzah Z; Yuliana A; Abidin UN; Dursin AN; Kurnia A; Susanti A; Handayani D; Aribawa MA; Arya A; Senapathi TGA; Utara UH; Wid WM; Wima S; Wir WM; Jehosua B; Kaunang J; Lantang EY; Najoan R; Waworuntu N; Awad H; Fuad A; Geddoa E; Geddoa B; Khalaf AR; Al Hussaini S; Albaj S; Kenber M; Bettinelli A; Spadaro S; Volta CA; Giancarlo L; Sottosanti V; Della Rocca G; Spagnesi L; Toretti I; Alloj C; Cardellino S; Carmino L; Costanzo E; Fanfani LC; Novelli MT; Roasio A; Bellandi M; Beretta L; Bignami E; Bocchino S; Cabrini L; Corti D; Landoni G; Meroni R; Moizo E; Monti G; Pintaudi M; Plumari VP; Taddeo D; Testa V; Winterton D; Zangrillo A; Cloro LM; Colangelo C; Colangelo A; Rotunno G; Angel MP; Maria CP; Pata A; Parrini V; Gatta A; Nastasi M; Tinti C; Spagnesi L; Arrigo M; Benevento A; Bottini C; Cannavo' M; Gastaldi C; Marchesi A; Pascazio A; Pata F; Pozzi E; Premoli A; Tessera G; Boschi L; D'Andrea R; Ghignone F; Poggioli G; Sibilio A; Taffurelli M; Ugolini G; Ab Majid MA; Ab Rahman R; Joseph J; Pathan F; Shah MHS; Yap HL; Cheah S; Chin II; Looi JK; Tan SC; Visvalingam S; Kwok FY; Lee CK; Tan TS; Wong SM; Abdullah NH; Liew CF; Luxuman L; Mohd Zin NH; Norddin MF; Alias RLR; Wong JY; Yong J; Bin Mustapha MT; Chan WK; Dzulkipli N; Kuan PX; Lee YC; Alias A; Guok EC; Jee CC; Ramon BR; Weng CW; Abd Ghafar FNI; Aziz FZ; Hussain N; Lee HS; Sukawi I; Woon YL; Abd Hadi HZ; Ahmad Azam UA; Alias AH; Kesut SA; Lee JM; Ooi DV; Sulaiman HA; Tengku Lih TA; Mansor M; Veerakumaran J; Luna P; Rojas E; Resendiz GEA; Zapata DDM; Aguilar López JCJ; Flores AAA; Amador JCB; Avila EJD; Aquino LPG; Rodriguez RL; Landa MT; Urias E; Hollmann M; Hulst A; Kirzner O; Preckel B; Koopman-van Gemert A; Bouwman A; Buise M; Tolenaar N; Weber E; de Fretes J; Houweling P; Ormskerk P; Van Bommel J; Buhre W; Lance M; Smit-Fun V; van Zundert T; Baas P; de Boer HD; Sprakel J; Elferink-Vonk R; Noordzij P; van Zeggeren L; Brand B; Spanjersberg R; Ten Bokkel-Andela J; Numan J; van Klei W; van Zaane B; Boer C; van Duivenvoorde Y; Hering JP; Zonneveldt H; Campbell D; Hoare S; Santa S; Allen SJ; Beavis V; Bell R; Choi HD; Drake M; Farrell H; Higgie K; Holmes K; Jenkins N; Kim CJ; Kim S; Law KC; McAllister D; Park K; Pedersen K; Pfeifer L; Salmond T; Steynor M; Tan M; Waymouth E; Ab Rahman AS; Armstrong J; Dudson R; Jenkins N; Nilakant J; Richard S; Virdi P; Dixon L; Donohue R; Farrow M; Kennedy R; Marissa H; McKellow M; Nicola D; Pascoe R; Roberts SJ; Rowell G; Sumner M; Templer P; Chandrasekharan S; Fulton G; Jammer I; Ali M; More R; Wilson L; Chang YH; Chang J; Fowler C; Panckhurst J; Sara R; Stapelberg F; Campbell D; Cherrett V; Ganter DL; McAllister D; McCann L; Foley J; Gilmour F; Lumsden R; Moores M; Olliff S; Sardareva E; Stapelberg F; Tai J; Wikner M; Wong C; Chaddock M; Czepanski C; McKendry P; Polakovic D; Polakovich D; Robert A; Tormo Belda M; Norton T; Stapelberg F; Alherz F; Barneto L; Ramirez A; Sayeed A; Smith N; Bennett C; McQuoid S; Bell R; Jansen TL; Nico Z; Scott J; Freschini D; Freschini A; Hopkins B; Manson L; Stoltz D; Bates A; Davis S; Freeman V; McGaughran L; Baskar Sharma S; Burrows T; Byrne K; English D; Johnson R; Chai Law K; Manikkam B; McAllister D; Naidoo S; Rumball M; Whittle N; Franks R; Gibson-Lapsley H; McAllister D; Salter R; Walsh D; Cooper R; Perry K; Obobolo A; Sule UM; Ahmad A; Atiku M; Mohammed AD; Sarki AM; Adekola O; Akanmu O; Durodola A; Olukoju O; Raji V; Olajumoke T; Oyebamiji E; Adenekan A; Adetoye A; Faponle F; Olateju S; Owojuyigbe A; Talabi A; Adenike O; Adewale B; Collins N; Ezekiel E; Fatungase OM; Grace A; Sola S; Stella O; Ademola A; Adeolu AA; Adigun T; Akinwale M; Fasina O; Gbolahan O; Idowu O; Olonisakin RP; Osinaike BB; Asudo F; Mshelia D; Abdur-Rahman L; Agodirin O; Bello J; Bolaji B; Oyedepo OO; Ezike H; Iloabachie I; Okonkwo I; Onuora E; Onyeka T; Ugwu I; Umeh F; Alagbe-Briggs O; Dodiyi-Manuel A; Echem R; Obasuyi B; Onajin-Obembe B; Bandeira ME; Martins A; Tomé M; Martins Costa ACM; Krystopchuk A; Branco T; Esteves S; Melo MA; Monte J; Rua F; Martins I; Pinho-Oliveira VM; Rodrigues CM; Cabral R; Marques S; Rêgo S; Teixeira Jesus JS; Conceição Marques M; Romao C; Dias S; Santos AM; Alves MJ; Salta C; Cruz S; Duarte C; Furtado Paiva AA; do Nascimento Cabral T; Fariae Maia D; Correia da Silva RFM; Langner A; Oliveira Resendes H; da Conceição Soares M; Abrunhosa A; Faria F; Miranda L; Pereira H; Serra S; Ionescu D; Margarit S; Mitre C; Vasian H; Manga G; Stefan A; Tomescu D; Filipescu D; Paunescu MA; Stefan M; Stoica R; Gavril L; Pătrăşcanu E; Ristescu I; Rusu D; Diaconescu C; Iosep GF; Pulbere D; Ursu I; Balanescu A; Grintescu I; Mirea L; Rentea I; Vartic M; Lupu MN; Stanescu D; Streanga L; Antal O; Hagau N; Patras D; Petrisor C; Tosa F; Tranca S; Copotoiu SM; Ungureanu LL; Harsan CR; Papurica M; Cernea DD; Dragoescu NA; Aflori L; Vaida C; Ciobotaru OR; Aignatoaie M; Carp CP; Cobzaru I; Mardare O; Purcarin B; Tutunaru V; Ionita V; Arustei M; Codita A; Busuioc M; Chilinciuc I; Ciobanu C; Belciu I; Tincu E; Blaj M; Grosu RM; Sandu G; Bruma D; Corneci D; Dutu M; Krepil A; Copaciu E; Dumitrascu CO; Jemna R; Mihaescu F; Petre R; Tudor C; Ursache E; Kulikov A; Lubnin A; Grigoryev E; Pugachev S; Protsenko D; Tolmasov A; Hussain A; Ilyina Y; Kirov M; Roshchina A; Iurin A; Chazova E; Dunay A; Karelov A; Khvedelidze I; Voldaeva O; Belskiy V; Dzhamullaev P; Grishkowez E; Kretov V; Levin V; Molkov A; Puzanov S; Samoilenko A; Tchekulaev A; Tulupova V; Utkin I; Allorto NL; Bishop DG; Builu PM; Cairns C; Dasrath A; de Wet J; den Hoedt M; Grey B; Hayes MP; Küsel BS; Shangase N; Wise R; Cacala S; Farina Z; Govindasamy V; Kruse CH; Lee C; Marais L; Naidoo TD; Rajah C; Rodseth RN; Ryan L; von Rhaden R; Adam S; Alphonsus C; Ameer Y; Anderson F; Basanth S; Bechan S; Bhula C; Biccard BM; Biyase T; Buccimazza I; Cardosa J; Chen J; Daya B; Drummond L; Elabib A; Goad EHA; Goga IE; Goga R; Harrichandparsad R; Hodgson RE; Jordaan J; Kalafatis N; Kampik C; Landers AT; Loots E; Madansein R; Madaree A; Madiba TE; Manzini VT; Mbuyisa M; Moodley R; Msomi M; Mukama I; Naidoo D; Naidoo R; Naidu TK; Ntloko S; Padayachee E; Padayachee L; Phaff M; Pillay B; Pillay D; Pillay L; Ramnarain A; Ramphal SR; Ryan P; Saloojee A; Sebitloane M; Sigcu N; Taylor JL; Torborg A; Visser L; Anderson P; Conradie A; de Swardt M; de Villiers M; Eikman J; Liebenberg R; Mouton J; Paton A; van der Merwe L; Wilscott-Davids C; Barrett WJ; Bester M; de Beer J; Geldenhuys J; Gouws H; Potgieter JH; Strydom M; Wilberforce-Turton E; Chetty RR; Chirkut S; Cronje L; de Vasconcellos K; Dube NZ; Sibusiso Gama N; Green GM; Green-Thompson R; Kinoo SM; Kistnasami P; Maharaj K; Moodley MS; Mothae SJ; Naidoo R; Aslam M; Noorbhai F; Rughubar V; Reddy J; Singh A; Skinner DL; Smith MJ; Singh B; Misra R; Naidoo M; Ramdharee P; Selibea Y; Sewpersad S; Sham S; Wessels JD; Africander C; Bejia T; Blakemore SP; Botes M; Bunwarie B; Hernandez CB; Jeeraz MA; Legutko DA; Lopez AG; De Meyer JN; Muzenda T; Naidoo N; Patel M; Pentela R; Junge M; Mansoor N; Rademan L; Scislowski P; Seedat I; van den Berg B; van der Merwe D; van Wyk S; Govender K; Naicker D; Ramjee R; Saley M; Kuhn WP; Matos-Puig R; Moolla Z; Lisi A; Perez G; Valle Beltran A; Lozano A; Delgado Navarro C; Duca A; Pastor Martinez E; Ferrando C; Fuentes I; García-Pérez ML; Gracia E; Izquierdo Palomares A; Katime A; Miñana A; Incertis R; Romero E; Romero Garcia CS; Rubio C; Socorro Artiles T; Soro M; Valls P; Laguarda GA; Benavent P; Cuenca VC; Cueva A; Lafuente M; Parra AM; Rodrigo AR; Sanchez-Morcillo S; Tormo S; Redondo FJ; De Andres J; Gómez Diago L; Hernández Cádiz MJ; Manuel GG; Peris R; Saiz C; Tatay J; Tebar Soto MT; Brunete T; Cancho D; Delgado García DR; Zamudio D; Garcia Del Valle S; Luz Serrano M; Alonso E; Anillo V; Maseda E; Salgado P; Suarez L; Suarez-de-la-Rica A; Villagrán MJ; Aldecoa C; Alonso JI; Cabezuelo E; Garcia-Saiz I; Lopez Del Moral O; Martín S; Perez Gonzalez A; Tovar Doncel S; Vera MA; Ávila Sánchez FJ; Castaño B; Castaño Moreira B; Flores Risco S; Paz Martín D; Pérez Martín F; Poza P; Ruiz A; Serna Martínez WF; Vicente BV; Dominguez SV; Fernández S; Munoz-López A; Bernat MJ; Mas A; Planas K; Jawad M; Saeed Y; Hedin A; Levander H; Chew M; Holmström S; Lönn D; Zoerner F; Åkring I; Widmark C; Zettergren J; Liljequist VA; Nystrom L; Odeberg-Wernerman S; Oldner A; Reje P; Lyckner S; Sperber J; Adolfsson A; Klarin B; Hedin A; Ögren K; Barras JP; Bührer T; Despotidis V; Helmy N; Holliger S; Raptis DA; Schmid R; Meyer A; Jaquet Y; Kessler U; Muradbegovic M; Nahum SR; Rotunno T; Schiltz B; Voruz F; Worreth M; Christoforidis D; Popeskou SG; Furrer M; Prevost GA; Stocker A; Lang K; Breitenstein S; Ganter MT; Geisen M; Soll C; Korkmaz M; Lubach I; Schmitz M; Meyer Zu Schwabedissen M; Zingg U; Hillermann T; Wildi S; Hofer C; Pinto BB; Walder B; Hübner M; Mariotti G; Slankamenac K; Namuyuga M; Kyomugisha E; Kituuka O; Wesonga Shikanda A; Kakembo N; Otim Tom C; Webombesa A; Bua E; Ditai J; Ssettabi EM; Epodoi J; Kabagenyi F; Kirya F; Dempsey G; Seasman C; Basit Nawaz Khan R; Kurasz C; Macgregor M; Shawki B; Hariharan V; Chau S; Ellis K; Butt G; Chicken DW; Christmas N; Allen S; Daniel GD; Dempster A; Kemp J; Matthews L; Mcglone P; Tambellini J; Trodd D; Freitas K; Garg A; Karpate S; Kulkarni A; O'Hara C; Troko J; Angus K; Bradley J; Brennan E; Brooks C; Brown J; Brown G; Finch A; Gratrix K; Hesketh S; Hill G; Jeffs C; Morgan M; Pemberton C; Slawson N; Spickett H; Swarbrick G; Thomas M; Van Duyvenvoorde G; Brennan A; Briscoe R; Cooper S; Lawton T; Northey M; Senaratne R; Stanworth H; Burrows L; Cain H; Craven R; Davies K; Jonas A; Pachucki M; Walkden G; Davies H; Gudaca M; Hobrok M; Arawwawala D; Fergey L; Gardiner M; Gunn J; Johnson L; Lofting A; Lyle A; Mc Neela F; Smolen S; Topliffe J; Williams S; Bland M; Kaura V; Lanka P; Naylor C; Smith N; Ahmed A; Myatt J; Shenoy R; Soon WC; Tan J; Karadia S; Self J; Durant E; Tripathi S; Bullock C; Campbell D; Ghosh A; Hughes T; Zsisku L; Bengeri S; Cowton A; Khalid MS; Limb J; McAdam C; Porritt M; Rafi MA; Shekar P; Harden C; Hollands H; King A; March L; Minto G; Patrick A; Waugh D; Kumara P; Simeson K; Yarwood J; Browning J; Hatton J; Julian H; Mitra A; Newton M; Pernu P; Wilson A; Commey T; Foot H; Glover L; Gupta A; Lancaster N; Levin J; Mackenzie F; Mestanza C; Nofal E; Pout L; Varden R; Wild J; Jones S; Moreton S; Pulletz M; Davies C; Martin M; Thomas S; Burns K; McArthur C; Patel P; Lau G; Rich N; Davis F; Self J; Lyons R; Port B; Prout R; Smith C; Adelaja Y; Bennett V; Bidd H; Dumitrescu A; Murphy JF; Keen A; Mguni N; Ong C; Adams G; Boshier P; Brown R; Butryn I; Chatterjee J; Freethy A; Lockwood G; Tsakok M; Tsiligiannis S; Peat W; Stephenson L; Bradburn M; Pick S; Cunha P; Olagbaiye O; Tayeh S; Abernethy C; Balasubramaniam M; Bennett R; Bolton D; Martinson V; Naylor C; Smith N; Bell S; Heather B; Kushakovsky V; Alcock L; Alexander H; Anderson C; Baker P; Brookes M; Cawthorn L; Cirstea E; Colling K; Coulter I; Das S; Haigh K; Hamdan A; Hugill K; Kottam L; Lisseter E; Mawdsley M; McGivern J; Padala K; Phelps V; Kumar VR; Stewart K; Towse K; Tregonning J; Vahedi A; Walker A; Baines D; Bilolikar A; Chande S; Copley E; Dunk N; Kulkarni R; Kumar P; Metodiev Y; Ncomanzi D; Raithatha B; Raymode P; Szafranski J; Twohey L; Watt P; Weatherall L; Weatherill J; Whitman Z; Wighton E; Abayasinghe C; Chan A; Darwish S; Gill J; Glasgow E; Hadfield D; Harris C; Kochhar A; Mellis C; Pool A; Riozzi P; Selman A; Smith EJ; Vele L; Gercek Y; Guy K; Holden D; Watson N; Whysall K; Andreou P; Hales D; Thompson J; Bowrey S; McDonald S; Thompson J; Gilmore J; Hills V; Kelly C; Kelly S; Lloyd G; Abbott T; Gall L; Torrance H; Vivian M; Berntsen E; Nolan T; Turner A; Vohra A; Brown A; Clark R; Coughlan E; Daniel C; Patvardhan C; Pearson R; Predeep S; Saad H; Shanmugam M; Varley S; Vohra A; Wylie K; Cooper L; Makowski A; Misztal B; Moldovan E; Pegg C; Donovan A; Foot J; Large S; Claxton A; Netke B; Armstrong R; Calderwood C; Kwok A; Mohr O; Oyeniyi P; Patnaik L; Post B; Ali S; Arshad H; Baker G; Brenner L; Brincat M; Brunswicker A; Cox H; Cozar OI; Durst A; Fengas L; Flatt J; Glister G; Narwani V; Photi E; Rankin A; Rosbergen M; Tan M; Beaton C; Horn R; Hunt J; Rousseau G; Stancombe L; Absar M; Allsop J; Drinkwater Z; Hodgkiss T; Smith K; Brown J; Pick S; Alexander-Sefre F; Campey L; Dudgeon L; Hall K; Hitchcock R; James L; Smith K; Winstone U; Ahmad N; Bauchmuller K; Harrison J; Jeffery H; Miller D; Pinder A; Pothuneedi S; Rosser J; Sanghera S; Swift D; Walker R; Bester D; Cavanagh S; Cripps H; Daniel H; Lynch J; Paton A; Pyke S; Scholefield J; Whitworth H; Bottrill F; Ramalingam G; Webb S; Akerman N; Antill P; Bourner L; Buckley S; Castle G; Charles R; Eggleston C; Foster R; Gill S; Lindley K; Lklouk M; Lowery T; Martin O; Milne D; O'Connor P; Ratcliffe A; Rose A; Simeson K; Smith A; Varma S; Ward J; Simeson K; Barcraft-Barnes H; Camsooksai J; Colvin C; Reschreiter H; Tbaily L; Venner N; Hamilton C; Kelly L; Toth-Tarsoly P; Dodsworth K; Foord D; Gordon P; Hawes E; Lamb N; Mouland J; Nightingale J; Rose S; Schrieber J; Al 'Amri K; Aladin H; Arshad MA; Barraclough J; Bentley C; Bergin C; Carrera R; Clarkson A; Collins M; Cooper L; Denham S; Griffiths E; Ip P; Jeyanthan S; Joory K; Kaur S; Marriott P; Mitchell N; Nagaiah S; Nilsson A; Parekh N; Pope M; Seager J; Serag H; Tameem A; Thomas A; Thunder J; Torrance A; Vohra R; Whitehouse A; Wong T; Blunt M; Wong K; Giles J; Reed I; Weller D; Bell G; Birch J; Damant R; Maiden J; Mewies C; Prince C; Radford J; Balain B; Banerjee R; Barnett A; Burston B; Davies K; Edwards J; Evans C; Ford D; Gallacher P; Hill S; Jaffray D; Karlakki S; Kelly C; Kennedy J; Kiely N; Lewthwaite S; Marquis C; Ockendon M; Phillips S; Pickard S; Richardson J; Roach R; Smith T; Spencer-Jones R; Steele N; Steen J; Van Liefland M; White S; Faulds M; Harris M; Kelly C; Nicol S; Pearson SA; Chukkambotla S; Andrew A; Attrill E; Campbell G; Datson A; Fouracres A; Graterol J; Graves L; Hong B; Ishimaru A; Karthikeyan A; King H; Lawson T; Lee G; Lyons S; Macalister Hall A; Mathoulin S; Mcintyre E; Mclaughlin D; Mulcahy K; Ratcliffe A; Robbins J; Sung W; Tayo A; Trembath L; Venugopal S; Walker R; Wigmore G; Boereboom C; Downes C; Humphries R; Melbourne S; Smith C; Tou S; Ullah S; Batchelor N; Boxall L; Broomby R; Deen T; Hellewell A; Helliwell L; Hutchings M; Hutchins D; Keenan S; Mackie D; Donna A; Smith F; Stone L; Thorpe K; Wassall R; Woodgate A; Baillie S; Campbell T; James S; King C; Marques de Araujo D; Martin D; Morkane C; Neely J; Rajendram R; Burton M; James K; Keevil E; Minik O; Morgan J; Musgrave A; Rajanna H; Roberts T; Szakmany T; Adamson M; Jumbe S; Kendall J; Muthuswamy MB; Anderson C; Cruikshanks A; Pothuneedi S; Walker R; Wrench I; Zeidan L; Ardern D; Harris B; Hellstrom J; Martin J; Thomas R; Varsani N; Wrey Brown C; Docherty P; Gillies M; McGregor E; Usher H; Craig J; Smith A; Ahmad T; Bodger P; Creary T; Everingham K; Fowler A; Hewson R; Ijuo E; Januszewska M; Jones T; Kantsedikas I; Lahiri S; McLean AL; Niebrzegowska E; Phull M; Wang D; Wickboldt N; Baldwin J; Doyle D; Mcmullan S; Oladapo M; Owen T; Tripathi S; Williams A; Daniel H; Gregory P; Husain T; Kirk-Bayley J; Mathers E; Montague L; White S; Avis J; Cook T; Dali-Kemmery L; Kerslake I; Lambourne V; Pearson A; Boyd C; Callaghan M; Lawson C; McCrossan R; Nesbitt V; O'connor L; Scott J; Sinclair R; Farid N; Morgese C; Bhatia K; Karmarkar S; Vohra A; Ahmed J; Branagan G; Hutton M; Swain A; Brookes J; Cornell J; Dolan R; Hulme J; Jansen van Vuuren A; Jowitt T; Kalashetty G; Lloyd F; Patel K; Sherwood N; Brown L; Chandler B; Deighton K; Emma T; Haunch K; Cheeseman M; Dent K; Garg S; Gray C; Hood M; Jones D; Juj J; Mitra A; Rao R; Walker T; Al Anizi M; Cheah C; Cheing Y; Coutinho F; Gondo P; Hadebe B; Onie Hove M; Khader A; Krishnachetty B; Rhodes K; Sokhi J; Baker KA; Bertram W; Looseley A; Mouton R; Arnold G; Arya S; Balfoussia D; Baxter L; Harris J; Jones C; Knaggs A; Markar S; Perera A; Scott A; Shida A; Sirha R; Wright S; Frost V; Gray C; MacGregor M; Andrews E; Arrandale L; Barrett S; Bidd H; Cifra E; Cooper M; Dragnea D; Elna C; Maclean J; Meier S; Milliken D; Munns C; Ratanshi N; Salvana A; Watson A; Ali H; Campbell G; Critchley R; Hicks C; Liddle A; Pass M; Ritchie C; Thomas C; Too L; Welsh S; Gill T; Johnson J; Reed J; Davis E; Papadopoullos S; Attwood C; Biffen A; Boulton K; Gray S; Hay D; Mills S; Montgomery J; Riddell R; Simpson J; Bhardwaj N; Paul E; Uwubamwen N; Vohra A; Berntsen E; Nolan T; Turner A; Alexander M; Arrich J; Arumugam S; Blackwood D; Boggiano V; Brown R; Lam Chan Y; Chatterjee D; Chhabra A; Christian R; Costelloe H; Coxwell Matthewman M; Dalton E; Darko J; Davari M; Dave T; Deacon M; Deepak S; Edmond H; Ellis J; El-Sayed A; Eneje P; English R; Ewe R; Foers W; Franklin J; Gallego L; Garrett E; Goldberg O; Goss H; Greaves R; Harris R; Hennings C; Jones E; Kamali N; Kokkinos N; Lewis C; Lignos L; Malgapo EV; Malik R; Milne A; Mulligan JP; Nicklin P; Palipane N; Parsons T; Piper R; Prakash R; Ramesh B; Rasip S; Reading J; Rela M; Reyes A; Robert S; Rooms M; Shah K; Simons H; Solanki S; Spowart E; Stevens A; Thomas C; Waggett H; Yassaee A; Kennedy A; Scott S; Somanath S; Berg A; Hernandez M; Nanda R; Tank G; Wilson N; Wilson D; Al-Soudaine Y; Baldwin M; Cornish J; Davies Z; Davies L; Edwards M; Frewer N; Gallard S; Glasbey J; Harries R; Hopkins L; Kim T; Koompirochana V; Lawson S; Lewis M; Makzal Z; Scourfield S; Ahmad Y; Bates S; Blackwell C; Bryant H; Coulter S; Cruickshank R; Daniel S; Daubeny T; Edwards M; Golder K; Hawkins L; Helen B; Hinxman H; Levett D; Skinner B; Walsgrove J; Bradburn M; Dickson J; Constantin K; Karen M; O'Brien P; O'Donohoe L; Payne H; Sundayi S; Walker E; Brooke J; Cardy J; Humphreys S; Kessack L; Kubitzek C; Kumar S; Cotterill D; Hodzovic E; Hosdurga G; Miles E; Saunders G; Campbell M; Chan P; Jemmett K; Raj A; Naik A; Ramamoorthy R; Shah N; Sylvan A; Blyth K; Burtenshaw A; Freeman D; Johnson E; Lo P; Martin T; Plunkett E; Wollaston J; Allison J; Carroll C; Craw N; Craw S; Pitt-Kerby T; Rowland-Axe R; Spurdle K; McDonald A; Simon D; Sinha V; Smith T; Banner-Goodspeed V; Boone M; Campbell K; Lu F; Scannell J; Sobol J; Balajonda N; Clemmons K; Conde C; Funk B; Hall R; Hopkins T; Olaleye O; Omer O; Pender M; Porto A; Stevens A; Waweru P; Yeh E; Bodansky D; Evans A; Kleopoulos S; Maril R; Mathney E; Sanchez A; Tinuoye E; Bateman B; Eng K; Jiang N; Ladha K; Needleman J; Chen LL; Chen LL; Lane R; Robinowitz D; Ghushe N; Irshad M; Patel S; Takemoto S; Wallace A; Mazzeffi M; Rock P; Wallace K; Zhu X; Chua P; Fleisher L; Mattera M; Sharar R; Thilen S; Treggiari M; Morgan A; Sofjan I; Subramaniam K; Avidan M; Maybrier H; Muench M; Wildes T
  •  go-up   go-down


74. Ekstrand ML, Rawat S, Patankar P, Heylen E, Banu A, Rosser BRS, Wilkerson JM: Sexual identity and behavior in an online sample of Indian men who have sex with men. AIDS Care; 2017 07;29(7):905-913

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Positive attitudes toward UAS and lower self-efficacy were associated with sexual risk in both groups; however, substance use was associated with sexual risk only among bisexually identified men.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS One. 2014 Sep 11;9(9):e107439 [25211511.001]
  • [Cites] AIDS Educ Prev. 2006 Aug;18(4):323-32 [16961449.001]
  • [Cites] AIDS Behav. 2014 Aug;18(8):1428-35 [24077974.001]
  • [Cites] Am J Mens Health. 2014 Nov;8(6):510-20 [24658284.001]
  • [Cites] Health Psychol. 1997 Sep;16(5):458-67 [9302543.001]
  • [Cites] Arch Intern Med. 1998 Sep 14;158(16):1789-95 [9738608.001]
  • [Cites] PLoS One. 2012;7(7):e40793 [22829885.001]
  • [Cites] PLoS One. 2015 May 14;10(5):e0126658 [25973907.001]
  • [Cites] Sex Transm Infect. 2010 Jun;86(3):187-92 [20522632.001]
  • [Cites] J Acquir Immune Defic Syndr. 2010 Feb;53(2):227-33 [19934765.001]
  • [Cites] Soc Sci Med. 2001 Mar;52(5):707-21 [11218175.001]
  • [Cites] AIDS Patient Care STDS. 2009 Nov;23(11):981-6 [19821722.001]
  • [Cites] Indian J Med Res. 2011 Dec;134(6):920-9 [22310824.001]
  • [Cites] AIDS Behav. 2016 Feb;20(2):304-16 [26386592.001]
  • [Cites] Am J Mens Health. 2014 May;8(3):190-204 [23832954.001]
  • [Cites] AIDS Behav. 2009 Aug;13(4):746-56 [18512143.001]
  • [Cites] Glob Public Health. 2017 Feb;12 (2):250-265 [26457339.001]
  • [Cites] AIDS Educ Prev. 2008 Dec;20(6):547-57 [19072529.001]
  • [Cites] Int J Sex Health. 2016;28(3):221-227 [27668029.001]
  • [Cites] J LGBT Health Res. 2008;4(2-3):111-26 [19856744.001]
  • [Cites] Am J Public Health. 2001 Jun;91(6):988-9 [11392947.001]
  • [Cites] AIDS Care. 2013;25(9):1109-13 [23339580.001]
  • [Cites] Psychol Health Med. 2011 Aug;16(4):450-62 [21749242.001]
  • [Cites] BMJ Open. 2013 Feb 04;3(2):null [23386580.001]
  • [Cites] AIDS Educ Prev. 2009 Aug;21(4):372-83 [19670971.001]
  • [Cites] JMIR Mhealth Uhealth. 2016 Oct 31;4(4):e120 [27799139.001]
  • [Cites] J Stud Alcohol. 2004 Nov;65(6):794-800 [15700518.001]
  • [Cites] AIDS. 2010 Aug 24;24(13):2099-107 [20601853.001]
  • [Cites] Arch Sex Behav. 2002 Apr;31(2):177-83 [11974643.001]
  • [Cites] J Postgrad Med. 2014 Apr-Jun;60(2):130-4 [24823510.001]
  • [Cites] Arch Sex Behav. 2016 Jul;45(5):1269-77 [26292840.001]
  • [Cites] Health Educ Res. 2007 Feb;22(1):120-7 [16849391.001]
  • [Cites] AIDS Behav. 2015 Dec;19(12):2255-69 [25893657.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2006 Nov-Dec;72(6):425-31 [17179617.001]
  • [Cites] Int J Sex Health. 2016 Jan 1;28(1):70-84 [27073588.001]
  • [Cites] Cyberpsychol Behav. 2005 Apr;8(2):131-9 [15938652.001]
  • [Cites] Arch Sex Behav. 2003 Aug;32(4):351-7 [12856896.001]
  • (PMID = 28027656.001).
  • [ISSN] 1360-0451
  • [Journal-full-title] AIDS care
  • [ISO-abbreviation] AIDS Care
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / R21 AI094676
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Keywords] NOTNLM ; India (major topic) / Sexual identity (major topic) / bisexual (major topic) / gay (major topic) / men who have sex with men (major topic) / sexual behavior (major topic)
  •  go-up   go-down


75. Holcomb JB, Swartz MD, DeSantis SM, Greene TJ, Fox EE, Stein DM, Bulger EM, Kerby JD, Goodman M, Schreiber MA, Zielinski MD, O'Keeffe T, Inaba K, Tomasek JS, Podbielski JM, Appana SN, Yi M, Wade CE, PROHS Study Group: Multicenter observational prehospital resuscitation on helicopter study. J Trauma Acute Care Surg; 2017 07;83(1 Suppl 1):S83-S91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Earlier use of in-hospital plasma, platelets, and red blood cells (RBCs) has improved survival in trauma patients with severe hemorrhage.
  • Retrospective studies have associated improved early survival with prehospital blood product transfusion (PHT).
  • We hypothesized that PHT of plasma and/or RBCs would result in improved survival after injury in patients transported by helicopter.
  • METHODS: Adult trauma patients transported by helicopter from the scene to nine Level 1 trauma centers were prospectively observed from January to November 2015.
  • All patients meeting predetermined high-risk criteria were analyzed.
  • Patients receiving PHT were compared with patients not receiving PHT.
  • Our primary analysis compared mortality at 3 hours, 24 hours, and 30 days, using logistic regression to adjust for confounders and site heterogeneity to model patients who were matched on propensity scores.
  • RESULTS: Twenty-five thousand one hundred eighteen trauma patients were admitted, 2,341 (9%) were transported by helicopter, of which 1,058 (45%) met the highest-risk criteria.
  • Five hundred eighty-five of 1,058 patients were flown on helicopters carrying blood products.
  • Twenty-four percent of eligible patients received a PHT.
  • Of patients receiving PHT, 24% received only plasma, 7% received only RBCs, and 69% received both.
  • With few units transfused to each patient and small outcome differences between groups, it is likely large, multicenter, randomized studies will be required to detect survival differences in this important population.

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transfusion. 2016 Apr;56 Suppl 2:S157-65 [27100752.001]
  • [Cites] J Trauma Acute Care Surg. 2012 Aug;73(2 Suppl 1):S89-94 [22847102.001]
  • [Cites] Transfusion. 2009 Dec;49(12):2625-30 [19682333.001]
  • [Cites] J Am Coll Surg. 2015 May;220(5):797-808 [25840537.001]
  • [Cites] Ann Surg. 2014 Jul;260(1):13-21 [24651132.001]
  • [Cites] Transfusion. 2013 Jan;53 Suppl 1:59S-64S [23301974.001]
  • [Cites] J Trauma Acute Care Surg. 2015 Jun;78(6 Suppl 1):S2-6 [26002259.001]
  • [Cites] J Trauma. 2007 Oct;63(4):805-13 [18090009.001]
  • [Cites] Transfusion. 2010 Feb;50(2):493-500 [19804568.001]
  • [Cites] Ann Surg. 2008 Sep;248(3):447-58 [18791365.001]
  • [Cites] Br J Anaesth. 2015 Jul;115(1):76-83 [25991760.001]
  • [Cites] Transfusion. 2013 Jan;53 Suppl 1:9S-16S [23301981.001]
  • [Cites] Transfusion. 2016 Apr;56 Suppl 2:S107-9 [27100745.001]
  • [Cites] Injury. 2017 Jan;48(1):5-12 [27847192.001]
  • [Cites] Shock. 2016 Jul;46(1):3-16 [26825635.001]
  • [Cites] J Trauma Acute Care Surg. 2012 Dec;73(6 Suppl 5):S445-52 [23192068.001]
  • [Cites] BMJ. 2016 Jun 22;353:i3051 [27333868.001]
  • [Cites] Anesth Analg. 2017 Jan;124(1):277-281 [27749352.001]
  • [Cites] JAMA Surg. 2013 Feb;148(2):170-5 [23426594.001]
  • [Cites] Shock. 2014 May;41 Suppl 1:35-8 [24317352.001]
  • [Cites] Vox Sang. 2016 Jan;110(1):36-50 [26178308.001]
  • [Cites] Blood. 2014 Nov 13;124(20):3052-8 [25293771.001]
  • [Cites] Ann Surg. 2015 May;261(5):997-1005 [24670858.001]
  • [Cites] Psychol Methods. 2004 Dec;9(4):403-25 [15598095.001]
  • [Cites] JAMA Surg. 2013 Feb;148(2):127-36 [23560283.001]
  • [Cites] Vox Sang. 2007 Jan;92(1):69-78 [17181593.001]
  • [Cites] J Spec Oper Med. 2014 Fall;14(3):13-38 [25344706.001]
  • [Cites] J Trauma Acute Care Surg. 2015 Jun;78(6 Suppl 1):S48-53 [26002263.001]
  • [Cites] JAMA. 2015 Feb 3;313(5):471-82 [25647203.001]
  • [Cites] Transfusion. 2013 Dec;53(12):3088-99 [23614333.001]
  • [Cites] J Trauma Acute Care Surg. 2012 Aug;73(2 Suppl 1):S49-53 [22847094.001]
  • [Cites] Ann Surg. 2013 Feb;257(2):330-4 [23291661.001]
  • [Cites] Prehosp Emerg Care. 2015 January-March;19(1):1-9 [24932734.001]
  • [Cites] Aviat Space Environ Med. 2014 Nov;85(11):1130-5 [25329947.001]
  • [Cites] JAMA. 2012 Apr 18;307(15):1602-10 [22511688.001]
  • [Cites] Surgery. 2015 Dec;158(6):1686-95 [26210224.001]
  • [Cites] Shock. 2013 Dec;40(6):444-50 [24089000.001]
  • [Cites] J Trauma. 2009 Apr;66(4 Suppl):S77-84; discussion S84-5 [19359974.001]
  • [Cites] J Trauma Acute Care Surg. 2013 Jun;74(6):1425-31 [23694868.001]
  • [Cites] J Trauma Acute Care Surg. 2012 Mar;72(3):567-73; discussion 573-5; quiz 803 [22491538.001]
  • [Cites] J Trauma. 2007 Feb;62(2):307-10 [17297317.001]
  • [Cites] Shock. 2014 May;41 Suppl 1:39-43 [24662780.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2013;2013:656-9 [24319247.001]
  • [Cites] Ann Surg. 2011 Oct;254(4):598-605 [21918426.001]
  • [Cites] J Trauma Acute Care Surg. 2016 Oct;81(4):780-94 [27389129.001]
  • [Cites] J Trauma Acute Care Surg. 2012 Jan;72(1):106-11 [22310123.001]
  • [Cites] Ann Surg. 2015 Mar;261(3):586-90 [25072443.001]
  • [Cites] Vox Sang. 2009 Jul;97(1):39-49 [19392782.001]
  • [Cites] J Trauma Acute Care Surg. 2015 Jun;78(6 Suppl 1):S26-30 [26002260.001]
  • [Cites] J Trauma. 2008 Aug;65(2):272-6; discussion 276-8 [18695461.001]
  • [Cites] US Army Med Dep J. 2011 Apr-Jun;:18-24 [21607903.001]
  • [Cites] Shock. 2014 May;41 Suppl 1:44-6 [24296431.001]
  • [Cites] Surgery. 2016 Mar;159(3):947-59 [26603848.001]
  • [Cites] Shock. 2014 May;41 Suppl 1:3-12 [24430539.001]
  • (PMID = 28383476.001).
  • [ISSN] 2163-0763
  • [Journal-full-title] The journal of trauma and acute care surgery
  • [ISO-abbreviation] J Trauma Acute Care Surg
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / U01 HL077863
  • [Publication-type] Journal Article; Multicenter Study; Observational Study
  • [Publication-country] United States
  • [Investigator] Holcomb JB; Wade CE; Fox EE; Podbielski JM; Tomasek JS; del Junco DJ; Swartz MD; DeSantis SM; Appana SN; Greene TJ; Yi M; Gonzalez MO; Baraniuk S; van Belle G; Leroux BG; Howard CL; Haymaker A; Stein DM; Scalea TM; Ayd B; Das P; Herrera AV; Bulger EM; Robinson BRH; Klotz P; Minhas A; Kerby JD; Melton SM; Williams CR; Stephens SW; Goodman M; Johannigman JA; McMullan J; Branson RD; Gomaa D; Barczak C; Schreiber MA; Underwood SJ; Watson C; Zielinski MD; Stubbs JR; Headlee A; O’Keeffe T; Rhee P; Rokowski LL; Santoro J; Seach A; Bradford D; Fealk M; Latifi F; Inaba K; Kim H; Chudnofsky C; Wong MD
  •  go-up   go-down


76. Kashiura M, Hamabe Y, Akashi A, Sakurai A, Tahara Y, Yonemoto N, Nagao K, Yaguchi A, Morimura N, SOS-KANTO 2012 Study Group: Association between cardiopulmonary resuscitation duration and one-month neurological outcomes for out-of-hospital cardiac arrest: a prospective cohort study. BMC Anesthesiol; 2017 Apr 21;17(1):59

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Data were utilized from a prospective multi-center cohort study of out-of-hospital cardiac arrest patients transported to 67 emergency hospitals between January 2012 and March 2013 in the Kanto area of Japan.
  • A total of 3,353 patients with out-of-hospital cardiac arrest (age ≥18 years) who underwent CPR by emergency medical service personnel and achieved the return of spontaneous circulation in a pre- or in-hospital setting were analyzed.
  • The CPR duration required to achieve return of spontaneous circulation in >99% of out-of-hospital cardiac arrest patients with a 1-month favorable neurological outcome was 45 min, considering both pre- and in-hospital settings.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Circulation. 2015 Nov 3;132(18 Suppl 2):S465-82 [26472996.001]
  • [Cites] Crit Care. 2014 Sep 26;18(5):535 [25255842.001]
  • [Cites] Crit Care Med. 1985 Nov;13(11):930-1 [4053643.001]
  • [Cites] Circulation. 1991 Aug;84(2):960-75 [1860248.001]
  • [Cites] Circulation. 2015 Nov 3;132(18 Suppl 2):S383-96 [26472991.001]
  • [Cites] Crit Care. 2015 Sep 10;19:322 [26353809.001]
  • [Cites] Resuscitation. 2007 Jun;73(3):394-9 [17289244.001]
  • [Cites] Resuscitation. 2014 Dec;85(12):1779-89 [25438253.001]
  • [Cites] Resuscitation. 2013 Jan;84(1):54-9 [22705831.001]
  • [Cites] Am J Emerg Med. 2015 May;33(5):677-81 [25753293.001]
  • [Cites] Resuscitation. 2015 Nov;96:323-7 [25986336.001]
  • [Cites] J Am Heart Assoc. 2016 Mar 18;5(3):e002819 [26994129.001]
  • [Cites] Circulation. 2013 Dec 3;128(23):2488-94 [24243885.001]
  • [Cites] Resuscitation. 2010 Nov;81(11):1479-87 [20828914.001]
  • [Cites] Resuscitation. 2015 Oct;95:302-11 [26477419.001]
  • [Cites] Resuscitation. 2008 Sep;78(3):355-8 [18573588.001]
  • [Cites] Emerg Med J. 2014 Jul;31(7):549-555 [23639589.001]
  • [Cites] Resuscitation. 2016 Apr;101:50-6 [26851705.001]
  • [Cites] N Engl J Med. 2010 Mar 18;362(11):994-1004 [20237345.001]
  • [Cites] Circulation. 2010 Nov 2;122(18 Suppl 3):S665-75 [20956219.001]
  • [Cites] Circ Cardiovasc Qual Outcomes. 2010 Jan;3(1):63-81 [20123673.001]
  • [Cites] Resuscitation. 2007 Mar;72(3):394-403 [17161519.001]
  • [Cites] Resuscitation. 2015 Nov;96:328-40 [25438254.001]
  • [Cites] Crit Care. 2016 Mar 01;20:49 [26926006.001]
  • [Cites] Circulation. 2013 Dec 3;128(23):2465-7 [24135072.001]
  • [Cites] Perfusion. 2016 Apr;31(3):200-6 [26081930.001]
  • [Cites] J Thorac Dis. 2016 Oct;8(10 ):E1435-E1437 [27867652.001]
  • [Cites] Resuscitation. 2016 Mar;100:25-31 [26774172.001]
  • [Cites] Lancet. 2008 Aug 16;372(9638):554-61 [18603291.001]
  • (PMID = 28431508.001).
  • [ISSN] 1471-2253
  • [Journal-full-title] BMC anesthesiology
  • [ISO-abbreviation] BMC Anesthesiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Cardiopulmonary resuscitation / Emergency medical services / Out-of-hospital cardiac arrest / Patient outcome assessment
  • [Investigator] Inokuchi S; Masui Y; Miura K; Tsutsumi H; Takuma K; Atsushi I; Nakano M; Tanaka H; Ikegami K; Arai T; Yaguchi A; Kitamura N; Oda S; Kobayashi K; Suda T; Ono K; Morimura N; Furuya R; Koido Y; Iwase F; Nagao K; Kanesaka S; Okada Y; Unemoto K; Sadahiro T; Iyanaga M; Muraoka A; Hayashi M; Ishimatsu S; Miyake Y; Yokokawa H; Koyama Y; Tsuchiya A; Kashiyama T; Hayashi M; Oshima K; Kiyota K; Hamabe Y; Yokota H; Hori S; Inaba S; Sakamoto T; Harada N; Kimura A; Kanai M; Otomo Y; Sugita M; Kinoshita K; Sakurai T; Kitano M; Matsuda K; Tanaka K; Yoshihara K; Yoh K; Suzuki J; Toyoda H; Mashiko K; Shimizu N; Muguruma T; Shimada T; Kobe Y; Nakanishi K; Shiga T; Yamamoto T; Sekine K; Izuka S
  •  go-up   go-down


77. Petersen PB, Jørgensen CC, Kehlet H, Lundbeck Foundation Centre for Fast-track Hip and Knee Replacement Collaborative Group: Delirium after fast-track hip and knee arthroplasty - a cohort study of 6331 elderly patients. Acta Anaesthesiol Scand; 2017 Aug;61(7):767-772

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delirium after fast-track hip and knee arthroplasty - a cohort study of 6331 elderly patients.
  • BACKGROUND: Postoperative delirium (PD) is a well-known complication among elderly surgical patients and associated with increased morbidity, mortality and length of stay (LOS).
  • The multimodal optimization of perioperative care (fast-track) aims to enhance recovery and reduce morbidity and LOS, but limited data are available on the effect on PD.
  • METHODS: Prospective risk assessment study with retrospective analysis of discharge notes or medical records of signs of PD in 6331 elective primary unilateral THA and TKA patients ≥ 70 years, and LOS > 4 days.
  • Preoperative patient characteristics collected from eight high volume centers with similar standardized fast-track protocols from January 2010 to November 2013.
  • RESULTS: We identified 43 (0.7%) cases of PD symptoms mentioned as a reason for LOS > 4 days among the 789 patients with LOS > 4 days (12.5% of all THA and TKA).
  • PD patients had a mean age of 80.7 [[95% CI] 79.3-82.1] years, being 4.0 [[95% CI] 2.5-5.5] years older compared to patients without PD (P < 0.001).
  • CONCLUSION: Postoperative delirium symptoms contributing to LOS > 4 days in fast-track THA and TKA are rare in elderly patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
  • (PMID = 28681427.001).
  • [ISSN] 1399-6576
  • [Journal-full-title] Acta anaesthesiologica Scandinavica
  • [ISO-abbreviation] Acta Anaesthesiol Scand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Investigator] Madsen F; Hansen TB; Husted H; Laursen MB; Hansen LT; Kjaersgaard-Andersen P; Solgaard S
  •  go-up   go-down


78. Holt TA, Dalton A, Marshall T, Fay M, Qureshi N, Kirkpatrick S, Hislop J, Lasserson D, Kearley K, Mollison J, Yu LM, Hobbs FD, Fitzmaurice D: Automated Software System to Promote Anticoagulation and Reduce Stroke Risk: Cluster-Randomized Controlled Trial. Stroke; 2017 Mar;48(3):787-790
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated the effectiveness of a software tool (AURAS-AF [Automated Risk Assessment for Stroke in Atrial Fibrillation]) designed to identify such individuals during routine care through a cluster-randomized trial.
  • METHODS: Screen reminders appeared each time the electronic health records of an eligible patient was accessed until a decision had been taken over OAC treatment.
  • Control practices continued usual care.
  • Incidence of recorded transient ischemic attack was higher in the intervention practices (median 10.0 versus 2.3 per 1000 patients with atrial fibrillation; <i>P</i>=0.027), but at 12 months, we found a lower incidence of both all cause stroke (<i>P</i>=0.06) and hemorrhage (<i>P</i>=0.054).

  • MedlinePlus Health Information. consumer health - Atrial Fibrillation.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • [Cites] Trials. 2013 Nov 13;14:385 [24220602.001]
  • [Cites] Br J Gen Pract. 2012 Oct;62(603):e710-7 [23265231.001]
  • [Cites] Lancet. 2014 Mar 15;383(9921):955-62 [24315724.001]
  • [Cites] Am J Med. 2010 Jul;123(7):638-645.e4 [20609686.001]
  • [Cites] Cochrane Database Syst Rev. 2009 Jul 08;(3):CD001096 [19588323.001]
  • [Cites] Stroke. 1991 Aug;22(8):983-8 [1866765.001]
  • [Cites] Thromb Res. 2006;118(3):321-33 [16198396.001]
  • (PMID = 28119433.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / / WMCLAHRC-2014-1
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants
  • [Keywords] NOTNLM ; anticoagulants (major topic) / atrial fibrillation (major topic) / electronic health records (major topic) / reminder systems (major topic) / stroke (major topic)
  •  go-up   go-down


79. Schaefer F, Trachtman H, Wühl E, Kirchner M, Hayek SS, Anarat A, Duzova A, Mir S, Paripovic D, Yilmaz A, Lugani F, Arbeiter K, Litwin M, Oh J, Matteucci MC, Gellermann J, Wygoda S, Jankauskiene A, Klaus G, Dusek J, Testa S, Zurowska A, Caldas Afonso A, Tracy M, Wei C, Sever S, Smoyer W, Reiser J, ESCAPE Trial Consortium and the 4C Study Group: Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children. JAMA Pediatr; 2017 Sep 05;:e172914
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Importance: Conventional methods to diagnose and monitor chronic kidney disease (CKD) in children, such as creatinine level and cystatin C-derived estimated glomerular filtration rate (eGFR) and assessment of proteinuria in spot or timed urine samples, are of limited value in identifying patients at risk of progressive kidney function loss.
  • In the 2 trials, a total of 898 children were observed at 30 (ESCAPE Trial; n = 256) and 55 (4C Study; n = 642) tertiary care hospitals in 13 European countries.
  • Results: Of the 898 included children, 560 (62.4%) were male, and the mean (SD) patient age at enrollment was 11.9 (3.5) years.
  • In patients with baseline eGFR greater than 40 mL/min/1.73 m2, higher log-transformed suPAR levels were associated with a higher risk of CKD progression after adjustment for traditional risk factors (hazard ratio, 5.12; 95% CI, 1.56-16.7; P = .007).
  • Conclusions and Relevance: Patients with high suPAR levels were more likely to have progression of their kidney disease.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28873129.001).
  • [ISSN] 2168-6211
  • [Journal-full-title] JAMA pediatrics
  • [ISO-abbreviation] JAMA Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M, Dujmovic I, van der Flier W, Frölich L, Galimberti D, Gnanapavan S, Hemmer B, Hoff E, Hort J, Iacobaeus E, Ingelsson M, Jan de Jong F, Jonsson M, Khalil M, Kuhle J, Lleó A, de Mendonça A, Molinuevo JL, Nagels G, Paquet C, Parnetti L, Roks G, Rosa-Neto P, Scheltens P, Skårsgard C, Stomrud E, Tumani H, Visser PJ, Wallin A, Winblad B, Zetterberg H, Duits F, Teunissen CE: Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement (Amst); 2017;8:111-126

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consensus guidelines for lumbar puncture in patients with neurological diseases.
  • RESULTS: Our consensus guidelines address contraindications, as well as patient-related and procedure-related risk factors that can influence the development of post-LP complications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurol Scand. 1998 Dec;98(6):445-51 [9875625.001]
  • [Cites] Br J Anaesth. 2012 Feb;108(2):308-15 [22157954.001]
  • [Cites] Acad Emerg Med. 2014 Feb;21(2):130-6 [24673668.001]
  • [Cites] Ann Emerg Med. 1993 Dec;22(12):1863-70 [8239110.001]
  • [Cites] Eur J Neurol. 2014 Feb;21(2):305-11 [24320927.001]
  • [Cites] Neurology. 1959 Apr;9(4):290-7 [13644562.001]
  • [Cites] J Neurol. 1998 Sep;245(9):589-92 [9758296.001]
  • [Cites] Anaesthesia. 1999 Jul;54(7):647-50 [10417455.001]
  • [Cites] Neurology. 2000 Oct 10;55(7):909-14 [11061243.001]
  • [Cites] J Neurol Sci. 2011 Jul 15;306(1-2):24-8 [21549395.001]
  • [Cites] Ann Chir Gynaecol. 1981;70(3):107-11 [7325577.001]
  • [Cites] Can J Anaesth. 1995 Aug;42(8):706-10 [7586110.001]
  • [Cites] Neurology. 2002 Oct 8;59(7):1120; author reply 1120-1 [12370487.001]
  • [Cites] Pediatrics. 1992 May;89(5 Pt 1):895-7 [1579400.001]
  • [Cites] BMJ. 2001 Apr 21;322(7292):993-4 [11312243.001]
  • [Cites] Cephalalgia. 2016 Feb;36(2):131-8 [25908221.001]
  • [Cites] Neurologist. 2009 Jan;15(1):17-20 [19131853.001]
  • [Cites] Spine J. 2015 Jul 1;15(7):1571-6 [25794941.001]
  • [Cites] Acta Neurol Scand. 2001 Jun;103(6):396-8 [11421853.001]
  • [Cites] Haematologica. 2007 Jul;92(7):1007-8 [17606461.001]
  • [Cites] Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):632-4 [23834161.001]
  • [Cites] Neurology. 2006 Oct 24;67(8):1492-4 [17060584.001]
  • [Cites] BMJ. 1999 Mar 13;318(7185):728-30 [10074024.001]
  • [Cites] S Afr Med J. 1978 Apr 29;53(17):666-8 [675447.001]
  • [Cites] Anesth Analg. 1995 Feb;80(2):303-9 [7818117.001]
  • [Cites] Ulster Med J. 2014 May;83(2):93-102 [25075138.001]
  • [Cites] Reg Anesth. 1997 Jan-Feb;22(1):66-72 [9010949.001]
  • [Cites] Reg Anesth Pain Med. 2000 Mar-Apr;25(2):163-9 [10746529.001]
  • [Cites] Acad Radiol. 2014 May;21(5):612-6 [24703473.001]
  • [Cites] Lancet Neurol. 2014 Jun;13(6):614-29 [24849862.001]
  • [Cites] Anesth Analg. 1989 Oct;69(4):457-60 [2782645.001]
  • [Cites] Neurology. 2002 Dec 24;59(12):2008-9 [12499507.001]
  • [Cites] Headache. 1972 Jul;12(2):73-8 [4262477.001]
  • [Cites] Neurology. 2001 Dec 26;57(12):2310-2 [11756618.001]
  • [Cites] Br J Anaesth. 2003 Nov;91(5):718-29 [14570796.001]
  • [Cites] Neurology. 1993 Mar;43(3 Pt 1):625-7 [8451016.001]
  • [Cites] AJNR Am J Neuroradiol. 2014 Aug;35(8):1475-80 [24722309.001]
  • [Cites] Cephalalgia. 2004;24 Suppl 1:9-160 [14979299.001]
  • [Cites] Clin Anat. 2004 Oct;17(7):544-53 [15376294.001]
  • [Cites] J Alzheimers Dis. 2014;39(4):719-26 [24254700.001]
  • [Cites] Ann Clin Biochem. 1995 Mar;32 ( Pt 2):210-2 [7785952.001]
  • [Cites] BMJ. 2001 Apr 21;322(7292):994 [11312245.001]
  • [Cites] Alzheimers Dement. 2011 May;7(3):263-9 [21514250.001]
  • [Cites] Clin Radiol. 1991 Nov;44(5):338-41 [1836989.001]
  • [Cites] Neurology. 1996 Jul;47(1):33-7 [8710120.001]
  • [Cites] Alzheimer Dis Assoc Disord. 2005 Oct-Dec;19(4):220-5 [16327349.001]
  • [Cites] JRSM Short Rep. 2012 Dec;3(12):82 [23476725.001]
  • [Cites] CMAJ. 1993 Mar 15;148(6):961-5 [8448711.001]
  • [Cites] Paediatr Anaesth. 1999;9(5):429-34 [10447907.001]
  • [Cites] AJR Am J Roentgenol. 2008 Jun;190(6):1686-9 [18492925.001]
  • [Cites] Eur Radiol. 2002 Mar;12 (3):686-91 [11870488.001]
  • [Cites] Eur Radiol. 1996;6(2):184-7 [8797976.001]
  • [Cites] BMJ. 1998 Mar 28;316(7136):1018 [9550978.001]
  • [Cites] J Neurol. 1994 May;241(6):376-80 [7931432.001]
  • [Cites] Eur J Neurol. 2013 Mar;20(3):410-9 [23323801.001]
  • [Cites] Neurology. 2014 Feb 25;82(8):734-5 [24566228.001]
  • [Cites] Dan Med J. 2012 Jul;59(7):A4483 [22759849.001]
  • [Cites] J Headache Pain. 2005 Oct;6(5):400-4 [16362713.001]
  • [Cites] Biol Psychiatry. 1996 Jun 15;39(12):1058-60 [8780844.001]
  • [Cites] Alzheimers Dement. 2016 Feb;12(2):154-63 [26368321.001]
  • [Cites] Int J Nurs Stud. 2011 Nov;48(11):1315-22 [21561619.001]
  • [Cites] Neurol Clin. 1998 Feb;16(1):83-105 [9421542.001]
  • [Cites] J Clin Neurosci. 2014 Mar;21(3):536-7 [24156907.001]
  • [Cites] Cochrane Database Syst Rev. 2010 Jan 20;(1):CD001791 [20091522.001]
  • [Cites] Cephalalgia. 2012 Sep;32(12):916-23 [22843225.001]
  • [Cites] Dan Med J. 2013 Sep;60(9):A4684 [24001459.001]
  • [Cites] Br J Haematol. 2011 Aug;154(3):311-24 [21671894.001]
  • [Cites] Neurology. 2005 Apr 12;64(7):E24 [15824326.001]
  • [Cites] Neurology. 2005 Aug 23;65(4):510-2 [16116106.001]
  • [Cites] N Engl J Med. 2001 Dec 13;345(24):1727-33 [11742046.001]
  • [Cites] Neurol Sci. 2014 Dec;35(12):1997-9 [25139108.001]
  • [Cites] Eur Heart J. 2013 Jul;34(27):2094-106 [23625209.001]
  • [Cites] Neurology. 2012 Jan 10;78(2):109-13 [22205758.001]
  • [Cites] JAMA. 2006 Oct 25;296(16):2012-22 [17062865.001]
  • [Cites] Headache. 2001 Apr;41(4):385-90 [11318885.001]
  • [Cites] Alzheimers Dement. 2011 May;7(3):270-9 [21514249.001]
  • [Cites] Headache. 1986 May;26(5):224-6 [3721858.001]
  • [Cites] J Neurol. 2012 Aug;259(8):1530-45 [22278331.001]
  • [Cites] BMJ. 2001 Apr 21;322(7292):993; author reply 994 [11312241.001]
  • [Cites] Paediatr Anaesth. 2008 Mar;18(3):230-4 [18230066.001]
  • [Cites] Arch Dis Child. 2014 Mar;99(3):203-7 [24233069.001]
  • [Cites] Cochrane Database Syst Rev. 2015 Jul 15;(7):CD007887 [26176166.001]
  • [Cites] Cephalalgia. 2001 Sep;21(7):738-43 [11595002.001]
  • [Cites] JAMA Neurol. 2015 Mar;72(3):325-32 [25622095.001]
  • [Cites] J Emerg Med. 2014 Jul;47(1):59-64 [24775990.001]
  • [Cites] BMJ. 2000 Oct 21;321(7267):986-90 [11039963.001]
  • [Cites] Anaesthesia. 1989 Feb;44(2):147-9 [2929939.001]
  • [Cites] AJR Am J Roentgenol. 2016 Jan;206(1):20-5 [26700333.001]
  • [Cites] Anesthesiology. 2001 Aug;95(2):334-9 [11506102.001]
  • [Cites] Anesth Analg. 2004 Jul;99(1):303; author reply 303-4 [15281552.001]
  • [Cites] Clin Neurol Neurosurg. 2015 Mar;130:74-9 [25590665.001]
  • [Cites] Acta Neurol Scand. 1992 Jul;86(1):50-4 [1519474.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1987 Aug;50(8):1071-4 [3655817.001]
  • [Cites] Cephalalgia. 1989 Jun;9(2):99-106 [2743417.001]
  • [Cites] Neurology. 2013 Apr 23;80(17):e180-2 [23610152.001]
  • [Cites] Cephalalgia. 1993 Aug;13(4):296-7 [8374947.001]
  • [Cites] Psychosom Med. 1967 Jun-Aug;29(4):376-9 [4862603.001]
  • [Cites] Neurology. 2011 Jul 5;77(1):71-4 [21593442.001]
  • [Cites] J Neurointerv Surg. 2014 May;6(4):324-8 [23729498.001]
  • [Cites] Cephalalgia. 1998 Nov;18(9):635-7; discussion 591 [9876888.001]
  • [Cites] Cephalalgia. 1992 Aug;12(4):259 [1525802.001]
  • [Cites] Acta Anaesthesiol Scand. 2000 Feb;44(2):210-3 [10695916.001]
  • (PMID = 28603768.001).
  • [ISSN] 2352-8729
  • [Journal-full-title] Alzheimer's & dementia (Amsterdam, Netherlands)
  • [ISO-abbreviation] Alzheimers Dement (Amst)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Back pain / Cerebrospinal fluid / Consensus guidelines / Evidence-based guidelines / Headache / Lumbar puncture / Post-LP complications
  •  go-up   go-down


81. Chookalayi H, Heidarzadeh M, Hasanpour M, Jabrailzadeh S, Sadeghpour F: A Study on the Psychometric Properties of Revised-nonverbal Pain Scale and Original-nonverbal Pain Scale in Iranian Nonverbal-ventilated Patients. Indian J Crit Care Med; 2017 Jul;21(7):429-435

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Study on the Psychometric Properties of Revised-nonverbal Pain Scale and Original-nonverbal Pain Scale in Iranian Nonverbal-ventilated Patients.
  • BACKGROUND AND AIMS: The nonverbal pain scale is one of the instruments which study pain in nonverbal-ventilated patients with regard to the changes of behavioral and physiological indices.
  • The purpose of the study is to survey the psychometric properties of revised-nonverbal pain scale (R-NVPS) and original-nonverbal pain scale (O-NVPS) in ventilated patients hospitalized in critical care units.
  • MATERIALS AND METHODS: Four nurses studied pain in sixty patients hospitalized in trauma, medical, neurology, and surgical critical care units using R-NVPS and O-NVPS at six times (before, during, and after nociceptive and nonnociceptive procedures).
  • The test was repeated in 37 patients after 8-12 h.
  • The meaningful difference in pain score between nociceptive and nonnociceptive procedures (<i>P</i> < 0.001) and a higher pain score in patients who confirmed pain (<i>P</i> < 0.001) showed a discriminant and criterion validity for both scales of NVPS, respectively.
  • CONCLUSIONS: R-NVPS and O-NVPS can both be used as valid and reliable scales in studying pain in ventilated patient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pain Res Manag. 2013 Nov-Dec;18(6):e107-14 [24308026.001]
  • [Cites] Crit Care Nurse. 2005 Feb;25(1):14-5 [15756730.001]
  • [Cites] Anesth Analg. 2009 May;108(5):1546-52 [19372334.001]
  • [Cites] Dimens Crit Care Nurs. 2010 Nov-Dec;29(6):307-15 [20940589.001]
  • [Cites] Dimens Crit Care Nurs. 2003 Nov-Dec;22(6):260-7 [14639117.001]
  • [Cites] Intensive Crit Care Nurs. 2010 Apr;26(2):83-90 [20044256.001]
  • [Cites] Am J Nurs. 2002 Jan;102(1):59-60 [11839910.001]
  • [Cites] Crit Care Nurs Clin North Am. 2001 Jun;13(2):181-94 [11866401.001]
  • [Cites] Pain Manag Nurs. 2006 Jun;7(2):44-52 [16730317.001]
  • [Cites] Crit Care. 2014 Jul 25;18(5):R160 [25063269.001]
  • [Cites] J Crit Care. 2015 Feb;30(1):167-72 [25446372.001]
  • [Cites] Pain Pract. 2016 Apr;16(4):451-8 [25857484.001]
  • [Cites] Pain. 2010 Dec;151(3):711-21 [20843604.001]
  • [Cites] Crit Care Med. 2001 Dec;29(12):2258-63 [11801819.001]
  • [Cites] Pain Med. 2015 Aug;16(8):1622-8 [25800546.001]
  • [Cites] Pain Res Treat. 2014;2014:175794 [24639895.001]
  • [Cites] Am J Nurs. 2002 Oct;102(10):55-8 [12394307.001]
  • [Cites] Crit Care Nurse. 2009 Feb;29(1):59-66 [19182281.001]
  • [Cites] Pain Manag Nurs. 2003 Mar;4(1):23-30 [12707865.001]
  • [Cites] J Pain Symptom Manage. 2014 Nov;48(5):975-82 [24793506.001]
  • [Cites] Intensive Crit Care Nurs. 2006 Feb;22(1):32-9 [16198570.001]
  • [Cites] Clin J Pain. 2007 Jul-Aug;23(6):497-505 [17575489.001]
  • [Cites] Pain Manag Nurs. 2010 Sep;11(3):134-40 [20728062.001]
  • [Cites] Int J Nurs Stud. 2011 Apr;48(4):438-48 [20728886.001]
  • [Cites] Am J Crit Care. 2006 Jul;15(4):420-7 [16823021.001]
  • (PMID = 28808362.001).
  • [ISSN] 0972-5229
  • [Journal-full-title] Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine
  • [ISO-abbreviation] Indian J Crit Care Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Keywords] NOTNLM ; Instrument / Intensive Care Unit / mechanical ventilation / pain / pain measurement
  •  go-up   go-down


82. Tammes P, Morris RW, Brangan E, Checkland K, England H, Huntley A, Lasserson D, MacKichan F, Salisbury C, Wye L, Purdy S: Exploring the relationship between general practice characteristics and attendance at Walk-in Centres, Minor Injuries Units and Emergency Departments in England 2009/10-2012/2013: a longitudinal study. BMC Health Serv Res; 2017 Aug 08;17(1):546

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study investigated associations of general practice and practice population characteristics with emergency care service attendance rates.
  • METHODS: A longitudinal design with practice-level measures of access and continuity of care, patient population demographics and use of emergency care for the financial years 2009/10 to 2012/13.
  • The main outcome measures were self-referred discharged ED attendance rate, and combined self-referred discharged ED, self-referred Walk-in Centre (WiC) and self-referred Minor Injuries Unit (MIU) attendance rate per 1000 patients.
  • Multilevel models estimated adjusted regression coefficients for relationships between patients' emergency attendance rates and patients' reported satisfaction with opening hours and waiting time at the practice, proportion of patients having a preferred GP, and use of WiC and MIU, both between practices, and within practices over time.
  • RESULTS: Practice characteristics associated with higher ED attendance rates included lower percentage of patients satisfied with waiting time (0.22 per 1% decrease, 95%CI 0.02 to 0.43) and lower percentage having a preferred GP (0.12 per 1% decrease, 95%CI 0.02 to 0.21).
  • Population influences on higher attendance included more elderly, more female and more unemployed patients, and lower male life-expectancy and urban conurbation location.
  • Combined emergency care attendance fell over time if more patients within a practice were satisfied with opening hours (-0.26 per 1% increase, 95%CI -0.45 to -0.08).
  • CONCLUSION: Practices with more patients satisfied with waiting time, having a preferred GP, and using MIU and WIC services, had lower ED attendance.
  • Increases over time in attendance at MIUs, and patient satisfaction with opening hours was associated with reductions in service use.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Gen Pract. 2011 Dec;61(593):e787-93 [22137415.001]
  • [Cites] Emerg Med J. 2012 Jun;29(6):487-91 [21561984.001]
  • [Cites] Emerg Med J. 2011 May;28(5):373-7 [20961936.001]
  • [Cites] Br J Gen Pract. 2014 Jul;64(624):e434-9 [24982496.001]
  • [Cites] BMJ Open. 2013 Aug 19;3(8):e003320 [23959757.001]
  • [Cites] PLoS One. 2013 Jun 12;8(6):e66699 [23776694.001]
  • [Cites] Emerg Med J. 2007 Apr;24(4):265-9 [17384380.001]
  • [Cites] J Health Serv Res Policy. 2006 Oct;11(4):196-201 [17018192.001]
  • [Cites] BMJ. 2003 Mar 8;326(7388):532 [12623914.001]
  • [Cites] Emerg Med J. 2010 Jan;27(1):22-5 [20029001.001]
  • [Cites] BMJ Qual Saf. 2011 Nov;20(11):953-8 [21685185.001]
  • [Cites] Emerg Med J. 2016 Oct;33(10 ):702-8 [27317586.001]
  • [Cites] BMJ. 2014 Nov 11;349:g6423 [25389120.001]
  • [Cites] Br J Gen Pract. 2015 Oct;65(639):e649-54 [26412841.001]
  • [Cites] BMJ Open. 2013 Dec 06;3(12):e003612 [24319279.001]
  • [Cites] Emerg Med J. 2015 Apr;32(4):295-300 [24406328.001]
  • [Cites] Arch Intern Med. 2010 Oct 11;170(18):1671-7 [20937927.001]
  • [Cites] BMJ Open. 2014 May 23;4(5):e004746 [24860000.001]
  • [Cites] BMJ Open. 2013 Aug 19;3(8):e003482 [23959760.001]
  • [Cites] Br J Hosp Med (Lond). 2014 Nov;75(11):627-30 [25383432.001]
  • [Cites] Pediatrics. 2001 Mar;107(3):524-9 [11230593.001]
  • (PMID = 28789652.001).
  • [ISSN] 1472-6963
  • [Journal-full-title] BMC health services research
  • [ISO-abbreviation] BMC Health Serv Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Alternative health care service / Continuity of care / Longitudinal study / Multilevel modelling / Population characteristics / Primary health care / hospital’ / ‘Emergency service
  •  go-up   go-down


83. Volkers EJ, Greving JP, Hendrikse J, Algra A, Kappelle LJ, Becquemin JP, Bonati LH, Brott TG, Bulbulia R, Calvet D, Eckstein HH, Fraedrich G, Gregson J, Halliday A, Howard G, Jansen O, Roubin GS, Brown MM, Mas JL, Ringleb PA, Carotid Stenosis Trialists' Collaboration: Body mass index and outcome after revascularization for symptomatic carotid artery stenosis. Neurology; 2017 May 23;88(21):2052-2060
MedlinePlus Health Information. consumer health - Angioplasty.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine whether the obesity paradox exists in patients who undergo carotid artery stenting (CAS) or carotid endarterectomy (CEA) for symptomatic carotid artery stenosis.
  • METHODS: We combined individual patient data from 2 randomized trials (Endarterectomy vs Angioplasty in Patients with Symptomatic Severe Carotid Stenosis and Stent-Protected Angioplasty vs Carotid Endarterectomy) and 3 centers in a third trial (International Carotid Stenting Study).
  • Baseline body mass index (BMI) was available for 1,969 patients and classified into 4 groups: <20, 20-<25, 25-<30, and ≥30 kg/m<sup>2</sup>.
  • This outcome was compared between different BMI strata in CAS and CEA patients separately, and in the total group.
  • Stroke or death occurred in 159 patients in the periprocedural (cumulative risk 8.1%) and in 270 patients in the postprocedural period (rate 4.8/100 person-years).
  • BMI did not affect periprocedural risk of stroke or death for patients assigned to CAS (<i>p</i><sub>trend</sub> = 0.39) or CEA (<i>p</i><sub>trend</sub> = 0.77) or for the total group (<i>p</i><sub>trend</sub> = 0.48).
  • Within the total group, patients with BMI 25-<30 had lower postprocedural risk of stroke or death than patients with BMI 20-<25 (BMI 25-<30 vs BMI 20-<25; hazard ratio 0.72; 95% confidence interval 0.55-0.94).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Academy of Neurology.
  • [Cites] J Vasc Surg. 2009 Jan;49(1):140-7, 147.e1; discussion 147 [19028047.001]
  • [Cites] Int J Cardiol. 2014 Apr 1;172(3):600-1 [24491866.001]
  • [Cites] BMJ. 2016 May 04;353:i2156 [27146380.001]
  • [Cites] J Clin Epidemiol. 2013 Feb;66(2):192-6 [23257150.001]
  • [Cites] Stroke. 1988 May;19(5):604-7 [3363593.001]
  • [Cites] Int J Stroke. 2015 Jan;10(1):99-104 [25635277.001]
  • [Cites] Stroke. 2011 Oct;42(10):2872-7 [21836099.001]
  • [Cites] Stroke. 2010 May;41(5):e418-26 [20299666.001]
  • [Cites] Am J Cardiol. 2015 May 15;115(10):1428-34 [25772740.001]
  • [Cites] Stroke. 1989 Jun;20(6):828 [2728057.001]
  • [Cites] Neurology. 2012 Aug 28;79(9):856-63 [22895584.001]
  • [Cites] Lancet. 2016 Aug 20;388(10046):776-86 [27423262.001]
  • [Cites] N Engl J Med. 2006 Oct 19;355(16):1660-71 [17050890.001]
  • [Cites] Lancet. 2006 Oct 7;368(9543):1239-47 [17027729.001]
  • [Cites] Am J Cardiol. 2005 Dec 15;96(12):1743-5 [16360369.001]
  • [Cites] Lancet. 2010 Sep 25;376(9746):1062-73 [20832852.001]
  • [Cites] Stroke. 1991 Jun;22(6):711-20 [2057968.001]
  • [Cites] J Am Coll Surg. 2012 Feb;214(2):148-55 [22192895.001]
  • [Cites] Eur Heart J. 2013 Jan;34(4):268-77 [23076781.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1759-61 [15548500.001]
  • [Cites] Cochrane Database Syst Rev. 2012 Sep 12;(9):CD000515 [22972047.001]
  • [Cites] Lancet. 2010 Mar 20;375(9719):985-97 [20189239.001]
  • [Cites] N Engl J Med. 2008 Nov 13;359(20):2105-20 [19005195.001]
  • [Cites] JAMA. 2011 Feb 23;305(8):822-3 [21343582.001]
  • [Cites] J Vasc Surg. 2012 May;55(5):1306-12 [22542344.001]
  • [Cites] Lancet. 2009 Mar 28;373(9669):1083-96 [19299006.001]
  • [Cites] N Engl J Med. 2010 Jul 1;363(1):11-23 [20505173.001]
  • [Cites] Chest. 2008 Nov;134(5):925-930 [18641109.001]
  • [Cites] J Hypertens. 2012 Dec;30(12):2271-5 [23151882.001]
  • [Cites] Neuroepidemiology. 2008;30(2):93-100 [18309248.001]
  • (PMID = 28446644.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


84. Miyauchi R, Itoh Y, Kawamura M, Hirakawa A, Shibata K, Kajiyama H, Nakahara R, Kubota S, Ito J, Okada T, Kikkawa F, Naganawa S: Postoperative chemoradiation therapy using high dose cisplatin and fluorouracil for high- and intermediate-risk uterine cervical cancer. Nagoya J Med Sci; 2017 Feb;79(2):211-220

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this retrospective study was to analyze data in patients with stage IB-IIB uterine cervical cancer who were treated with concurrent chemoradiotherapy (CCRT) with high dose cisplatin and fluorouracil as postoperative adjuvant therapy.
  • Between February 2003 and November 2011, 76 patients with FIGO stage IB-IIB cervical cancer were analyzed.
  • Seventy patients were treated with postoperative CCRT and 6 patients were treated with radiation therapy alone.
  • The median patient age was 45 years (range, 20-80 years).
  • Fifty-eight patients (76.3%) had a squamous cell histologic type, 55 patients (72.4%) had lymphovascular invasion, 31 patients (40.8%) had parametrial invasion, and 28 patients (36.8%) had lymph node metastases.
  • Five-year DFS in stage IB1 patients was significantly higher than in stage IB2-IIB patients (p = 0.022).
  • Nineteen patients (25%) had grade 3 or 4 neutropenia, 13 patients (17.1%) had grade 3 anemia, and 2 patients (2.6%) had grade 3 thrombocytopenia, but none of these patients died from the disease.
  • Three patients experienced chronic toxicity: one had bladder perforation, one had hydronephrosis, and one experienced ileus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1606-13 [10764420.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e577-81 [21840137.001]
  • [Cites] Int J Clin Oncol. 2015 Apr;20(2):240-8 [25800808.001]
  • [Cites] Eur J Cancer Care (Engl). 2008 Mar;17(2):174-81 [18302655.001]
  • [Cites] Gynecol Oncol. 2006 Feb;100(2):288-93 [16182347.001]
  • [Cites] Gynecol Oncol. 2012 Jan;124(1):63-7 [22004904.001]
  • [Cites] J Obstet Gynaecol Res. 2015 Oct;41(10 ):1638-43 [26177790.001]
  • [Cites] Int J Gynecol Cancer. 2013 Mar;23(3):567-75 [23385284.001]
  • [Cites] J Obstet Gynaecol Res. 2010 Oct;36(5):1009-14 [20722988.001]
  • [Cites] Radiat Oncol. 2015 Jan 13;10:18 [25582425.001]
  • [Cites] Radiat Oncol. 2015 Aug 25;10:180 [26300325.001]
  • [Cites] Obstet Gynecol Sci. 2013 Jan;56(1):15-21 [24327975.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):118-25 [17869451.001]
  • [Cites] JAMA. 1995 Aug 2;274(5):387-93 [7616634.001]
  • [Cites] Radiat Oncol. 2012 Nov 23;7:197 [23176540.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):727-32 [15943983.001]
  • [Cites] Gynecol Oncol. 1989 Apr;33(1):34-9 [2703164.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jul-Aug;17(4):833-42 [17367320.001]
  • [Cites] Gynecol Oncol. 1999 May;73(2):177-83 [10329031.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):721-8 [15721417.001]
  • [Cites] Gynecol Oncol. 1997 Mar;64(3):463-7 [9062151.001]
  • [Cites] J Gynecol Oncol. 2009 Dec;20(4):227-31 [20041099.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):169-76 [16427212.001]
  • [Cites] Gynecol Oncol. 1990 Sep;38(3):352-7 [2227547.001]
  • (PMID = 28626256.001).
  • [ISSN] 0027-7622
  • [Journal-full-title] Nagoya journal of medical science
  • [ISO-abbreviation] Nagoya J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; 5-FU. / Cisplatin / Concurrent chemoradiotherapy / Hysterectomy / Uterine cervical cancer
  •  go-up   go-down


85. Gurria JP, Haas L, Troutt M, Moody S, Hossain MM, Bhuiyan MAN, Falcone RA Jr: Pediatric trauma undertriage in Ohio. J Trauma Acute Care Surg; 2017 Jun;82(6):1007-1013
MedlinePlus Health Information. consumer health - Wounds and Injuries.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Overall, 53% of transferred patients had a more than 2-hour transfer time.
  • LEVEL OF EVIDENCE: Therapeutic/care management study, level IV; epidemiological, level IV.
  • [MeSH-minor] Age Factors. Child. Child, Preschool. Female. Humans. Infant. Injury Severity Score. Male. Ohio / epidemiology. Patient Transfer / statistics & numerical data. Retrospective Studies. Time Factors. Trauma Centers / statistics & numerical data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28520684.001).
  • [ISSN] 2163-0763
  • [Journal-full-title] The journal of trauma and acute care surgery
  • [ISO-abbreviation] J Trauma Acute Care Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Breathett K, D'Amico R, Adesanya TMA, Hatfield S, Willis S, Sturdivant RX, Foraker RE, Smith S, Binkley P, Abraham WT, Peterson PN: Patient Perceptions on Facilitating Follow-Up After Heart Failure Hospitalization. Circ Heart Fail; 2017 Jun;10(6)
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient Perceptions on Facilitating Follow-Up After Heart Failure Hospitalization.
  • Patient-centered solutions for facilitating follow-up post-HF hospitalization have not been extensively evaluated.
  • METHODS AND RESULTS: Face-to-face surveys were conducted between 2015 and 2016 among 83 racially diverse adult patients (61% African American, 34% Caucasian, and 5% Other) hospitalized for HF at a university hospital centered in a low-income area of Columbus, Ohio.
  • Patient perceptions of methods to facilitate follow-up post-HF hospitalization and likelihood of using interventions were investigated using a Likert scale: 1=very much to 5=not at all.
  • The annual household income was <$35 000 for 49% of patients.
  • An appointment near the patient's home was the most desired intervention (77%), followed by reminder message (73%), transportation to appointment (63%), and elimination of copayment (59%).
  • CONCLUSIONS: Among this cohort of racially diverse low-income patients hospitalized with HF, an appointment near the patient's home and a reminder message were the most desired interventions to facilitate follow-up.
  • [MeSH-major] Appointments and Schedules. Heart Failure / therapy. Hospitalization / statistics & numerical data. Patient Compliance. Reminder Systems / instrumentation

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • [Cites] J Cardiovasc Nurs. 1999 Oct;14(1):55-74 [10533692.001]
  • [Cites] Med Care. 2016 Apr;54(4):365-72 [26978568.001]
  • [Cites] J Am Geriatr Soc. 1990 Dec;38(12):1290-5 [2254567.001]
  • [Cites] Am Heart J. 2006 Aug;152(2):371-8 [16875925.001]
  • [Cites] Health Aff (Millwood). 2011 Apr;30(4):746-54 [21471497.001]
  • [Cites] Patient Educ Couns. 2002 Apr;46(4):287-95 [11932128.001]
  • [Cites] Am J Cardiol. 2001 Jun 15;87(12):1367-71 [11397355.001]
  • [Cites] JAMA. 2005 Sep 14;294(10):1248-54 [16160133.001]
  • [Cites] Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):444-50 [23861483.001]
  • [Cites] Ann Fam Med. 2015 Nov;13(6):562-71 [26553896.001]
  • [Cites] J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239 [23747642.001]
  • [Cites] Heart Lung. 2002 May-Jun;31(3):161-72 [12011807.001]
  • [Cites] Clin Interv Aging. 2016 Sep 26;11:1325-1332 [27713623.001]
  • [Cites] JAMA. 2010 May 5;303(17):1716-22 [20442387.001]
  • [Cites] Heart. 2005 Jul;91(7):899-906 [15958358.001]
  • [Cites] Circulation. 2002 Jun 18;105(24):2861-6 [12070114.001]
  • [Cites] Am J Med. 2010 Jun;123(6):542-8 [20569761.001]
  • [Cites] Circ Cardiovasc Qual Outcomes. 2013 Mar 1;6(2):171-7 [23386663.001]
  • [Cites] Eur Heart J. 2004 Sep;25(18):1570-95 [15351157.001]
  • [Cites] Am Heart J. 2001 Oct;142(4):E7 [11579371.001]
  • [Cites] Circ Heart Fail. 2013 May;6(3):606-19 [23616602.001]
  • [Cites] Am J Med. 2014 Sep;127(9):886.e15-20 [24768966.001]
  • [Cites] J Multidiscip Healthc. 2011 Mar 31;4:39-51 [21544247.001]
  • [Cites] Ann Fam Med. 2015 Mar;13(2):115-22 [25755032.001]
  • [Cites] Circulation. 1997 Feb 18;95(4):1085-90 [9054774.001]
  • [Cites] J Gen Intern Med. 2013 Feb;28(2):269-82 [23054925.001]
  • (PMID = 28615367.001).
  • [ISSN] 1941-3297
  • [Journal-full-title] Circulation. Heart failure
  • [ISO-abbreviation] Circ Heart Fail
  • [Language] eng
  • [Grant] United States / NIMHD NIH HHS / MD / L60 MD010857; United States / NHLBI NIH HHS / HL / T32 HL116276
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; adult / heart failure / hospitalization / poverty / survey / transportation
  •  go-up   go-down


87. Beukelman T, Kimura Y, Ilowite NT, Mieszkalski K, Natter MD, Burrell G, Best B, Jones J, Schanberg LE, CARRA Registry Investigators: The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months. Pediatr Rheumatol Online J; 2017 Apr 17;15(1):30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months.
  • BACKGROUND: Herein we describe the history, design, and rationale of the new Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry and present the characteristics of patients with juvenile idiopathic arthritis (JIA) enrolled in the first 12 months of operation.
  • Data are collected every 6 months and include clinical assessments, detailed medication use, patient-reported outcomes, and safety events.
  • RESULTS: As of July 2016, 1192 patients with JIA were enrolled in the CARRA Registry at 49 clinical sites.
  • Owing to preferential enrollment, patients with systemic JIA (13%) and with a polyarticular course (75%) were over-represented compared to patients in typical clinical practice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 2008 Apr;58(4):919-28 [18383377.001]
  • [Cites] Arthritis Care Res (Hoboken). 2014 Mar;66(3):404-10 [23983017.001]
  • [Cites] Arthritis Care Res (Hoboken). 2012 Apr;64(4):546-53 [22076847.001]
  • [Cites] Arthritis Rheum. 1997 Jul;40(7):1202-9 [9214419.001]
  • [Cites] Arthritis Rheum. 2009 May 15;61(5):658-66 [19405003.001]
  • [Cites] J Rheumatol. 2012 Dec;39(12):2341-51 [23070991.001]
  • [Cites] Arthritis Care Res (Hoboken). 2014 Jul;66(7):1063-72 [24339215.001]
  • [Cites] Am J Epidemiol. 2003 Nov 1;158(9):915-20 [14585769.001]
  • [Cites] J Am Med Inform Assoc. 2013 Jan 1;20(1):172-9 [22733975.001]
  • [Cites] Arthritis Care Res (Hoboken). 2013 May;65(5):745-52 [23139240.001]
  • [Cites] Pediatrics. 2013 Nov;132(5):e1384-94 [24144710.001]
  • [Cites] J Rheumatol. 2013 Dec;40(12):2088-96 [24187099.001]
  • [Cites] Pediatr Rheumatol Online J. 2016 Mar 10;14 (1):14 [26965173.001]
  • [Cites] J Rheumatol. 2016 Sep;43(9):1755-62 [27307527.001]
  • [Cites] J Rheumatol. 2016 Apr;43(4):799-803 [26879356.001]
  • [Cites] J Rheumatol. 2013 Jun;40(6):936-42 [23588937.001]
  • [Cites] Lupus. 2016 Jun;25(7):749-53 [26980741.001]
  • [Cites] Arthritis Care Res (Hoboken). 2012 Aug;64(8):1175-85 [22505322.001]
  • [Cites] Arthritis Care Res (Hoboken). 2012 Mar;64(3):375-83 [22162255.001]
  • [Cites] Pediatr Rheumatol Online J. 2016 Feb 16;14 (1):9 [26879972.001]
  • [Cites] Am Heart J. 2011 Nov;162(5):844-51 [22093200.001]
  • [Cites] J Rheumatol. 2004 Feb;31(2):390-2 [14760812.001]
  • [Cites] Lupus. 2014 Aug;23(9):898-904 [24729278.001]
  • [Cites] Arthritis Care Res (Hoboken). 2012 Jul;64(7):1001-10 [22290637.001]
  • [Cites] J Rheumatol. 2012 Sep;39(9):1867-74 [22859354.001]
  • [Cites] J Rheumatol. 2002 May;29(5):1058-64 [12022323.001]
  • [Cites] Ann Rheum Dis. 2013 Dec;72(12):1983-8 [23256951.001]
  • [Cites] Pediatr Clin North Am. 2012 Apr;59(2):301-27 [22560572.001]
  • [Cites] J Am Heart Assoc. 2014 Feb 07;3(1):e000523 [24510115.001]
  • [Cites] Arthritis Care Res (Hoboken). 2011 Jul;63(7):929-36 [21717596.001]
  • (PMID = 28416023.001).
  • [ISSN] 1546-0096
  • [Journal-full-title] Pediatric rheumatology online journal
  • [ISO-abbreviation] Pediatr Rheumatol Online J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Investigator] Abramson L; Akoghlanian S; Anderson E; Andrew M; Baszis K; Becker M; Bell-Brunson H; Benham H; Birmingham J; Blier P; Brunner H; Chalom E; Chang J; Charpentier P; Chowdhury N; Dean J; Dedeoglu F; Dionizovik-Dimanovski M; Feldman B; Ferguson P; Fox M; Francis K; Franco L; Gervasini M; Goh I; Goldsmith D; Graham TB; Griffin T; Helfrich D; Hickey K; Hoeltzel M; Holtschlag S; Hsu J; Huber A; Huttenlocher A; Imundo L; Inman C; Jaquith J; Jerath R; Jones S; Kahn P; Kingsbury D; Klein K; Klein-Gitelman M; Kramer S; Kunkel A; Lapidus S; Latham D; Lehman T; Lindsley C; Linehan S; Lorenzo J; Malla B; Martyniuk A; Mason T; McConnell K; McCurdy D; McKibben K; McMullen-Jackson C; Milojevic D; Mims K; Moniz C; Morgan S; Murray E; Nicely K; O'Neil K; Onel K; Orange J; Ponder L; Prahalad S; Punaro M; Rabinovich CE; Rakestraw A; Rauch S; Reichley L; Rhea A; Ringold S; Riordan ME; Roberson S; Robinson A; Rosenkranz M; Ross K; Rothman D; Ruas Y; Ruth N; Sanders R; Schikler K; Singer N; Smith C; Stapp H; Swann S; Syed R; Tangarone A; Thatayatikom A; Trejo D; Tress J; Vehe R; von Scheven E; Watts A; Weiss J; Weiss P; Woo J; Yalcindag A; Zeft A; Zemel L; Zhu A
  •  go-up   go-down


88. Joseph B, Orouji Jokar T, Hassan A, Azim A, Mohler MJ, Kulvatunyou N, Siddiqi S, Phelan H, Fain M, Rhee P: Redefining the association between old age and poor outcomes after trauma: The impact of frailty syndrome. J Trauma Acute Care Surg; 2017 Mar;82(3):575-581
MedlinePlus Health Information. consumer health - Wounds and Injuries.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Frailty syndrome (FS) is a well-established predictor of outcomes in geriatric patients.
  • The aim of this study was to quantify the prevalence of FS in geriatric trauma patients and to determine its association with trauma readmissions, repeat falls, and mortality at 6 months.
  • METHODS: we performed a 2-year (2012-2013) prospective cohort analysis of all consecutive geriatric (age, ≥ 65 years) trauma patients.
  • Patients were stratified into: nonfrail, TSFI ≤ 0.12; prefrail, TSFI = 0.1 to 0.27; and frail, TSFI > 0.27.
  • Patient follow-up occurred at 6 months to assess outcomes.
  • RESULTS: Three hundred fifty patients were enrolled.
  • Frail patients were more likely to develop in-hospital complications (nonfrail, 12%; prefrail, 17.4%; and frail, 33.4%; p = 0.02) and an adverse discharge disposition compared with nonfrail and prefrail (nonfrail, 8%; prefrail,18%; and frail, 47%; p = 0.001).
  • Six-month follow-up was recorded in 80% of the patients.
  • Compared with nonfrail patients, frail patients were more likely to have had a trauma-related readmission (odds ratio [OR], 1.4; 95% confidence interval [CI], 1.2-3.6) and/or repeated falls (OR, 1.6; 95%CI, 1.1-2.5) over the 6-month period.
  • Overall 6-month mortality was 2.8% (n = 10), and frail elderly patients were more likely to have died (OR, 1.1; 95% CI, 1.04-4.7) compared with nonfrail patients.
  • CONCLUSION: Over a third of geriatric trauma patients had FS.
  • TSFI provides a practical and accurate assessment tool for identifying elderly trauma patients who are at increased risk of both short-term and long-term outcomes.
  • Early focused intervention in frail geriatric patients is warranted to improve long-term outcomes.
  • [MeSH-minor] Accidental Falls / statistics & numerical data. Aged. Aged, 80 and over. Female. Hospital Mortality. Humans. Male. Patient Readmission / statistics & numerical data. Prevalence. Prognosis. Prospective Studies. Recurrence. Risk Factors. Syndrome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28225741.001).
  • [ISSN] 2163-0763
  • [Journal-full-title] The journal of trauma and acute care surgery
  • [ISO-abbreviation] J Trauma Acute Care Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Davies A, Merli F, Mihaljević B, Mercadal S, Siritanaratkul N, Solal-Céligny P, Boehnke A, Berge C, Genevray M, Zharkov A, Dixon M, Brewster M, Barrett M, MacDonald D: Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol; 2017 Jun;4(6):e272-e282
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Intravenous rituximab is the standard of care in B-cell non-Hodgkin lymphoma, and is administered over 1·5-6 h.
  • A subcutaneous formulation could reduce patients' treatment burden and improve resource utilisation in health care.
  • Eligible patients were aged 18 years or older and had histologically confirmed, previously untreated, CD20-positive grade 1, 2, or 3a follicular lymphoma; Eastern Co-operative Oncology Group performance statuses of 0-2; bidimensionally measurable disease (by CT or MRI); life expectancy of 6 months or more; adequate haematological function for 28 days or more; and one or more symptoms requiring treatment according to the Groupe d'Etudes des Lymphomes Folliculaires criteria.
  • Patients were randomly assigned (1:1) by investigators or members of the research team via a dynamic randomisation algorithm to 375 mg/m<sup>2</sup> intravenous rituximab or 1400 mg subcutaneous rituximab, plus chemotherapy (six-to-eight cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP] or eight cycles of cyclophosphamide, vincristine, and prednisone [CVP]), every 3 weeks during induction, then rituximab maintenance every 8 weeks.
  • Pooled data from stages 1 and 2 are reported on the basis of the clinical cutoff date of the last patient completing the maintenance phase of the study.
  • This trial is registered with ClinicalTrials.gov, number NCT01200758; new patients are no longer being recruited, but some patients are still being followed up.
  • FINDINGS: Between Feb 15, 2011, and May 15, 2013, 410 patients were randomly assigned, 205 to intravenous rituximab and 205 to subcutaneous rituximab.
  • The most common grade 3 or higher adverse event was neutropenia, which occurred in 44 patients (21%) in the intravenous group and 52 (26%) in the subcutaneous group.
  • Serious adverse events occurred in 72 patients (34%) in the intravenous group and 73 (37%) in the subcutaneous group.
  • Administration-related reactions occurred in 73 patients (35%) in the intravenous group and 95 (48%) patients in the subcutaneous group (mainly grade 1 or 2 local injection-site reactions).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28476440.001).
  • [ISSN] 2352-3026
  • [Journal-full-title] The Lancet. Haematology
  • [ISO-abbreviation] Lancet Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


90. Koami H, Sakamoto Y, Sakurai R, Ohta M, Imahase H, Yahata M, Umeka M, Miike T, Nagashima F, Iwamura T, Yamada KC, Inoue S: Thromboelastometric analysis of the risk factors for return of spontaneous circulation in adult patients with out-of-hospital cardiac arrest. PLoS One; 2017;12(4):e0175257

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thromboelastometric analysis of the risk factors for return of spontaneous circulation in adult patients with out-of-hospital cardiac arrest.
  • It is well known that coagulopathy is observed in patients with out-of-hospital cardiac arrest (OHCA).
  • Thrombolytic therapy for those patients has been controversial until now.
  • The purpose of this study was to identify a significant predictor for return of spontaneous circulation (ROSC) of OHCA patients in the emergency department (ED) using whole blood viscoelastic testing.
  • Adult non-trauma OHCA patients transported to our hospital that underwent thromboelastometry (ROTEM) during cardiopulmonary resuscitation between January 2013 and December 2015 were enrolled in this study.
  • We divided patients into two groups based on the presence or absence of ROSC, and performed statistical analysis utilizing patient characteristics, prehospital data, laboratory data, and ROTEM data.
  • Seventy-five patients were enrolled.
  • The ROSC group and non-ROSC group included 23 and 52 patients, respectively.
  • We defined a positive prediction for ROSC if the patient presented lower lactate level (<12.0 mmol/L) and higher A30 of EXTEM (≥48.0 mm) with high specificity (94.7%) and accuracy (75.0%).
  • The present study showed that lactate level and ROTEM parameter of clot firmness were reliable predictors of ROSC in the ED for adult patients with OHCA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Anaesth. 2015 Jan;114(1):91-102 [25303988.001]
  • [Cites] Resuscitation. 2006 Jul;70(1):31-6 [16762481.001]
  • [Cites] N Engl J Med. 2002 May 16;346(20):1522-8 [12015391.001]
  • [Cites] Resuscitation. 2007 May;73(2):189-201 [17239516.001]
  • [Cites] Transplant Proc. 2013;45(10):3637-9 [24314981.001]
  • [Cites] Crit Care. 2010;14(2):R55 [20374650.001]
  • [Cites] Resuscitation. 2001 Jul;50(1):71-6 [11719132.001]
  • [Cites] Arch Intern Med. 2000 May 22;160(10):1529-35 [10826469.001]
  • [Cites] J Intern Med. 1991 Apr;229(4):331-5 [2026986.001]
  • [Cites] Resuscitation. 2006 Jun;69(3):399-406 [16563599.001]
  • [Cites] Medicine (Baltimore). 2016 Aug;95(31):e4514 [27495106.001]
  • [Cites] Circulation. 1995 Nov 1;92(9):2572-8 [7586359.001]
  • [Cites] Resuscitation. 2013 Apr;84(4):454-9 [22922072.001]
  • [Cites] Thromb Res. 1999 Oct 15;96(2):107-13 [10574588.001]
  • [Cites] Crit Care Med. 2011 Dec;39(12):2652-8 [21765358.001]
  • [Cites] Resuscitation. 2003 Apr;57(1):49-55 [12668299.001]
  • [Cites] J Cardiothorac Vasc Anesth. 2014 Apr;28(2):210-6 [24630470.001]
  • [Cites] N Engl J Med. 2008 Dec 18;359(25):2651-62 [19092151.001]
  • [Cites] Resuscitation. 2012 Dec;83(12):1451-5 [22634432.001]
  • (PMID = 28380019.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lactates
  •  go-up   go-down


91. Johnson SR, Soowamber ML, Fransen J, Khanna D, Van Den Hoogen F, Baron M, Matucci-Cerinic M, Denton CP, Medsger TA Jr, Carreira PE, Riemekasten G, Distler J, Gabrielli A, Steen V, Chung L, Silver R, Varga J, Müller-Ladner U, Vonk MC, Walker UA, Wollheim FA, Herrick A, Furst DE, Czirjak L, Kowal-Bielecka O, Del Galdo F, Cutolo M, Hunzelmann N, Murray CD, Foeldvari I, Mouthon L, Damjanov N, Kahaleh B, Frech T, Assassi S, Saketkoo LA, Pope JE: There is a need for new systemic sclerosis subset criteria. A content analytic approach. Scand J Rheumatol; 2017 Oct 09;:1-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Thirty experts from 13 countries were included; 67% were male, 63% were from Europe and 37% from North America; median experience of 22.5 years, with a median of 55 new SSc patients annually.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28990485.001).
  • [ISSN] 1502-7732
  • [Journal-full-title] Scandinavian journal of rheumatology
  • [ISO-abbreviation] Scand. J. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


92. Mayanja BN, Kasamba I, Levin J, Namakoola I, Kazooba P, Were J, Kaleebu P, Munderi P, CoLTART study team: COHORT PROFILE: The Complications of Long-Term Antiretroviral Therapy study in Uganda (CoLTART), a prospective clinical cohort. AIDS Res Ther; 2017;14:26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were no differences in renal dysfunction between patients on Tenofovir and Non-Tenofovir containing ART regimens.
  • Patients on PI regimens had higher total cholesterol, lower high density lipoprotein, higher low density lipoprotein, higher triglycerides, and a high atherogenic index for plasma than the non-PI regimen, p = 0.001 or < 0.001.
  • Patients on Non-PI regimens had higher mean diastolic hypertension than patients on PI regimens, p < 0.001.
  • CONCLUSIONS: Our finding of no differences in renal dysfunction between patients on Tenofovir and those on Non-Tenofovir containing ART regimens means that Tenofovir based first line ART can safely be initiated even in settings without routine renal function monitoring.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 2006 Jan 15;42(2):283-90 [16355343.001]
  • [Cites] AIDS. 2007 Jun 19;21(10):1273-81 [17545703.001]
  • [Cites] PLoS One. 2015 Aug 24;10(8):e0135188 [26301416.001]
  • [Cites] Biomed Pharmacother. 2008 Jan;62(1):6-11 [17574807.001]
  • [Cites] PLoS One. 2009;4(3):e4724 [19266092.001]
  • [Cites] Lancet. 2010 Jan 9;375(9709):123-31 [20004464.001]
  • [Cites] HIV Med. 2011 Oct;12(9):553-61 [21535347.001]
  • [Cites] Bioinformatics. 2009 May 1;25(9):1197-8 [19304876.001]
  • [Cites] AIDS. 2011 Mar 13;25(5):671-8 [21252634.001]
  • [Cites] AIDS Patient Care STDS. 2008 Feb;22(2):99-103 [18260800.001]
  • [Cites] J Hypertens. 2011 Jun;29(6):1061-8 [21505357.001]
  • [Cites] AIDS. 2009 Mar 27;23(6):689-96 [19262355.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2006 Jun;2(3):429-45 [16863444.001]
  • [Cites] Int J Epidemiol. 2013 Feb;42(1):129-41 [23364209.001]
  • [Cites] Curr Med Chem. 2006;13(26):3121-32 [17168701.001]
  • [Cites] Diabetes Obes Metab. 2008 Jun;10(6):441-50 [17825081.001]
  • [Cites] J Trop Med. 2011;2011:598341 [21845196.001]
  • [Cites] J Infect Dis. 2013 May 1;207(9):1359-69 [23382571.001]
  • [Cites] AIDS. 2004 Apr 30;18(7):1074-6 [15096814.001]
  • [Cites] Afr Health Sci. 2009 Sep;9(3):143-6 [20589141.001]
  • [Cites] J Infect Dis. 2008 Jun 1;197(11):1490-2 [18422454.001]
  • [Cites] Popul Health Metr. 2011 Aug 04;9:36 [21816100.001]
  • [Cites] CMAJ. 2004 Jan 20;170(2):229-38 [14734438.001]
  • [Cites] Trop Med Int Health. 2010 Jun;15(6):697-705 [20406428.001]
  • [Cites] Clin Infect Dis. 2013 Feb;56(4):567-75 [23143096.001]
  • [Cites] Afr Health Sci. 2006 Sep;6(3):139-44 [17140334.001]
  • [Cites] AIDS. 1997 Apr;11(5):633-40 [9108945.001]
  • [Cites] Clin Infect Dis. 2006 May 15;42(10):1488-95 [16619164.001]
  • [Cites] PLoS One. 2015 May 14;10(5):e0126166 [25974077.001]
  • [Cites] Curr Opin Infect Dis. 2009 Feb;22(1):43-8 [19106702.001]
  • [Cites] AIDS. 2008 Oct 18;22(16):2155-63 [18832879.001]
  • [Cites] Lancet. 2000 Jun 17;355(9221):2106-11 [10902624.001]
  • [Cites] AIDS. 2005 Aug 12;19(12):1332-3 [16052093.001]
  • [Cites] Int J STD AIDS. 2001 Sep;12(9):555-62; quiz 563-4 [11516363.001]
  • [Cites] J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):388-95 [23254151.001]
  • (PMID = 28484508.001).
  • [ISSN] 1742-6405
  • [Journal-full-title] AIDS research and therapy
  • [ISO-abbreviation] AIDS Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Antiretroviral therapy / Cohort profile / HIV / Metabolic abnormalities / Renal complications / Uganda
  • [Investigator] Mayanja BN; Nalwadda J; Nakibuuka G; Namugenyi H; Kazooba P; Lubega R; Mugisha A; Tereka A; Kalyebara A; Namara A; Nakitto D; Wangi D; Nume F; Ssemwanga G; Nabulime G; Nassuna G; Lubega G; Namakoola I; Lutaakome J; Generous L; Matama L; Massa R; Tino S; Nakahima W; Kapaata AA; Magambo B; Parry C; Lyagoba F; Nazziwa J; Nannyonjo M; Muhigirwa E; Wamalugu F; Kabajuma F; Nakazibwe HG; Were J; Bwandinga J; Bukenya J; Kamushaaga MZ; Hughes P; Nkurunziza P; Balungi PA; Mukasa S; Nassimbwa S; Vudriko T; Senyonga W; Ochola W; Nakimbugwe A; Nampewo C; Nambuba D; Naphtali E; Barigye G; Nakamanya I; Kasamba I; Levin J; Kahwa J; Matovu JN; Namayirira L; Lubega RN; Nabalayo S; Kaddu S; Munderi P
  •  go-up   go-down


93. Subbe CP, Kellett J, Barach P, Chaloner C, Cleaver H, Cooksley T, Korsten E, Croke E, Davis E, De Bie AJ, Durham L, Hancock C, Hartin J, Savijn T, Welch J, Crisis Checklist Collaborative: Crisis checklists for in-hospital emergencies: expert consensus, simulation testing and recommendations for a template determined by a multi-institutional and multi-disciplinary learning collaborative. BMC Health Serv Res; 2017 May 08;17(1):334
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: 'Failure to rescue' of hospitalized patients with deteriorating physiology on general wards is caused by a complex array of organisational, technical and cultural failures including a lack of standardized team and individual expected responses and actions.
  • The aim of this study using a learning collaborative method was to develop consensus recomendations on the utility and effectiveness of checklists as training and operational tools to assist in improving the skills of general ward staff on the effective rescue of patients with abnormal physiology.
  • We sought to achieve a consensus on procedures and clinical simulation technology to determine the requirements, develop and test a safe using a checklist template that is rapidly accessible to assist in emergency management of common events for general ward use.
  • RESULTS: Safety considerations about deteriorating patients were agreed upon and summarized.
  • 'Stop & Think'), and, a list of items required for the safe "handover" of patients that remain on the general ward (i.e. 'Check Out').
  • Simulation usability assessment of the template demonstrated feasibility for clinical management of deteriorating patients.
  • CONCLUSIONS: Emergency checklists custom-designed for general ward patients have the potential to guide the treatment speed and reliability of responses for emergency management of patients with abnormal physiology while minimizing the risk of adverse events.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acute Med. 2014;13(2):56-60 [24940567.001]
  • [Cites] N Engl J Med. 2010 Nov 11;363(20):1928-37 [21067384.001]
  • [Cites] Emerg Med J. 2011 Jun;28(6):507-12 [21036796.001]
  • [Cites] Surg Neurol Int. 2012;3:2 [22347672.001]
  • [Cites] BMJ Qual Saf. 2013 Jun;22(6):507-14 [23457361.001]
  • [Cites] BMJ Qual Saf. 2015 Jul;24(7):428-31 [25969512.001]
  • [Cites] J Nurs Care Qual. 2012 Jan-Mar;27(1):43-50 [21849908.001]
  • [Cites] Med Care. 1992 Jul;30(7):615-29 [1614231.001]
  • [Cites] Clin Med (Lond). 2012 Dec;12 (6):501-3 [23342400.001]
  • [Cites] Implement Sci. 2011 Apr 16;6:39 [21496276.001]
  • [Cites] Qual Saf Health Care. 2005 Oct;14(5):326-31 [16195564.001]
  • [Cites] Ann Surg. 2014 Apr;259(4):807-13 [24096751.001]
  • [Cites] Qual Saf Health Care. 2010 Oct;19(5):e44 [20538629.001]
  • [Cites] J Am Coll Surg. 2011 Aug;213(2):212-217.e10 [21658974.001]
  • [Cites] Crit Care Med. 2004 Oct;32(10):2014-20 [15483409.001]
  • [Cites] Jt Comm J Qual Patient Saf. 2015 May;41(5):212-20 [25977248.001]
  • [Cites] Ann Surg. 2003 Jun;237(6):844-51; discussion 851-2 [12796581.001]
  • [Cites] N Engl J Med. 2014 Mar 13;370(11):1029-38 [24620866.001]
  • [Cites] Lancet. 2009 Aug 8;374(9688):444-5 [19681190.001]
  • [Cites] Ann Surg. 2012 Dec;256(6):925-33 [22968074.001]
  • [Cites] Crit Care Med. 2011 Nov;39(11):2401-6 [21705896.001]
  • [Cites] Crit Care. 2006 Feb;10(1):R30 [16507153.001]
  • [Cites] Intensive Care Med. 2010 Jan;36(1):100-6 [19760206.001]
  • [Cites] Ann Intern Med. 2005 May 3;142(9):756-64 [15867408.001]
  • [Cites] Crit Care. 2005;9(6):R808-15 [16356230.001]
  • [Cites] Jt Comm J Qual Patient Saf. 2005 May;31(5):243-8 [15960014.001]
  • [Cites] Resuscitation. 2011 Jul;82(7):810-4 [21497982.001]
  • [Cites] BMJ Qual Saf. 2015 Sep;24(9):545-9 [26089207.001]
  • [Cites] Resuscitation. 2010 Nov;81(11):1509-15 [20673606.001]
  • [Cites] QJM. 2001 Oct;94(10 ):521-6 [11588210.001]
  • [Cites] BMJ Qual Saf. 2012 Sep;21(9):737-45 [22927487.001]
  • [Cites] N Engl J Med. 2009 Jan 29;360(5):491-9 [19144931.001]
  • [Cites] N Engl J Med. 2013 Jan 17;368(3):246-53 [23323901.001]
  • [Cites] Anaesth Intensive Care. 1995 Apr;23(2):183-6 [7793590.001]
  • [Cites] Implement Sci. 2013 Jun 20;8:70 [23786847.001]
  • [Cites] BMJ Qual Saf. 2011 Jan;20(1):102-7 [21228082.001]
  • [Cites] Hum Factors. 2008 Jun;50(3):442-8 [18689051.001]
  • (PMID = 28482890.001).
  • [ISSN] 1472-6963
  • [Journal-full-title] BMC health services research
  • [ISO-abbreviation] BMC Health Serv Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Crisis / Learning Collaborative / Patient safety / Rapid response teams / Reliability / Simulation
  • [Investigator] Barach P; Beaugrand H; Breen D; Byrne D; Chalmers C; Cleaver H; Cooksley T; Croke E; Davis E; De Bie A; Donnelly P; Dunne E; Durham L; Ellis B; Goel R; Hancock C; Hartin J; Hinge D; Holland M; Hueske-Kraus D; Kellett J; Kennelly S; Korsten E; Lighthall G; Lunn R; Müller M; O'Dwyer C; O'Mahony K; Paice N; Roberts L; Savijn T; Subbe CP; Thomas D; Walsh R; Weber F; Welch J; Woodworth S
  •  go-up   go-down


94. Weimar C, Bilbilis K, Rekowski J, Holst T, Beyersdorf F, Breuer M, Dahm M, Diegeler A, Kowalski A, Martens S, Mohr FW, Ondrášek J, Reiter B, Roth P, Seipelt R, Siggelkow M, Steinhoff G, Moritz A, Wilhelmi M, Wimmer-Greinecker G, Diener HC, Jakob H, Ose C, Scherag A, Knipp SC, CABACS Trial Investigators: Safety of Simultaneous Coronary Artery Bypass Grafting and Carotid Endarterectomy Versus Isolated Coronary Artery Bypass Grafting: A Randomized Clinical Trial. Stroke; 2017 Oct;48(10):2769-2775

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: The optimal operative strategy in patients with severe carotid artery disease undergoing coronary artery bypass grafting (CABG) is unknown.
  • METHODS: Patients with asymptomatic high-grade carotid artery stenosis ≥80% according to ECST (European Carotid Surgery Trial) ultrasound criteria (corresponding to ≥70% NASCET [North American Symptomatic Carotid Endarterectomy Trial]) who required CABG surgery were randomly assigned to synchronous carotid endarterectomy+CABG or isolated CABG.
  • RESULTS: From 2010 to 2014, a total of 129 patients were enrolled at 17 centers in Germany and the Czech Republic.
  • At 30 days, the rate of any stroke or death in the intention-to-treat population was 12/65 (18.5%) in patients receiving synchronous carotid endarterectomy+CABG as compared with 6/62 (9.7%) in patients receiving isolated CABG (absolute risk reduction, 8.8%; 95% confidence interval, -3.2% to 20.8%; <i>P</i><sub>WALD</sub>=0.12).
  • Also for all secondary end points at 30 days and 1 year, there was no evidence for a significant treatment-group effect although patients undergoing isolated CABG tended to have better outcomes.
  • Five-year follow-up of patients is still ongoing.
  • [MeSH-major] Carotid Stenosis / diagnosis. Ca